EP4017375A1 - Systèmes et procédés de test de cycle menstruel - Google Patents

Systèmes et procédés de test de cycle menstruel

Info

Publication number
EP4017375A1
EP4017375A1 EP20854747.1A EP20854747A EP4017375A1 EP 4017375 A1 EP4017375 A1 EP 4017375A1 EP 20854747 A EP20854747 A EP 20854747A EP 4017375 A1 EP4017375 A1 EP 4017375A1
Authority
EP
European Patent Office
Prior art keywords
result
diagnostic test
threshold
absence
indication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20854747.1A
Other languages
German (de)
English (en)
Other versions
EP4017375A4 (fr
Inventor
Amy BECKLEY
Jeffrey Schell
Ellen SCHELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mfb Fertility Inc
MFB Fertility Inc
Original Assignee
Mfb Fertility Inc
MFB Fertility Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/544,554 external-priority patent/US20210055310A1/en
Priority claimed from US16/732,823 external-priority patent/US11061026B2/en
Priority claimed from US16/732,766 external-priority patent/US11029321B2/en
Application filed by Mfb Fertility Inc, MFB Fertility Inc filed Critical Mfb Fertility Inc
Publication of EP4017375A1 publication Critical patent/EP4017375A1/fr
Publication of EP4017375A4 publication Critical patent/EP4017375A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/0012—Ovulation-period determination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B2010/0003—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements including means for analysis by an unskilled person
    • A61B2010/0006—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements including means for analysis by an unskilled person involving a colour change

Definitions

  • the present invention relates to diagnostic testing associated with the female reproductive system, and more specifically, testing associated with the menstrual cycle.
  • Hormone change patterns associated with the above symptoms may be detectable if women have the capacity to test on a repetitive and sufficiently simplified basis.
  • existing testing protocols are generally difficult to track, require at least partial serum testing or laboratory work, and deliver results inappropriate for many lay users.
  • Existing testing paradigms including serum tests, at-home pregnancy and ovulation predictor kits (OPKs) configured to evaluate urine for luteinizing hormone (LH), are often technical in nature and difficult for lay users to interpret.
  • OPKs at-home pregnancy and ovulation predictor kits
  • LH luteinizing hormone
  • due in part to the sporadic timeframes for testing hormones at different times during a menstrual cycle or otherwise trend identification associated with hormonal concentrations is often difficult or impossible.
  • suboptimal hormonal patterns may result in additional difficulty with attempts to conceive or infertility.
  • negative impacts may include hot flashes, night sweats, osteoporosis, insomnia, vaginal dryness, pain associated with sexual intercourse, weight gain, lack of interest in sex and mood swings.
  • E1G anterior pituitary gonadotropins follicle- stimulating hormone
  • LH luteinizing hormone
  • E1G Estrone-3 -glucuronide
  • Urinary levels of E3G correspond to the serum levels of estradiol.
  • pregnanediol glucuronide (PdG) is a principal metabolite of progesterone. The urinary levels of pregnanediol glucuronide correspond to the serum levels of progesterone.
  • follicle stimulating hormone is associated with the start of the menstrual cycle, as FSH stimulates growth of a follicle or follicles.
  • the growing follicle triggers estrogen production.
  • Increased estrogen from a growing follicle then triggers a sudden spike in LH.
  • the surge in LH causes the follicle to rupture, which is ovulation.
  • the ruptured follicle then secretes progesterone.
  • Progesterone acts to thicken the uterine wall to prepare for implantation and protect the growing fetus. Once a fertilized embryo has implanted in the uterine wall, human chorionic gonadotropin (hCG) is released and is detectable in urine within a short period of time.
  • hCG human chorionic gonadotropin
  • BSA Bovine Serum Albumin
  • a common problem associated with prior art attempts is that the specifically chosen antibodies with such solutions are undesirably cross-reactive.
  • chosen antibodies have suboptimal affinities for the application of a PdG test.
  • the chosen antibodies in prior art attempts often fall outside of a desired threshold detection range. For instance, the chosen antibodies have resulted in an attempt at a diagnostic test that is not sensitive enough to allow a user to distinguish a positive and negative result. Sensitivity in such context may derive from suboptimal levels of affinity, avinity and specificity.
  • the chosen antibody having a particular antibody isotype binds on items other than a PdG target.
  • Diagnostic tests also vary in terms of the correlation of a positive or negative result to the presence or absence of a line. For instance, most LH (ovulation prediction) and hCG (pregnancy) tests as known in the art provide two lines in association with a positive result. However, in association with testing for other hormones and/or hormonal analytes, the presence of only one line, or the absence of a line, may indicate a positive result. Therefore there is a need for an improved mechanism that optionally allows for the interpretation of the indicated results for laypersons in a less confusing manner, particularly in a case where multiple results are indicated on the same test for a single sample. It also remains preferable to provide an inexpensive or commonly available mechanism that is less complicated than relying exclusively upon uncommonly used external computing devices or computing devices provided directly within in a cartridge containing the diagnostic test.
  • seed cycling is a naturopathic remedy that balances hormones by regulating the hormone estrogen in the first half of a woman’s menstrual cycle and the hormone progesterone in the second half of a woman’s menstrual cycle.
  • a problem remains associated with the inconvenience of measuring a specific amount of a specific type of seed to consume in relation to seed cycling.
  • a related problem is knowing precisely when to consume each specific type of seed to consume, especially in relation to a level of hormone present in the blood.
  • the phytoestrogens in flax seeds can help moderate estrogen levels.
  • Phytoestrogens are compounds in plants that can mimic the action of estrogen.
  • zinc present in pumpkin seeds has been demonstrated to promote progesterone production.
  • lignans a type of polyphenol present in sesame seeds, may inhibit estrogen levels from increasing too much.
  • the vitamin E in sunflower seeds has been demonstrated to boost progesterone levels.
  • progesterone which in some instances can be estimated in accordance with a urine measurement of progesterone analyte PdG, and corresponding changes over time within a menstrual cycle, and corresponding trends from one menstrual cycle to the next, are crucial aspects associated with many important methods associated with tracking fertility, the menstrual cycle, menopause, or triggering the consumption of certain foods at specified timeframes during the menstrual cycle or the prescription of certain hormone supplementations for supplementation at specified timeframes during the menstrual cycle. It is impractical to identify the hormonal levels, particularly the levels of progesterone, via serum testing on a daily basis in association with such important methods given the logistical challenges (i.e. travel to a laboratory, waiting for evaluated results) involved.
  • the present invention solves the previously existing inability to detect, organize and interpret a specific concentration of progesterone in blood or its corresponding analyte in urine, and other hormones and analytes related to the menstrual cycle, due to configurations of previously existing diagnostic tests and the unavailability of a system configured to detect and interpret the results of diagnostic tests.
  • a variety of novel diagnostic tests have allowed for the creation of a system to track hormonal levels associated with the menstrual cycle without requiring the assistance of a laboratory.
  • Such tests include diagnostic tests configured to evaluate an applied fluid to detect and provide an indication for the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 0.1 pg/mL-20 pg/mL to provide usefulness for nearly all women, and more particularly 1 pg/mL-10 pg/mL to provide usefulness for the vast majority of women.
  • the solution in an example comprises mechanisms for testing bodily fluids and providing an immediate interpretation of the results of such tests to a layperson user, optionally for further delivery to a healthcare professional.
  • An aspect of the solution in an example described herein comprises a system for conducting a telemedicine consultation in such a manner that the collected results of such tests are made available to a medical provider for discussion at a time convenient to both the layperson user and the healthcare professional.
  • the suggested treatment protocol optionally comprising a directive to consume certain types of hormone balancing seeds at certain times in the menstrual cycle as prompted by an application operating on the layperson user’s computing device, which forms an aspect of the solution in an example.
  • a single package comprising a specified quantity of diagnostic tests, the quantity of diagnostic tests optionally capable of evaluating a bodily fluid for the presence of hormones or analytes selected from the group of FSH, LH, PdG, an estrogen metabolite such as E3G and hCG each optionally corresponding to important indications and trigger points for the consumption of seeds at differing points in a single menstrual cycle, and/or a specified quantity of snack bars comprising pumpkin seeds and flax seeds and snack bars comprising sesame seeds and sunflower seeds, forms an aspect of the solution in an example.
  • An application and/or a digital reader configured to evaluate the diagnostic tests and generate one or more unique messages related to the interpretations of the diagnostic tests, the unique messages optionally including prompts to consume a certain type of seeds at a certain time, forms an aspect of the solution in an example.
  • the examples of the invention as described herein provide a number of advantageous effects relevant to addressing undesirable conditions associated with the menstrual cycle, hormonal balances and the fertility of a patient.
  • the diagnostic tests comprising an aspect of the invention, when taken repeatedly on a daily basis over the course of a menstrual cycle in an example, provide an indication for the specific dates on which the phases of the menstrual cycle change.
  • the results of such diagnostic tests can be automatically interpreted by an associated application, optionally operating on a smartphone capable of photographing the diagnostic tests to determine the color intensity indicated on such diagnostic tests.
  • the application in an example is configured to detect the indications provided by either a single diagnostic test or a series of diagnostic tests and generate interpretations of the single diagnostic test or series of diagnostic tests as described herein.
  • the results of such diagnostic tests and the generated interpretations may be delivered to a healthcare provider and made accessible to the healthcare provider via a communicatively connected storage medium for further evaluation of the patient, and during consultation with a patient during a telemedicine consultation, optionally triggered by one or more results of a diagnostic test as detected by the application or associated interpretations.
  • the telemedicine consultation or the interpretations in an aspect are useful in generating a suggested treatment protocol.
  • the suggested treatment protocol involves the consumption of one or more certain types of seeds based upon the detected result of the diagnostic test to address hormonal imbalances as described further herein.
  • FIG. 1 depicts a configuration of an embodiment of the diagnostic test featuring four testing zones and four corresponding result indication lines associated with aspects of the invention, and specifically the location of the result indication lines associated with an exemplary configuration of the diagnostic test.
  • Fig. 2 depicts an exploded view of an embodiment of the diagnostic test featuring four testing zones and four corresponding result indication lines associated with aspects of the invention, and specifically the location of the result indication lines associated with an exemplary configuration of the diagnostic test.
  • FIG. 3 depicts an exemplary diagnostic test key corresponding to an embodiment of the diagnostic test configured to evaluate specifically for the presence or absence of PdG at a threshold and the presence or absence of LH at a threshold.
  • Fig. 4 depicts an exemplary graphical user interface of the Healthcare Professional- Facing Application specifically configured to display a list of one or more patients and provide the capability to search for a patient.
  • Fig. 5 depicts an exemplary smartphone and an exemplary unique message.
  • Fig. 6 depicts an exemplary color intensity key.
  • Fig. 7 depicts an example of aspects of the system as used together to photographically capture a diagnostic test.
  • Fig. 8 depicts an example of aspects of the system as used together to photographically capture a diagnostic test in association with a stand featuring markings of a known distance apart intended to aid in the calculation of the dimensions of the diagnostic test.
  • Fig. 9 depicts an exemplary graphical user interface of the Patient-Facing Application specifically configured at least to display a list of one or more diagnostic test results, set a location, and schedule a telemedicine consultation.
  • Fig. 10 depicts various configurations of components of the system configured to either hold the diagnostic test for capture of a result and/or to display unique messages deriving from one or more interpretations of the indicated results.
  • Fig. 11 depicts an exemplary graphical user interface comprising a calendar.
  • Fig. 12 depicts an exemplary graphical user interface associated with the Scheduler associated with a specifically detected location of the user.
  • Fig. 13 depicts an exemplary graphical user interface associated with the seed consumption system, wherein the result of a diagnostic test is displayed in association with an interpretation displayed as a unique message.
  • Fig. 14 depicts an exemplary single consumable food item substantially in the form of a snack bar.
  • Fig. 15 depicts embodiments of the system comprising a plurality of diagnostic tests and a container.
  • Fig 16. depicts an exemplary method of use of the system.
  • Fig. 17 depicts an exemplary method of use of a system associated with the scheduler.
  • Fig. 18 depicts an exemplary method of use of a system associated with the healthcare professional-facing application.
  • Fig. 19 depicts an exemplary method of use of a system associated with the patientfacing application.
  • Fig. 20 depicts an exemplary method of use of the telemedicine system.
  • Fig. 21 depicts an exemplary method of use of the telemedicine system incorporating testing for at least FSH and E3G.
  • Fig. 23 depicts an exemplary method of determining results based on color intensity associated with various embodiments.
  • Fig. 24 depicts an exemplary method of generating an interpretation from one or more diagnostic tests associated with various embodiments.
  • Fig. 25 depicts an exemplary method of calibrating systems configured to interpret the indication or indications of one or more diagnostic tests.
  • Fig. 26 depicts an exemplary graphical user interface associated with the scheduler.
  • Fig. 27 depicts an exemplary method of progesterone supplementation.
  • An embodiment of the invention comprises a menstrual cycle testing system comprising a Diagnostic Test, Camera, Patient-Facing Application, Healthcare-Facing Application, Storage, Graphical User Interface, Processor, Computing Device, Calendar, and Scheduler.
  • Various other embodiments of the invention described herein incorporate and/or interact with the Menstrual Cycle Testing System.
  • Various embodiments of the Menstrual Cycle Testing System comprise a Fertility Tracking System, Telemedicine System, Seed Consumption System, and/or Predicting Fertile Window System as described elsewhere herein.
  • the diagnostic test consists of a lateral flow assay comprising at least one testing zone configured to detect for the presence or absence of pregnanediol glucuronide (PdG) in urine at a threshold selected from within the inclusive range of 1 pg/mL-10 pg/mL.
  • PdG pregnanediol glucuronide
  • the diagnostic test configured to detect for the presence or absence of pregnanediol glucuronide comprises a lateral flow assay test comprising anti-pregnanediol glucuronide antibodies conjugated to visual label, optionally colloidal gold, and pregnanediol glucuronide conjugated to a globulin carrier protein, optionally bovine gamma globulin (BGG).
  • a lateral flow assay test comprising anti-pregnanediol glucuronide antibodies conjugated to visual label, optionally colloidal gold, and pregnanediol glucuronide conjugated to a globulin carrier protein, optionally bovine gamma globulin (BGG).
  • the diagnostic test consisting of a lateral flow assay is configured to evaluate for the presence or absence of at least pregnanediol glucuronide at a threshold selected from within the range of 1 pg/mL-10 pg/mL incorporates specific reagent combinations uniquely enabling a strong enough interaction in the testing zone to allow for visual, naked eye inspection of the test results in accordance with the teachings in this disclosure and those incorporated by reference herein.
  • pregnanediol glucuronide is a small hormone metabolite
  • pregnanediol glucuronide requires a strong carrier protein.
  • the diagnostic test 100 should be configured to facilitate the binding of 7 or more PdG molecules per carrier protein molecule to create enough reaction to enable a visual and/or optical indication for the presence or absence of PdG at a threshold in an applied fluid associated with the diagnostic test 100.
  • such limitation is incorporated into the result indication line configured to provide a optical and/or visual result for the presence or absence of PdG at a threshold.
  • the present inventor has recognized that by presenting more than 6 PdG molecules to each of the gold-conjugated anti-PdG antibodies, this results in the efficient binding and reactivity from the PdG-carrier protein and antibody, and thereby enables the proper functionality of the result indication line relevant to the presence or absence of PdG at a threshold in an applied fluid associated with the preferred embodiment of the diagnostic test 100.
  • the at least one additional testing zone is placed onto the conjugate pad 190, corresponding to the second result indication line 108 placed onto the membrane 193, and configured to evaluate a fluid for the presence or absence of luteinizing hormone at a specified threshold selected from the range including 15 mlU/mL-50mlU/mL.
  • At least a portion of the conjugate pad 190, or optionally the entirety of the conjugate pad 190, is sprayed at 2- 5ul/cm with a Potassium Phosphate buffer including 0.5% BSA, 0.1% surfactant, 5-15 OD anti-LH gold conjugate of concentration selected from the range inclusive of 6 ug/ml -8 ug/ml.
  • a 1 mg/ml anti-LH antibody test is placed in a line across substantially the entire width of the membrane 193 to form a result indication line, optionally the second result indication line 108.
  • the present inventor has discovered that, for the preferred embodiment of the invention to function as intended, not only does the strong carrier protein need to bind the nitrocellulose membrane, but the strong carrier protein also needs to bind the pregnanediol glucuronide and present it to the anti-pregnanediol glucuronide antibody.
  • the strong carrier protein Prior to the embodiments of the invention as disclosed herein, other attempts in the prior art have failed to include an optimal combination of a strong carrier protein able to bind the pregnanediol glucuronide and present it to the anti-pregnanediol glucuronide antibody.
  • diagnostic test configured to detect for only the presence of the absence or presence of pregnanediol glucuronide at a threshold
  • diagnostic test configured to detect the presence of the absence or presence of pregnanediol glucuronide at a threshold in addition to detecting for the presence of other hormones and or analytes, such as luteinizing hormone (LH), in the same sample of fluid.
  • other hormones and or analytes such as luteinizing hormone (LH)
  • Another important component of the preferred embodiment of invention is the specifically chosen anti-pregnanediol glucuronide antibody.
  • the specifically chosen anti- pregnanediol glucuronide antibody must be monoclonal, due to the nature of the pregnanediol glucuronide antigen presentation on the BGG conjugate.
  • the specifically chosen anti-pregnanediol glucuronide antibody must consist of one of the following isotypes: IgGl, IgG2a, IgG2b, or IgG2c.
  • isotypes other than IgGl, IgG2a, IgG2b, or IgG2c including but not limited to IgM, IgS, and IgE anti-pregnanediol glucuronide antibody isotypes, remain unable to effectively bind the colloidal gold (or other visual label) and likewise unable to produce a strong enough color signal on the reaction zone due to their size and structure and are therefore excluded from the preferred embodiment of the invention.
  • the present inventor Since the colloidal gold must bind the Ig region of the anti-pregnanediol glucuronide antibody, the present inventor has discovered that the IgGl, IgG2a, IgG2b, and IgG2c isotypes of the anti-pregnanediol glucuronide antibody sufficiently bind colloidal gold and are therefore incorporated into embodiments of the invention. As a result, the IgGl, IgG2a, IgG2b and IgG2c isotypes of the anti-pregnanediol glucuronide antibody therefore produce the strongest color.
  • the IgG2b isotype is included in the invention, as the present inventor has recognized that the IgG2b isotype performs slightly better when producing color. Therefore, the preferred embodiment of the invention incorporates the IgG2b isotype of the anti-pregnanediol glucuronide antibody. Alternative embodiments incorporate the IgG2a, IgG2c or IgGl isotypes of the anti- pregnanediol glucuronide antibody.
  • the conjugate striped on the membrane 193 in the test zone area is pregnanediol glucuronide-BGG and the anti- pregnanediol glucuronide antibody must be a monoclonal anti-pregnanediol glucuronide antibody of one of the following isotypes: IgGl, IgG2a, IgG2b, or IgG2c.
  • diagnostic test configured to detect the presence of the absence or presence of pregnanediol glucuronide at a threshold alone
  • diagnostic test configured to detect the presence of the absence or presence of pregnanediol glucuronide at a threshold in addition to the presence of other hormones and/or analytes, such as luteinizing hormone (LH), in the same sample of fluid.
  • LH luteinizing hormone
  • a fluid sample is applied to the lateral flow assay as described in the above referred-to patent applications.
  • the sample is allowed to permeate through the strip material into or through the one or more testing zones, whereby which the conjugate pad 190 of the diagnostic test 100 is coated with specific binding partners, optionally as described elsewhere herein.
  • pregnanediol glucuronide from the fluid sample becomes bound within the first testing zone and the extent to which analyte becomes bound can be determined by labeled secondary reagents such as colored latex beads or colloidal gold.
  • each result indication line in an example is correlated with the concentration of the analyte in the fluid sample, optionally as indicated on the Diagnostic Test Key 200.
  • the diagnostic test 100 is configured to evaluate for the presence or absence of at least pregnanediol glucuronide at a threshold selected from within the range of 1 pg/mL-10 pg/mL is single-use and disposable after results are indicated.
  • the diagnostic test 100 comprises with a result indication line configured to generate a visual or optical signal for the presence or absence of pregnanediol glucuronide at a threshold of 5 pg/mL.
  • the diagnostic test consists of a single lateral flow assay test configured to simultaneously or near-simultaneously detect for the presence or absence of pregnanediol glucuronide at a threshold in addition to detecting for the presence of one additional hormone or hormonal analyte or a plurality of additional hormones or hormonal analytes selected from the group consisting of luteinizing hormone, estrogen, estriol glucuronide, estradiol, progesterone and human chorionic gonadotropin, each optionally at a (distinct) threshold, in the same fluid sample, with each indication provided in association with a separate result indication line.
  • test 100 embodied as a lateral flow assay configured to simultaneously analyze urine beyond mere analysis for the presence or absence of pregnanediol glucuronide at a threshold, by further analyzing up to six additional analytes and/or hormones each in a separate testing zone located distal from the fluid application zone 106 on the same lateral flow assay.
  • the diagnostic test 100 incorporates a first testing zone located within the conjugate pad 190 and a first result indication line 107 and a control line 105, and no other testing zones or result indication lines. In an embodiment, the diagnostic test 100 incorporates a first testing zone and second testing zone located within the conjugate pad 190 and a first result indication line 107 and a second result indication line 108 and a control line 105, and no other testing zones or result indication lines.
  • the diagnostic test 100 consists of a lateral flow assay comprising a conjugate pad 190 comprising at least a first testing zone configured to evaluate urine for the presence or absence of pregnanediol glucuronide at a specific threshold, and additionally at least a second testing zone and optionally a third testing zone and/or fourth testing zone located within the conjugate pad 190.
  • the first testing zone, the second testing zone, the third testing zone and the fourth testing zone each occupy distinct areas on the conjugate pad 190 along the entire width of the conjugate pad 190, configured such that applied fluid must come into contact with each applied testing zone as it travels through the conjugate pad 190 to come into contact with the membrane 193 during lateral flow of the applied fluid.
  • the various conjugates may either be mixed prior to application or applied sequentially in an overlapping fashion onto the same area of the conjugate pad 190.
  • the present inventor has recognized various advantages and disadvantages to either approach. The present inventor has noted a higher precision and a lower risk of cross-contamination with regard to the indicated results in the example where the testing zones each occupy distinct areas on the conjugate pad 190. However, the present inventor has also noted that it is easier to manufacture a diagnostic test 100 in the example where at least two of the testing zones are applied together. Both approaches are incorporated as teachings relevant to embodiments of the invention.
  • the diagnostic test 100 to optionally incorporate one or more additional testing zones located within the conjugate pad 190, optionally a second testing zone, a third testing zone, and a fourth testing zone, beyond the first testing zone configured to analyze urine for the presence or absence of pregnanediol glucuronide, and further to incorporate a result indication line on the membrane 193 corresponding to each testing zone configured to provide an indication for the presence, the indication for the presence optionally consisting of a visual signal corresponding to the presence or absence at a threshold, of an item selected from the group consisting of LH,
  • HCG HCG
  • FSH Testosterone
  • Estrogen an estrogen metabolite such as E3G.
  • the diagnostic test 100 consists of a lateral flow assay comprising a sample pad 191 configured to receive an applied fluid and transfer the applied fluid to the conjugate pad 190, and following the transit of the applied fluid to the conjugate pad 190 (and its at least one testing zone) to a a membrane 193 comprising at least one result indication line, optionally the first result indication line 107, configured to provide indication for the presence or absence of pregnanediol glucuronide at a specified threshold selected from the range including 1 pg/mL-10 pg/mL in the applied fluid.
  • its conjugate pad 190 is at least sprayed at 2-6ul/cm with a Potassium Phosphate buffer including 0.5% BSA, 0.1% surfactant, 5-15 OD anti-PdG gold (at a concentration selected from the range of 2ug/ml - 8ug/ml) to form a testing zone, optionally the first testing zone.
  • a Potassium Phosphate buffer including 0.5% BSA, 0.1% surfactant, 5-15 OD anti-PdG gold (at a concentration selected from the range of 2ug/ml - 8ug/ml) to form a testing zone, optionally the first testing zone.
  • the membrane 193 is separately and additionally applied with a conjugate of PdG-BGG in an amount of 0.5 mg/ml, placed in a line across substantially the entire width of the membrane 193, which provides a configuration able to display an indication (optionally an optical signal) in the form of a result indication line for the presence or absence of PdG at threshold amount of 5 pg/mL in an applied fluid.
  • a conjugate of PdG-BGG in an amount of 0.5 mg/ml, placed in a line across substantially the entire width of the membrane 193, which provides a configuration able to display an indication (optionally an optical signal) in the form of a result indication line for the presence or absence of PdG at threshold amount of 5 pg/mL in an applied fluid.
  • the membrane 193 is applied with a conjugate of PdG conjugated to a mixture of complement factor H (in an embodiment, comprising 15% of the mixture), BSA (in an embodiment, comprising 20% of the mixture), BGG (in an embodiment, comprising 50% of the mixture), beta-2-glycoprotein (in an embodiment, comprising 10% of the mixture), compliment favor B (in an embodiment, comprising 5% of the mixture), placed in a line across substantially the entire width of the membrane 193, thereby configured to display an indication (optionally an optical signal) in the form of a result indication line, optionally the first result indication line 107, of the presence or absence of PdG at an amount selected from the range inclusive of 1 pg/mL-10 pg/mL based upon the relative concentration of such elements in an applied sample, in the form of and to create at least one result indication line.
  • complement factor H in an embodiment, comprising 15% of the mixture
  • BSA in an embodiment, comprising 20% of the mixture
  • BGG in an embodiment, comprising 50% of the mixture
  • the membrane 193 is further applied with a 1.2 mg/ml goat anti-mouse antibody placed in a line across substantially the entire width of the membrane distal from the fluid application point relative to any applied result indication lines in the form of and to create a control line 105.
  • each result indication line and control line is simultaneously (or as necessary, sequentially) dispensed onto the membrane using a BioDot XYZ3210 dispenser, and allowed to dry following application.
  • the conjugate pad 190 is additionally sprayed with, optionally in distinct areas encompassing the entire width of the conjugate pad 190 or optionally all together encompassing substantially the entire area of the surface of the conjugate pad 190, one or more additional buffers each comprising a testing zone (alternatively each referred to as a “receiving zone”).
  • a separate result indication line is placed onto the membrane 193 in substantially the same manner but with a unique conjugate configured to create a visual indication line corresponding to the hormone or hormone analyte evaluated in association with the pertinent testing zone.
  • the at least one additional testing zone is placed onto the conjugate pad 190 and configured to evaluate a fluid for the presence or absence of luteinizing hormone at a specified threshold selected from the range including 15 mlU/mL-50mlU/mL.
  • a specified threshold selected from the range including 15 mlU/mL-50mlU/mL.
  • at least a portion of the conjugate pad 190, or optionally the entirety of the conjugate pad 190 is sprayed at 2-5ul/cm with a Potassium Phosphate buffer including 0.5% BSA, 0.1% surfactant, 5-15 OD anti-LH gold conjugate of concentration selected from the range inclusive of 6 ug/ml -8 ug/ml.
  • an anti-LH antibody at a concentration of 1 mg/ml is sprayed in a line across substantially the entire width of the membrane 193 to form a result indication line, optionally the second result indication line 108.
  • a step of applying a plurality of testing zones and the control line to the membrane 193 simultaneously is performed.
  • the PdG test line forming the first result indication line 107, the LH test line forming the second result indication line 108, and the control line 105 are simultaneously dispensed onto the membrane 193 component of the lateral flow assay using a dispenser, optionally a BioDot XYZ3210 and allowed to dry.
  • a step of creating a plurality of conjugates is performed.
  • a first conjugate is created of Potassium Phosphate buffer including 0.5% BSA or 0.5% BGG, 0.1% surfactant, 5-15 OD anti-PDG gold (cone. 2-8ug/ml), and a second conjugate is created of Potassium Phosphate buffer including 0.5% BSA, 0.1% surfactant, 5-15 OD anti-LH gold (cone. 6-8ug/ml).
  • a step of spraying the plurality of conjugates onto the conjugate pad 190 of the lateral flow assay is performed, wherein the first conjugate is sprayed at 2-6ul/cm onto at least the portion of the conjugate pad 190 corresponding to the first testing zone and the second conjugate is sprayed at 2-5ul/cm onto at least the portion of the conjugate pad 190 corresponding to the second testing zone.
  • the portions of the conjugate pad first testing zone and second testing zone (and optionally other testing zones) partially or fully overlap, and optionally are mixed together prior to application such that all testing zones are pre-mixed and applied in a single spray to a single area onto the conjugate pad 190.
  • a further step of the method comprises forming a mastercard.
  • the membrane 193 and conjugate pad 190 components are applied, further comprising a sample pad 191, optionally blocked with 0.1 M Borate buffer including 1% PVP-10 and 1% detergent and a wicking pad optionally consisting of a 901 Ahlstrom wicking pad, are attached to a backing card (the backing card comprising one of those readily available and known in the art).
  • the membrane 193 also optionally referred to as the “testing zone”
  • conjugate pad 190 also optionally referred to as the “receiving zone”
  • sample pad 191 also optionally comprising the fluid application zone 106
  • wicking pad also optionally referred to as the “adsorbent pad,” which collects the applied fluid following lateral flow to mitigate leakage
  • backing card 194 is attached together by a clamshell laminator, optionally the BioDot LM5000 Clamshell Laminator.
  • the method further comprises cutting the mastercard into strips.
  • the mastercard is cut into strips optionally with a guillotine cutter, optionally the BioDot CM4000 Guillotine Cutter, each strip then ready for subsequent placement into a sealed aluminum pouch with a desiccant for preservation.
  • a guillotine cutter optionally the BioDot CM4000 Guillotine Cutter
  • the diagnostic test consisting of a lateral flow assay is configured to simultaneously indicate a positive or negative result for the presence or absence of pregnanediol glucuronide at a threshold in a sample of urine applied to the lateral flow assay.
  • a positive or negative result for the presence or absence of pregnanediol glucuronide at a threshold in addition to indicating a positive or negative result for the presence or absence of pregnanediol glucuronide at a threshold, in a second testing zone, a positive or negative result for the presence of at least one additional analyte and/or hormone, and, optionally, indicating in an third testing zone, a positive or negative result for the presence of at least one additional analyte and/or hormone, each contained within a single diagnostic test consisting of a lateral flow assay.
  • the at least one additional analyte and/or hormone to be tested within the second testing zone and optionally the at least one additional analyte and/or hormone to be tested within the third testing zone is selected from the following group: (1), estradiol (E2) with a threshold set at a concentration chosen from the range inclusive of 25-250 pg/ml in a competitive assay format; (2), follicle stimulating hormone (FSH) with a threshold set at a concentration chosen from the range inclusive of 3-20 mlU/ml in a sandwich assay format; (3), luteinizing hormone (LH) with a threshold set at a concentration chosen from the range inclusive of 0-25 mlU/ml in a sandwich assay format; (4) , progesterone (P4) with a threshold set at a concentration chosen from the range inclusive of of 0-40 ng/ml in a competitive or sandwich assay format; (5) human chorionic gonadotropin, (hCG) with a threshold
  • E2 estradi
  • the second testing zone is configured to detect for the presence of a hormone or analyte differing from the hormone or analyte detected by the third testing zone.
  • the diagnostic test consists of a lateral flow assay comprising at least one testing zone configured to detect for the presence or absence of pregnanediol glucuronide in urine at a threshold selected from within the range of 1 pg/mL-10 pg/mL further comprising one or more additional testing zones each configured to detect for the presence or absence of a hormone or hormonal analyte selected from the group consisting of: estradiol or estriol glucuronide (E3G) at a threshold selected from the range inclusive of 25 ng/mL-250 ng/mL, follicle stimulating hormone at a threshold selected from the range inclusive of 3 mIU/ml-20 mlU/ml, luteinizing hormone at a threshold selected from a range inclusive of 15 mIU/ml-50 mlU/m
  • E3G
  • the one or more testing zone(s) corresponding to the hormone or hormonal analyte selected from the group consisting of LH, FSH, hCG and/or an estrogen metabolite such as E3G are applied in a similar manner to the testing zone configured to facilitate evaluation of an applied fluid for PdG as described herein.
  • an exemplary method of assembly comprising the step of creating a plurality of conjugates, one or more additional conjugates are created.
  • a FSH conjugate comprising a Potassium Phosphate buffer including 0.5% BSA, 0.1% surfactant, 5-15 OD anti-FSH gold (cone.
  • step of spraying the conjugate onto the conjugate pad 190 further comprises spraying the FSH conjugate at 2 ul/cm-4 ul/cm onto at least the portion of the conjugate pad 190 corresponding to a testing zone, optionally the third testing zone.
  • step of spraying the conjugate onto the conjugate pad 190 further comprises spraying the FSH conjugate at 2 ul/cm-4 ul/cm onto at least the portion of the conjugate pad 190 corresponding to a testing zone, optionally the third testing zone.
  • the applying a plurality of testing zones and the control line to the membrane 193 simultaneously step further comprises applying in the testing zone configured to evaluate for FSH the 1 mg/ml anti-FSH antibody test line, optionally comprising the third result indication line 109.
  • a hCG conjugate comprising Potassium Phosphate buffer including 0.5% BSA, 0.1% surfactant, 5-15 OD anti-HCG gold (cone. 2-9ug/ml), in which case the step of spraying the conjugate onto the conjugate pad 190 further comprises spraying the hCG conjugate at 2- 6ul/cm onto at least the portion of the conjugate pad 190 corresponding to a testing zone, optionally the fourth testing zone.
  • the applying a plurality of testing zones and the control line to the membrane 193 simultaneously step further comprises applying in the testing zone configured to evaluate for hCG by striping 1.5 mg/ml anti-HCG antibody in the test line area, optionally comprising the fourth result indication line 110.
  • the diagnostic test is configured as a lateral flow assay comprising a first testing zone configured to simultaneously indicate a positive or negative result for the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 1 pg/mL-10 pg/mL in a sample of urine and a second testing zone configured to evaluate urine for the presence or absence of luteinizing hormone at a specified threshold selected from the range including 15 mlU/mL-50mlU/mL, with the diagnostic zones located in a specific order at specific locations on the diagnostic test corresponding to match instructions provided on a printed material located within a system further comprising a plurality of diagnostic tests, or otherwise a digitized or programmed Diagnostic Test Key 200 configured as further described elsewhere herein optionally also included within the system.
  • each individual diagnostic test is configured to evaluate for the presence or absence of both progesterone glucuronide at a threshold and luteinizing hormone at a threshold in a single lateral flow assay, packaged together in quantity.
  • a plural quantity of diagnostic tests is a specific teaching of the system, the quantity correlating to the testing needs associated with one menstrual cycle as further described elsewhere herein.
  • the fertility testing system comprises a quantity of diagnostic tests each configured to evaluate for the presence or absence of both progesterone glucuronide at a threshold and luteinizing hormone at a threshold in a single lateral flow assay in a quantity selected from the range inclusive of 10 through 35 diagnostic tests.
  • the present inventor has recognized that such a range of quantities of diagnostic tests configured to evaluate for the presence or absence of both progesterone glucuronide and luteinizing hormone in a single lateral flow assay adequately would allow for daily or twice daily testing over the relevant timeframe to collect enough results for the presence or absence of progesterone glucuronide at a threshold and luteinizing hormone at a threshold, and optionally the presence or absence of other hormones and/or analytes each at a threshold, to capture useful information relevant to fertility tracking over a single menstrual cycle.
  • the diagnostic test is intended for use in association with a digital reader 670 configured to evaluate at least the second testing zone and optionally the third testing zone, the second testing zone and third testing zone each configured to evaluate for the presence or absence of a distinct hormone or analyte each at a threshold, in association with the methods described herein.
  • the diagnostic test incorporates, in addition to a first testing zone configured for the presence or absence of pregnanediol glucuronide at a threshold as described herein, a second testing zone configured to evaluate for the presence or absence of second hormone or analyte (optionally LH) at a threshold, and a third testing zone configured to evaluate for the presence or absence of third hormone or analyte (optionally E3G or FSH) at a threshold, and a fourth testing zone configured to similarly detect for the presence of a fourth hormone or analyte differing from the hormone(s) or analyte(s) detected by the other (first, second and third) testing zones (optionally FSH or hCG) within the diagnostic test.
  • a fourth testing zone configured to similarly detect for the presence of a fourth hormone or analyte differing from the hormone(s) or analyte(s) detected by the other (first, second and third) testing zones (optionally FSH or hCG) within the diagnostic test.
  • having different colors corresponding to the presence or absence of different hormones and/or analytes each at a distinct threshold provides a benefit by allowing an observer to determine whether cross-reactivity has taken place with or without the assistance of a digital reader 670. For example, if an area designated to test for the presence of LH displayed the coloration of the label for hCG, such a result indicates that cross-reactivity has been demonstrated, and it is a teaching of an embodiment that an indicated cross-reactivity would render the diagnostic test result invalid.
  • the present inventor has noted that due to the similarities in structure between estrogen analytes and progesterone analytes (in at least one example, said progesterone analytes consisting of PdG), cross reactivity may take place between those two hormone metabolites specifically.
  • the present inventor has discovered and it is a teaching of an embodiment to incorporate a plurality of testing zones each configured to evaluate a different hormone and/or hormone metabolite with the indication associated with different colors.
  • the first testing zone is configured to evaluate a fluid for the presence or absence of PdG at a threshold
  • the second testing zone is configured to evaluate a fluid for the presence or absence of LH at a threshold
  • the third testing zone is configured to evaluate for the presence of FSH
  • the fourth testing zone is configured to evaluate for the presence or absence of hCG at a threshold, each testing zone located within the conjugate pad 190 and corresponding to a specific result indication line located within the membrane 193.
  • Such labelling of the different tested hormone and hormone metabolites is accomplished in an embodiment by binding to colloidal gold and/or one or more differently colored latex beads, each testing zone within the exemplary diagnostic test 100 featuring a differently colored label, optionally as further described elsewhere herein.
  • the diagnostic test 100 consisting of a lateral flow assay is configured to incorporate a plurality of result indication lines, each result indication line at a specified distance and/or in a specified sequence from one end of the lateral flow assay, and each result indication line corresponding to an optically and/or visually perceptible label to indicate the presence of a distinct hormone or hormonal analyte, or optionally the presence or absence of one distinct hormone or hormonal analyte at a threshold, in a fluid sample placed into contact with the lateral flow assay.
  • the diagnostic test 100 it is a teaching of an embodiment of the invention to configure the diagnostic test 100 to incorporate precise measurements and/or a specified sequence of hormones and/or analytes to identify the distance from at least one end of the lateral flow assay to each result indication line and/or the specified sequence from one end 111 of the lateral flow assay to aid in the interpretation of any result indicated by each result indication line of the lateral flow assay.
  • An example of such a sequence with such measurements is depicted by Fig. 1 and Fig.
  • first testing zone and the first result indication line 107 is configured to detect and indicate for the presence or absence of PdG at a threshold
  • second testing zone and the second result indication line 108 is configured to detect and indicate for the presence or absence of LH at a threshold
  • third testing zone and the third result indication line 109 is configured to detect and indicate for the presence of E3G
  • fourth testing zone and the fourth result indication line 110 is configured to detect and indicate for the presence of FSH.
  • the sequence of the testing zones or distance of each testing zone from at least one of the ends 111 of the lateral flow assay is then used to identify the hormone or analyte tested within each testing zone, with a indication provided by the corresponding result indication line, optionally in association with the use of a Diagnostic Test Key 200 as described elsewhere herein, and optionally in conjunction with a digital reader 670 as described elsewhere herein and within the disclosures incorporated by reference herein.
  • the first result indication ine 107 is located 29 mm from the end of the diagnostic test 111
  • the second result indication line 108 is located 32 mm from the end of the diagnostic test 111
  • the third result indication line 109 is located 35 mm from the end of the diagnostic test 111
  • the fourth result indication line 110 is located 38 mm from the end of the diagnostic test 111 in an embodiment of the invention.
  • the first result indication line 107 provides an indication for the presence or absence of pregnanediol glucuronide at a threshold in a fluid sample applied to the diagnostic test 100 at the fluid application zone 106
  • the second result indication line 108 provides a result for the presence or absence of luteinizing hormone in a fluid sample applied to the diagnostic test 100 at the fluid application zone 106
  • the third result indication line 109 provides a color intensity result pre-correlated to a concentration of E3G in a fluid sample applied to the diagnostic test 100 at the fluid application zone 106
  • the fourth result indication line 110 provides a color intensity result pre-correlated to a concentration of FSH in a fluid sample applied to the diagnostic test 100 at the fluid application zone 106.
  • the digital reader 670 and/or the Patient-Facing Application is programmed to associate one indication or a plurality of indications detectable in association with result indication lines on a lateral flow assay each located at the distances as specified above, or at alternative distances in accordance with the specific configuration of the lateral flow assay, from at least one end 111 of the lateral flow assay.
  • Each specific indication present at a distance optionally in association with a color intensity as described elsewhere herein, is pre-associated with an interpretation for the presence or absence of specific hormones and or analytes, each optionally at a threshold or in association with a predetermined concentration, in accordance with the teachings elsewhere herein.
  • the manufacturing processes associated with such lateral flow assays are so configured to reproduce lateral flow assays in a standardized manner such that the digital reader 670 and/or the Patient-Facing Application, optionally in association with other elements of the system, may be preprogrammed with the one distance or plurality of distances from one end of the lateral flow assay, and the association of the one distance or plurality of distances from one end 111 of the lateral flow assay each with a distinct hormone or analyte.
  • the digital reader 670 and/or the Patient-Facing Application in an embodiment is additionally pre-programmed with the color intensity, with is optionally determined in advance by spiking a sample of male urine with the specific threshold of hormone or analyte and detecting the color intensity displayed in a testing zone following the application of the sample to the lateral flow assay to establish the color intensity associated with the threshold to indicate the presence or absence of such hormone or analyte for subsequent use in association with configuring the system.
  • the Diagnostic Test Key 200 is configured to incorporate such color intensity or color intensities to a threshold or thresholds of different hormones and/or analytes, optionally at specified locations on the diagnostic test 100 consisting of a lateral flow assay.
  • the Diagnostic Test Key 200 is preconfigured within the digital reader 670, Patient-Facing Application and/or smartphone 600, optionally in association with other elements of the system, via coding and computer programming mechanisms as well understood by those skilled in the art.
  • a Smartphone featuring a Camera is utilized to photograph and identify the shape of the diagnostic test 100 consisting of a lateral flow assay and calculate the distance from one end 111 with preprogrammed dimensions of the lateral flow assay, and optionally via the use of the Pythagorean Theorem, to determine the dimensions of the lateral flow assay and location of each of any subset of the group consisting of the first result indication line 107, the second result indication line 108, the third result indication line 109 and the fourth result indication line 110 on the diagnostic test 100 to accomplish the recognition of each indications, optionally by calculating the color intensity in each testing zone and comparing it to the pre-programmed color intensity of the threshold, or optionally by detecting the HEX or RGB color number displayed on each result indication line and comparing it to a preprogrammed HEX color number, RGB color number or other color identifier associated with a specific quantity of hormone or hormone analyte optionally in comparison to the HEX color number, RGB color number or other
  • the sequence of the testing zones is detected and interpreted with the assistance of one or more digital readers 670, in association with methods as well understood by those in the art, such as those described in PCT Patent Application PCT/CN2017/085010 filed on May 19, 2017 and corresponding United States Patent Application 16/302,085 filed on May 29, 2019, and PCT Patent Application PCT/US2018/038173 filed on June 20, 2019 claiming priority to United States Patent Application 62/688,970, each of which is incorporated by reference.
  • the second result indication line 108 is configured to provide an indication for the presence or absence of luteinizing hormone at a threshold
  • the first result indication line 107 is configured to provide an indication for the presence or absence of progesterone glucuronide
  • the control line 105 is configured to provide a visual indication upon the application of any fluid, to ensure that the fluid has passed through each of the testing zones and each of the result indication lines present within the diagnostic test 100 from the fluid application zone 106.
  • control line 105 is the most distal from the fluid application zone 106, and must pass through the one or more testing zones and the one or more result indication lines to provide a visual indication that the lateral flow assay has been performed correctly.
  • Each analyte and/or hormone tested in each testing zone of a diagnostic test 100 as indicated by a corresponding result indication line, and/or the control line 105 optionally corresponds to a different label to produce a distinct color (such as colloidal gold and or latex beads).
  • the first result indication line 107 appears on the lateral flow assay at a distance selected from within the range of 25-45 mm and the second result indication line 108 appears at a specified and differentiated distance on the lateral flow assay from a distance range selected from the range including 28-50 mm from the end 111 at which a fluid is applied.
  • the third result indication line 109 appears on the lateral flow assay at a distance selected from within the range of 35-55 mm and the fourth result indication line 110 appears at a specified and differentiated distance on the lateral flow assay from a distance range selected from the range including 38-58 mm from the end 111 at which a fluid is applied.
  • control line 105 is located distal from the end 111 at which a fluid is applied at a distance selected from the range of 2-10 mm from the edge of the testing zone located most distal from the end 111 at which a fluid is applied.
  • first result indication line 107 appears on the lateral flow assay at a distance of 29 mm from the end 111 at which a fluid is applied
  • second result indication line 108 appears on the lateral flow assay from a distance range of 32 mm from the end 111 at which a fluid is applied.
  • the specific sequence of the each result indication line (or the locations thereof, for example, in the absence of an indicated line where the absence of an indicated line at the location of a result indication line signifies a result) on the diagnostic test 100 and the control line 105 is associated with a specific sequence of hormones and/or analytes tested by the diagnostic test 100 and correlates to information provided in association with a Diagnostic Test Key 200 which optionally is included within system embodiments of the invention, or pre-programmed on a digital reader 670 or a Patient-Facing Application for use in association with associating the each result indication line with a specific hormone or hormone analyte.
  • each result indication line depicted in association with a Diagnostic Test Key 200 is utilized as an alternative to distinct color labeling of each analyte and/or hormone tested to provide an representation of which distinct analyte and/or hormone is indicated on each result indication line of a diagnostic test 100.
  • the presence or absence of result indication lines in a pre-defined sequence is programmed and/or coded in association with a Patient-Facing Application which may be utilized to detect the presence or absence of each hormone as a result of the specific indications of a diagnostic test 100.
  • the present inventor has recognized the importance of external mechanisms such as the Patient Facing Application and/or Diagnostic Test Key 200 in association with the utilization of the preferred embodiment of the diagnostic test 100, as some hormones or analytes such as PdG are associated with the absence of a visual indication line to indicate a positive result, whereas distinct hormones or analytes such as LH are associated with the presence of a visual indication line to indicate a positive result. Further, especially due to the possibility that the presence of one line may indicate a positive result and the presence of a separate and distinct line on the same strip may indicate a negative result, for instance as indicated on the printed Diagnostic Test Key 200 embodiment illustrated by Fig.
  • an external mechanism such as a printed Diagnostic Test Key 200, a Patient Facing App, or a Diagnostic Test Key coded into a Patient-Facing Application is transformative in facilitating layperson understanding of the visual results indicated on a diagnostic test 100. It will be appreciated by those skilled in the art that a variety of diagnostic tests for uses in association with a variety of contexts may be collected, read and interpreted by the Patient-Facing Application, for example either by color labeling or by the sequence of the hormones and/or analytes being tested on the diagnostic test 100.
  • diagnostic test 100 consisting of a lateral flow assay further comprises a visual label configured to display or not display a specific color based indicating the presence or absence of a hormone or hormonal analyte within a fluid sample placed into contact with the lateral flow assay.
  • the presence or absence of a color at a specified intensity provides an indication of the presence or absence of a hormone or hormonal analyte within a fluid sample placed into contact with the lateral flow assay.
  • the labels (such as colloidal gold) are varied, with a separate and distinct label configured to attach to a separate and distinct hormone or analyte.
  • the diagnostic test 100 is configured to provide a different color for each distinct hormone and analyte indicating either the presence or absence of each hormone analyte at a threshold following application of urine to the diagnostic test.
  • the diagnostic test 100 is configured as a lateral flow assay comprising a conjugate pad 190 (the conjugate pad also optionally referred to as the “receiving zone”) comprising anti-PdG antibody-collodial gold conjugate placed to form a testing zone, and at least one other conjugate placed within another testing zone.
  • the at least one other conjugate comprises anti-LH antibody-conjugated with a different label, optionally differently colored latex beads.
  • the configurations of the diagnostic test 100 featuring a different color representing an indication of the presence or absence of a distinct hormone or analyte are as described in United States Patent Application No. 16/381,229 filed April 11, 2019, and PCT Application No. PCT/US 18/68027, filed December 28, 2018, each of which are incorporated by reference with priority claimed thereto.
  • the method of use of the system comprises the step of determining a result from a lateral flow assay test configured to detect for at least one additional hormone or hormonal analyte (other than PdG) from the group consisting of: the presence or absence of luteinizing hormone at a threshold at a threshold, the presence or absence of and human chorionic gonadotropin at a threshold, the presence of E3G in a concentration correlating to a color intensity, and the presence of FSH in a concentration correlating to a color intensity 2009.
  • the diagnostic test 100 configured as described herein has numerous advantageous not previously known in the art.
  • the configurations as described herein are easily performed and recorded - optionally in association with a Patient-Facing Application, the Seed Consumption System, and/or a mechanism to trigger the prescription and delivery of progesterone supplementation to a patient user and other components of the system - on a daily basis by a layperson user over an extended period comprising several or many consecutive days, unlike prior art mechanisms such as serum testing, laboratory-based tests, and/or tests that require a technician or healthcare professional.
  • the present inventor has recognized that the system may facilitate a more accurate, immediate and/or effective diagnosis of menopause than other mechanisms requiring interactions with healthcare professionals or technicians.
  • the present inventor has recognized that the diagnostic test 100, when performed on a daily basis at home, and when utilized in association with the Patient-Facing Application and Seed Consumption System as described elsewhere herein, may signal the specific days on which it is most beneficial to consume one or more specified types of seeds to facilitate hormone balancing, particularly beneficial to menopausal and perimenopausal women.
  • the diagnostic test 100 is useful in association with trend identification.
  • the present inventor has recognized the benefit associated with the “at home,” disposable nature of the test in that it can be taken daily that allows for the identification of the trends associated with the undesirable absence of pregnanediol glucuronide as indicated by the stored results associated with any of the dates occurring from 7-10 days past the subject woman’s ovulation date.
  • the Diagnostic Test Key 200 comprises a printed card featuring a graphical depiction of each possible visual result of the diagnostic test, and what each possible visual result of the diagnostic test indicates, as depicted in Fig. 3.
  • the Diagnostic Test Key 200 comprises a digitized graphic, or a virtual representation generated in association with coded instructions, for utilization in association with the Patient-Facing Application described elsewhere herein and/or a digital reader 670 as described elsewhere herein.
  • the Diagnostic Test Key 200 comprises a digitized map of the correlation of the presence or absence of a specified color intensity (optionally represented by HEX or RGB codes) at a of specified location measured from one end of the lateral flow assay on a photographed lateral flow assay corresponding to the presence or absence of a hormone or analyte in a tested bodily fluid.
  • the Diagnostic Test Key 200 comprises multiple correlations of the presence or absence of a specified color intensity at a of specified location directed to a single lateral flow assay.
  • configuration of the Diagnostic Test Key 200 comprising a digitized map may be made available to the Patient Facing Application in association with the other components of the system described herein and in accordance with computer application configuration mechanisms (i.e.
  • a result indication line configured to provide a result for the presence or absence of PdG at a threshold in an applied fluid sample and a separate result indication line configured to provide a result for the presence or absence of LH at a threshold in an applied fluid sample is depicted in association with the Diagnostic Test Key, as shown on Fig. 3.
  • the Diagnostic Test Key 200 depicts a diagnostic test 100 at least featuring a result indication line configured to provide an indication with regard to an applied fluid sample for the presence or absence of PdG at a threshold whereby the absence of a visual line, or the presence of a visual line below a specified color intensity, indicates the presence of PdG at the threshold in the applied fluid sample.
  • the Diagnostic Test Key 200 depicts a diagnostic test 100 further comprising a result indication line configured to provide an indication with regard to an applied fluid sample for the presence or absence of LH at a threshold whereby the presence of a visual line, or the presence of a visual line above a specified color intensity, indicates the presence of LH at the threshold in the applied fluid sample.
  • the Diagnostic Test Key 200 depicts at least one printed graphical representation of a diagnostic test 100 at a similar scale to the diagnostic test 100 with exemplary results depicted thereon alongside a verbal description of the exemplary results. [0080]
  • the Diagnostic Test Key 200 is printed on to the same card as the instructions for use of the diagnostic test 100.
  • the Diagnostic Test Key 200 is digitally produced and incorporated into a Patient-Facing Application configured to utilize a processor to compare a photographed result to a the results indicated on a digitally reproduced Diagnostic Test Key.
  • the Diagnostic Test Key 200 is programmed in conjunction with the Patient-Facing Application.
  • the Diagnostic Test Key 200 is coded for usage in association with a digital reader 670 configured for use in association with a diagnostic test 100 as described elsewhere herein.
  • the Diagnostic Test Key 200 is configured for use in association with a digital reader 670 also comprising a display 605 configured to depict a result and/or interpretation 607 of the test collected by directing a processor to compare the result digitally obtained by the test via a Diagnostic Test Key 200 and displaying the result on a display located on the screen.
  • the Diagnostic Test Key 200 is configured for utilization in coordination with the systems comprising digital readers 670 described in the following patent applications, hereby incorporated by reference: United States Patent Application 16/302,085 filed on May 19, 2017; PCT Patent Application PCT/US2019/038173 filed on June 20, 2019; PCT/US2005/024422 filed on July 8, 2005; United States Patent Application 10/888,676 filed on July 9, 2004; and PCT/GB2014/052962 filed on October 1, 2014, for example.
  • the term “application” is synonymous with a computer program.
  • the term “application” means a computer program designed to run on a mobile device, such as a smartphone.
  • the term “application” refers to a computer program designed to run on an alternative computing device such as a personal computer.
  • the Healthcare Professional-Facing Application in embodiments of the system is intended for usage by healthcare professionals.
  • the term “healthcare professional,” refers to a person who support implementations of health care, treatment and referral plans usually established by medical, nursing, respiratory care, and other health professionals, and usually require formal qualifications to practice their profession.
  • the term “healthcare professional” may also refer to an unlicensed assistive personnel assist with providing health care services as permitted or customary in their professional.
  • the Healthcare Professional-Facing Application is intended for use by healthcare professionals specializing in care associated with fertility or primary care.
  • the Healthcare Professional-Facing Application features access controls designed to limit the ability or means necessary to read, write, modify, or communicate data/information or otherwise use any system resource to a validated healthcare professional.
  • each healthcare professional is validated prior to providing access to the Healthcare Professional- Facing Application, optionally in association with identification cross-check or API access to the national provider identifier (NPI) database in accordance with log in and access control systems as well understood by those skilled in the art.
  • NPI national provider identifier
  • the Healthcare Professional-Facing Application in an exemplary implementation incorporates a healthcare professional profile.
  • the healthcare professional profile is made accessible to a healthcare professional validated and logged into the Healthcare Professional-Facing Application (referred to herein as the “healthcare professional user”) in association with methods and mechanisms readily understood by those skilled in the art.
  • the healthcare professional profile displayed to a healthcare professional user via a graphical user interface allows for the healthcare professional user to input information pertinent to their professional activities.
  • the healthcare professional profile allows for the input by a healthcare professional user of licensure information, optionally including his or her one or more jurisdictions of licensure relevant to his or her professional services.
  • the healthcare professional profile allows for the input by the healthcare professional user of identifying information, optionally including demographic information of the healthcare professional user, contact information of the healthcare professional user and/or the identification number of the healthcare professional user, such as the healthcare professional user’s national provider identifier (NPI).
  • NPI national provider identifier
  • the healthcare professional profile allows for the input by healthcare professional user of the conditions that the healthcare professional user has the capability to treat.
  • the information is input by the healthcare professional in association with the Graphical User Interface, input/output mechanisms and/or operating system mechanisms associated with the Computing Device associated with the system, so configured via programming and or computer programming mechanisms as well understood by those skilled in the art.
  • the Healthcare Professional-Facing Application features an element within its Graphical User Interface to allow a healthcare professional user to engage an ePHI importer/exporter 401 to export information relevant to any patient, any subset of patients and/or all patients that the healthcare professional is treating, has treated or intends to treat, as depicted in Fig. 4.
  • the ePHI importer/exporter is configured to package any information relevant to a patient, optionally inclusive of diagnostic test results captured via a Patient-Facing Application, into an interoperable format, such as HL7, a clinical document architecture, a continuity of care document or continuity of care record, structured product labeling, clinical context object workgroup, a format relevant to the fast healthcare interoperability resources, a format relevant to the services aware interoperability framework, Arden syntax, formats associated with the Trusted Exchange Framework and Common Agreement and/or other similar interoperable format to allow the interoperable export of information relevant to a patient profile or plurality of patient profiles.
  • an interoperable format such as HL7, a clinical document architecture, a continuity of care document or continuity of care record, structured product labeling, clinical context object workgroup, a format relevant to the fast healthcare interoperability resources, a format relevant to the services aware interoperability framework, Arden syntax, formats associated with the Trusted Exchange Framework and Common Agreement and/or other similar interoperable format
  • the ePHI importer/exporter is configured to receive such information pertinent to a specific patient, optionally a patient for whom the healthcare professional has scheduled a telemedicine appointment as described elsewhere herein.
  • the interoperable formatted ePHI is transmitted via the ePHI exporter to the healthcare professional user’s electronic health records (EHR) system, or an EHR system of another healthcare professional to whom the healthcare professional user intends to refer one or more patients.
  • EHR electronic health records
  • the Healthcare Professional-Facing Application incorporates a telemedicine block scheduling feature to facilitate the designation of certain time periods of the healthcare professional user as available periods to conduct a telemedicine appointment with a patient, optionally a patient user of a Patient-Facing Application.
  • the graphical user interface of the Healthcare Professional-Facing Application incorporates an element or elements configured to designate and store one or more specific time periods as an available period to conduct a telemedicine appointment with a patient.
  • the designated and stored time period(s) are made available for subsequent viewing by one patient or a plurality of patients, each by utilization of the Patient- Facing Application via its graphical user interface as described elsewhere herein.
  • a notification to both the relevant patient user and the relevant healthcare professional user is generated containing and/or providing access to the relevant patient user’s diagnostic test results and/or other electronic personal health information, optionally via a link to a profile depicting the patient user, and a link configured to initiate the telemedicine appointment by videoconference, VOIP call or phone call optionally as described elsewhere herein.
  • notifications via e-mail, SMS, delivery in association with an application operating on a smartphone (such as a “push notification”) or pre-recorded phone call are triggered to both the relevant patient user and the relevant healthcare professional user, optionally comprising a mechanism, optionally a hyperlink to a patient profile or the electronic medical record of a patient, to access diagnostic test results and other electronic personal health information of the patient user and a mechanism, optionally a hyperlink to an external application such as Zoom, Facetime, or a VOIP phone call conducted within the Graphical User Interface of the Healthcare Professional-Facing Application or the Patient-Facing Application, to trigger the telemedicine appointment.
  • an external application such as Zoom, Facetime, or a VOIP phone call conducted within the Graphical User Interface of the Healthcare Professional-Facing Application or the Patient-Facing Application, to trigger the telemedicine appointment.
  • the telemedicine system incorporates any of such technologies or other technologies in communications system to facilitate realtime discussion between the user and the healthcare provider during an appointment (or “virtual” appointment), as an aspect of the telemedicine system.
  • the present inventor has recognized that such embodiment more efficiently allows for the facilitation of a telemedicine appointment at times convenient for both a patient user and a healthcare professional user with the patient user’s relevant diagnostic test information made available to the healthcare professional user in an organized and consistent fashion in association with the scheduled appointment.
  • the telemedicine block scheduling feature comprises the Scheduler as described elsewhere herein.
  • the graphical user interface is configured to work in association with the other elements of the system as described elsewhere herein to display a variety of information related to the specifically chosen patient or list of patients 403, optionally including the display of patient diagnostic test results, display of patient demographic information, and the display of a suggested diagnosis of a medical condition relevant to the patient based on an evaluation of the patient’s diagnostic test results as described elsewhere herein, an example of which is depicted in Fig. 4.
  • the term “application” is synonymous with a computer program.
  • the term “application” means a computer program designed to run on a computing device, such as a smartphone.
  • the term “patient” when used in association with the terms “Patient-Facing Application” and/or “patient user” is a term of convenience and not necessarily literally intended to refer to or designate any user as a patient. Rather, the term “patient” in these contexts refers to persons that are not healthcare professionals, persons seeking health information or healthcare services, or persons not intended to use the associated features and components in the context of providing healthcare services.
  • the term “application” refers to a computer program designed to run on an alternative computing device such as a personal computer.
  • the Patient-Facing Application is a variant of the Healthcare Professional-Facing Application with a distinct subset of features and/or access limitations.
  • the Patient-Facing Application incorporates a patient profile.
  • the patient profile displayed to a patient user via a graphical user interface allows for the patient user to input demographic information associated with the patient.
  • the patient profile is made accessible to a patient validated and logged into the Patient-Facing Application (referred to herein as the “patient user”) in association with methods and mechanisms readily understood by those skilled in the art.
  • the patient user consists of the subject woman of a diagnostic test configured to detect for at least the presence or absence of pregnanediol glucuronide at a specific threshold.
  • the patient may manually input other electronic personal health information or otherwise import or link to the patient’s electronic personal health information, optionally by importing a continuity of care document or continuity of care record.
  • the patient profile allows for the input of desired characteristics of healthcare professionals that the patient would like to interact with, optionally demographic information or jurisdictions of licensure.
  • the patient profile allows for the input of the conditions that the patient seeks treatment for.
  • the patient profile is populated with conditions associated with the patient automatically upon receiving and/or interpreting the results of diagnostic tests relevant to the patient.
  • the results of the diagnostic tests 100 relevant to the patient are collected in accordance with other mechanisms of the system.
  • information is input into the patient profile by the patient in association with input output mechanisms and/or operating system mechanisms associated with the computer device associated with the system as well understood by those skilled in the art.
  • the Patient-Facing Application features an element to allow a patient to engage a ePHI exporter to export information relevant to that patient only.
  • the ePHI exporter can deliver the patient’s electronic personal health information (ePHI) to a destination associated with a healthcare professional of the patient’s choosing.
  • the ePHI exporter when activated via the graphical user interface of the Patient-Facing Application packages any information relevant to a patient into an interoperable format, such as HL7, a clinical document architecture, a continuity of care document or continuity of care record, structured product labeling, clinical context object workgroup, a format relevant to the fast healthcare interoperability resources, a format relevant to the services aware interoperability framework, Arden syntax, formats associated with the Trusted Exchange Framework and Common Agreement and/or other similar interoperable format to allow the interoperable export of information relevant to that patient’s profile.
  • the patient profile provides an element to allow the patient to provide consent to release the relevant patient user’s ePHI to one specific healthcare professional or a plurality of specified healthcare professionals.
  • the Patient-Facing Application is further configured to record and store the indicated result for the presence or absence of PdG at a pre-defined threshold and optionally the presence or absence of one or more additional hormones or hormone analytes at a pre-defined threshold of each diagnostic test 100 performed on a fluid sample of the patient.
  • the system it is a teaching of an embodiment for the system to instruct the patient user to conduct multiple diagnostic tests 100 each taken once every day for a number of consecutive days, optionally in association with the display of one or more interpretation(s) 607.
  • the Patient-Facing Application is optionally configured to display any of a variety of a limited subset of unique messages 501, an example of which is depicted by Fig. 5, each corresponding to an interpretation 607 of results indicated on a diagnostic test 100 captured in the Patient-Facing Application, following the generation of the interpretation 607 of the results in association with the Computing Device, Processor, Camera and/or other components as described elsewhere herein.
  • the present inventor has recognized the unique advantages of the diagnostic test(s) 100 as described herein, particularly when utilized in association with the Patient-Facing Application, associated with the ability for the collection of results on multiple consecutive days, optionally during an extended time period, to assist with detecting changes, which may comprise increases, decreases, or trends, of levels of hormones and/or analytes over time.
  • Such detected changes particularly when the diagnostic test 100 is utilized in combination with a physical or digital (for example, when coded into the Patient-Facing Application) form of the Diagnostic Test Key 200 and/or Color Intensity Key 800, may include information related to the extent of the change, such as a 1.5- fold change or 2-fold change, optionally indicated and/or calculated in association with the color intensity displayed on the diagnostic test 100 following use.
  • the present inventor has recognized that the specific messages generated, optionally corresponding to the interpretations 607 described herein, correspond to a subset of the specifically available and uniquely valuable interpretations 607 associated with each diagnostic test 100.
  • the specifically available interpretations may be limited in an example to a subset comprising the below interpretations, or for each a similar unique message 501 with the same effect.
  • each diagnostic test 100 in the preferred embodiment may be configured to evaluate for the presence or absence of any of FSH, an estrogen metabolite such as E3G, LH, PdG, or hCG, or any combination thereof, as described elsewhere herein.
  • Each unique message 501 optionally derives from and depicts one or more of the following specific interpretations, optionally by utilizing the Processor, Patient-Facing Application or other component of the system as described herein, of each diagnostic test 100 or series of diagnostic test results collected daily over a plurality of consecutive days within a menstrual cycle.
  • the interpretation comprising an indication that a follicle has been selected
  • the interpretation comprising an indication that it is the appropriate time to commence testing for an estrogen metabolite such as E3G and an instruction to commence testing for an estrogen metabolite such as E3G;
  • the interpretation comprising an indication that it is the appropriate time to discontinue testing for FSH and to commence testing for estrogen and an instruction to discontinue testing for FSH and to commence testing for estrogen;
  • the interpretation comprising an indication of the likelihood of onset of menopause
  • an interpretation comprising an indication that it is the appropriate time to commence testing for LH and an instruction to commence testing for LH;
  • an interpretation comprising an indication that it is the start of the fertile window and the appropriate time to engage in intercourse for conception;
  • an interpretation comprising an indication that the subject woman should engage in sexual intercourse to conceive;
  • an interpretation comprising an indication that the it is the appropriate time to commence testing for PdG and an instruction to commence testing for PdG;
  • an interpretation comprising an indication that the it is the appropriate time to commence testing for progesterone and an instruction to commence testing for progesterone;
  • an interpretation comprising an indication that the subject woman may engage in sexual intercourse with a low risk of conceiving or pregnancy until the onset of menstruation in the subsequent menstrual cycle;
  • an interpretation comprising an indication that the subject woman has likely not produced enough progesterone to sustain pregnancy.
  • any fold increase (i.e. 1.5 fold increase) or fold decrease (i.e. 1.5 fold decrease) as referred to herein in the context of the invention is considered to be at least that fold increase or fold decrease. For example, if a 3 fold increase for a hormone or analyte is indicated by a series of diagnostic tests, such indication also demonstrates a 1.5 fold increase. Also for example, if a 2 fold decrease is indicated for a hormone or analyte by a series of diagnostic tests, such indication also demonstrates a 1.5 fold decrease.
  • the Patient-Facing Application generates a unique message 501, chosen from a series of unique messages optionally consisting of the message depicted in Fig. 5 or optionally another message, for display to the patient user via the graphical user interface, display, and/or other mediums of communication, such as e-mail, SMS, automated phone call or push notification via a smartphone graphical user interface as illustrated by Fig. 5.
  • the unique message 501 may comprise an alert to change the diagnostic test 100 to test for a different hormone and/or analyte.
  • the unique message 501 may prompt a user to record the date of onset of menstruation.
  • the unique message 501 may prompt a user to record a baseline test to facilitate comparison by subsequently performed diagnostic tests in the same cycle. In an embodiment, the unique message 501 may prompt a user to apply a sample of the user’s urine to a diagnostic test 100.
  • the Patient-Facing Application in an embodiment is configured to aggregate the results of a plurality of diagnostic tests 100, each of which is performed daily by the patient user over a number of consecutive days for aggregation into a series to associate the results from each diagnostic test 100 taken daily during the period of the number of consecutive days with the patient user, optionally for transfer to a healthcare professional user via an ePHI importer/exporter.
  • the diagnostic test 100 is performed by the patient user by applying first morning urine to the sample pad 191 (in an embodiment comprising the fluid application zone 106) of the diagnostic test 100.
  • the patient user performs the diagnostic test 100 on consecutive days during the period of 7- 10 days past ovulation and utilizes the Patient-Facing Application to record the results of each diagnostic test 100, optionally in accordance with the teachings described in United States Patent Application 16/732,766 filed on January 2, 2020, hereby incorporated by reference in its entirety with priority claimed thereto.
  • the system comprises a unique message 501 comprising instructions to the patient user to perform the diagnostic test 100 on consecutive days during the period of the patient user’s single menstrual cycle and utilizes the Patient-Facing Application, in association with at least the camera, processor and computing device, to record the results of each diagnostic test 100.
  • the application generates a unique message 501 to a user to prompt the user to initiate and utilize the application to evaluate a new diagnostic test 100 by utilizing the Patient-Facing Application on a daily basis.
  • the relevant unique message 501 is generated in the morning to remind the user to utilize first morning urine in association with the diagnostic test 100, as opposed to a urine sample taken later in the day.
  • LH tests can be performed up to 3 times per day due to short time period associated with a LH surge, in which case it is a teaching of an embodiment of the invention to incorporate enough diagnostic tests 100 to evaluate thrice daily, and to actually perform in association with steps referring to testing a fluid for LH, testing at times corresponding to first morning urine, midday, and in the evening.
  • diagnostic tests 100 to evaluate thrice daily, and to actually perform in association with steps referring to testing a fluid for LH, testing at times corresponding to first morning urine, midday, and in the evening.
  • This is particularly useful in association with examples of the invention, as some studies show that a more precise measurement of LH in association with the diagnostic test 100 configured to measure LH at a threshold is performed in the evening, as LH is higher in the evening in some women.
  • the storage may exist on the mobile computing device itself or via a communicatively connected storage device, such as, for example, cloud connected storage.
  • the application is configured to present a graph of the results over a time series on the display of the smartphone 600 or other computing device.
  • the Patient-Facing Application in an embodiment is configured to utilize the results detected by one or more diagnostic tests 100, optionally within a series of diagnostic tests performed daily during the time period correlating to a menstrual cycle, to detect a trend or trends of hormonal concentrations from one menstrual cycle to at least one other menstrual cycle or a plurality of other menstrual cycles.
  • the trends are thereby interpreted by the Patient-Facing Application, and optionally delivered to a healthcare provider via a Healthcare Professional-Facing Application and/or the telemedicine system each described elsewhere herein, to generate suggested treatment protocols.
  • a suggested treatment protocol comprises progesterone supplementation following the persistent absence of PdG as indicated on a series diagnostic tests 100 as further described elsewhere herein.
  • a suggested treatment protocol comprises the consumption of a specified amount of pumpkin and flax seeds, optionally incorporated within a single consumable food item, optionally in snack bar form, commencing upon the first day of menstrual bleeding in a menstrual cycle.
  • a suggested treatment protocol comprises the consumption of a specified amount of sesame and sunflower seeds, optionally incorporated within a single consumable food item, optionally in snack bar form, following the indication of the presence of LH at a threshold as indicated on a diagnostic test 100, as further described elsewhere herein. It is therefore a teaching of the method embodiment to perform the step of utilizing the results detected by one or more diagnostic tests to detect a trend or trends of hormonal concentrations from one menstrual cycle to at least one other menstrual cycle 8080.
  • the suggested treatment protocol generated relates to the consumption of certain seeds as described elsewhere herein. It is a further teaching of the method embodiment to perform the step of supplementing progesterone following the identified trend of the persistent absence of PdG at a threshold over a time period as indicated by a series of diagnostic tests performed on a fluid of a subject woman 8085.
  • the present inventor recognizes the need to change the subset of steps or order in which the steps are performed or repeat steps or a subset of steps in certain examples, as the results of hormonal levels associated with the menstrual cycle may overlap at various and unexpected points in the menstrual cycle.
  • the Patient-Facing Application utilizes the detected hormonal levels or trends of hormonal levels as collected by a series of diagnostic tests to generate suggestions of diet changes applicable to the patient user.
  • the suggested treatment protocol optionally associated with the “suggesting” step described in the preceding paragraph, consists of generated suggestions of diet changes. For example, the ingestion of certain seeds, due to their chemical compound composition, is well known to affect the hormone levels of a person who ingests such seeds, and it is useful to correlate the timing and/or quantity of consumption of such seeds to the results of one or more diagnostic tests 100 as described herein.
  • the application is configured to generate suggestions for the consumption of certain seeds at specified times to affect hormonal concentrations of the patient user.
  • it is a further teaching to perform the step of prompting the purchase of one or more products containing the suggested amount of seeds to ingest.
  • the prompting takes place in the form of a subscription.
  • the photographed diagnostic test 100 is shown within the graphical user interface of the Patient-Facing Application following the generation of a suggestion for the consumption of certain seeds at specified times.
  • the Patient-Facing Application is configured to facilitate the purchase by the patient user of the one or more products containing the suggested amount of seeds to ingest at a time for delivery to the patient user prior to the suggested specified time.
  • the Patient-Facing Application triggered delivery to the home or other desired location by the patient user is orchestrated in an example via FedEx, UPS, Amazon or other logistical and delivery service as well understood by those skilled in the art.
  • the Patient-Facing Application further comprises a diagnostic test capture tool, illustrated by Fig. 7.
  • the diagnostic test capture tool is configured utilize the display of a smartphone 600 to facilitate the alignment of the diagnostic test 100 within a smartphone 600 display for photographing and interpreting the results of a detected diagnostic test 100.
  • diagnostic test 100 comprises a lateral flow assay comprising at least a testing zone configured to detect for the presence or absence of PdG at a threshold, the threshold optionally selected from the range inclusive of 1 pg/mL-10 pg/mL, as further described elsewhere herein.
  • the diagnostic test 100 comprises multiple testing zones, each configured to evaluate for the presence or absence of a single hormone or analyte, wherein one testing zone is configured to evaluate for the presence or absence of PdG at a threshold selected from the range inclusive of 1 pg/mL-10 pg/mL, as further described elsewhere herein.
  • the diagnostic test capture tool further comprises a stand 610 configured to hold a diagnostic test 100 in position during capture of a photograph in association with the Camera and the display 605 of the smartphone 600.
  • the stand 610 comprises markings 615 of a specified distance apart to aid in the calculation of the dimensions of the diagnostic test 100 held by the stand 610.
  • the interpretation of results of the diagnostic test 100 held by the stand 610 occurs in accordance with the teachings elsewhere herein associated with the specific sequence of result indication lines each corresponding to a specific testing zone each configured to evaluate for the presence of a specific hormone and/or analyte.
  • the interpretation of results of the diagnostic test 100 held by the stand 610 occurs in accordance with the teachings elsewhere herein associated with the specific distance of each result indication line from one end of a diagnostic test 100, optionally calculated by a Processor detecting the markings 615 on a stand 610 photographed by the smartphone 600 and comparing the predetermined distance between the markings 615 to the diagnostic test 100 held by the stand 610 to assist with the determination of the specific dimensions of the diagnostic test 100, optionally by counting the specific number of pixels contained in a straight line between the markings 615 and then allocating the pre-determined distance between the markings to that number of specific pixels to allocate a specific width to a pixel, and subsequently counting the number of pixels and allocating the specific width to each pixels to determine a result for the distance between the photographed edge of a diagnostic test 111 and one or more of the first testing zone, second testing zone, third testing zone, fourth testing zone, first result indication line 107, second result indication line 108, third result indication line 109, and fourth result indication line 110, to determine
  • the Patient-Facing Application works in association with the diagnostic test 100 capture tool to facilitate the capture of the diagnostic test 100 and the interpretation of results. Such results may then be utilized by the Processor and other components of the system to provide information to the graphical user interface related to the results, including treatment strategies and/or suggested treatment protocols, optionally comprising diet changes, optionally in accordance with the teachings and methods described elsewhere herein.
  • the Patient-Facing Application incorporates the Telemedicine System as described elsewhere herein, and is thus configured to allow a patient user to access available appointment times of healthcare professionals capable of treating medical conditions that may be suggested by the results of a diagnostic test or series of diagnostic tests captured and interpreted via the Patient-Facing Application.
  • the Patient- Facing Application in an example incorporates a graphical user element configured to allow the patient user to set the patient’s jurisdiction of residence 630, optionally within a graphical user interface as illustrated in Fig. 9.
  • the Patient-Facing Application is configured to facilitate the operation of the Telemedicine System within its graphical user interface, for instance via a graphical user interface element configured to allow a patient user to schedule a healthcare provider consultation 631, and optionally via a separate graphical user interface element configured to export information derived from the patient’s collected diagnostic test results 632 as depicted on Fig. 9, which may include the packaging and delivery of results of one or more diagnostic tests 100 collected via the Patient-Facing Application in association with other components of the system and/or other electronic personal health information to one healthcare professional or a plurality of healthcare professionals in an interoperable format in accordance with the teachings elsewhere herein.
  • the Patient-Facing Application is further configured to receive and distribute results from a sexual partner, optionally the results of a sexual partner’s sperm test or plurality of sperm tests, and optionally in association with information triggered for export by the patient user as described herein, for further interpretation by a healthcare professional.
  • the Patient-Facing Application incorporates the Seed Consumption System as described elsewhere herein, and is correspondingly configured to provide suggestions of the consumption of certain seeds and/or products containing certain seeds based on the interpreted results of a diagnostic test or series of diagnostic tests captured and interpreted via the Patient-Facing Application.
  • the Patient-Facing Application is configured to facilitate the operation of the Seed Consumption System described elsewhere herein within its graphical user interface.
  • the Patient-Facing Application is configured to provide suggestions, optionally in the form of suggested treatment protocols, for the consumption and/or supplementation of progesterone of a specific amount, optionally in droplet format and optionally in association with the triggering of a purchase and delivery of the progesterone, in response to a detected indication for the absence of pregnanediol glucuronide generated in association with a diagnostic test as described elsewhere herein.
  • such suggestions are delivered to a patient user each as a unique message 501 as illustrated by Fig. 5.
  • progesterone supplementation occurs in coordination with a progesterone supplement system.
  • An embodiment of the invention comprises a progesterone supplement system.
  • the progesterone supplement system comprises a plurality of diagnostic tests configured to detect for the presence or absence of LH at a threshold as defined herein, and a plurality of diagnostic tests configured to detect for the presence or absence of PdG at a threshold as defined elsewhere herein.
  • the progesterone supplement system further comprises a plurality of progesterone supplement doses.
  • each progesterone supplement dose contains a quantity of progesterone selected from the range of 25-35 mg.
  • each dose is formulated in an oil suspension.
  • An exemplary oil for use in association with the oil suspension is coconut oil or MCT oil.
  • the oil comprises mixed tocopherols (vitamin E).
  • the present inventor has recognized that by formulating the progesterone with vitamin E in the form of a progesterone supplement dose, the vitamin E acts as a carrier to deliver the progesterone directly into the blood stream and quickly.
  • the steps of formulating each progesterone supplement dose include adding 5-10% weight by volume of Vitamin E (also referred to as “mixed tocopherols”) with 90-95% weight by volume on MCT oil or coconut oil.
  • the present inventor by testing various steps has likewise determined a preferred method of progesterone supplementation in association with the progesterone supplement doses.
  • a user engages in the step of testing, on a daily basis, for the presence or absence of LH in a bodily fluid at a threshold via a diagnostic test as defined elsewhere herein 3450.
  • the user engages in applying a progesterone supplement dose containing 25-35 mg of progesterone formulated in an oil suspension to the membranes of the mouth three times for a period of at least 7 days or the period until the start of the next menstrual cycle, whichever is longer 3451.
  • the present inventor has determined the enhanced effectiveness of this form of progesterone supplementation, particularly in comparison to other forms of over-the-counter progesterone supplementation, in that progesterone applied in this manner is better absorbed into the blood stream.
  • the method may further comprise steps of testing, during the period of 7-10 days past ovulation, for the presence or absence of PdG in the bodily fluid with a diagnostic test comprising a testing zone and corresponding result indication line configured to detect for PdG at a threshold selected from the range of 1 pg/mL-10 pg/mL 3452; and Applying a quantity of 75-105 mg of progesterone formulated in an oil suspension to the membranes 193 of the mouth on a daily basis during the subsequent menstrual cycle if any of the diagnostic tests comprising a testing zone and corresponding result indication line configured to detect for PdG and provide a result indicating the absence of PdG on any of the days during the period of 7-10 days past ovulation (optionally by instruction generated in association with the
  • an interpretation 607 deriving from the result of a diagnostic test 100 as described elsewhere herein, optionally comprising an interpretation 607 collected in association with the Fertility Tracking System and/or methods of use of the Fertility Tracking System as described elsewhere herein, optionally collected in association with the Patient-Facing Application, is displayed to the user via the display 605, optionally the display
  • a prompt 606 or plurality of prompts in association with the Fertility Tracking System and/or methods of use of the Fertility Tracking System as described elsewhere herein is delivered to a patient user via the graphical user interface of the Patient- Facing Application, optionally each as a unique message 501.
  • a prompt 606 or other aspects of the Patient Facing Application are configured for delivery to a display 605 integrated within a cartridge containing a lateral flow assay 660 as illustrated by Fig. lOd, or the display 605 of a digital reader 670 configured to evaluate a lateral flow assay by placement of a cartridge containing a lateral flow assay 660 therein as illustrated by Fig. 10b, optionally in association with the other electronic components of the cartridge containing a lateral flow assay 660 and/or the digital reader 670.
  • a computing device is useful in capturing, processing and storing the results indicated by one or more diagnostic test(s), along with the demographic information of a specified subject woman and associated suggested treatment protocols, configured as described elsewhere herein.
  • the computing device consists of a smartphone 600.
  • the term “smartphone” is defined as a mobile phone that performs many of the functions of a personal computer, typically having a touchscreen interface, internet access, and an operating system capable of running downloaded applications.
  • a smartphone 600 may be defined more broadly as a mobile telecommunications device.
  • the smartphone 600 consists of either an Apple iPhone or Google Android device.
  • the smartphone 600 is configured to operate a version of the iOS or Android operating systems.
  • the computing device is operated in association with an application, optionally the Patient-Facing Application further configured to incorporate mechanisms to control, collect data from or otherwise interact with the computing device.
  • the computing device consists of a personal computer.
  • the computing device comprises a server or communicatively other connected computer accessed via the internet via a smartphone 600 or local personal computer.
  • the Patient-Facing Application or Healthcare Professional-Facing Application may be operated by a patient user, optionally consisting of a subject woman whose bodily fluid has been applied to at least one diagnostic test 100 as referred to elsewhere herein, or a healthcare professional user as applicable via a web browser in accordance with mechanisms and methods well understood by those skilled in the art.
  • the computing device consists of the system described in United States Patent Application 16/302,085 filed on May 19, 2017, incorporated by reference herein.
  • the computing device consists of the system described in PCT Patent Application PCTVUS2019/038173 filed on June 20, 2019, incorporated by reference herein.
  • the computing device incorporates and/or controls storage, at least one processor and at least one camera.
  • the Patient- Facing Application and Healthcare Professional-Facing Application are each configured to operate upon the operating system of the computing device in accordance with mechanisms and procedures well understood by those skilled in the art.
  • the computing device comprises a cloud system configured to communicatively connect with a smartphone 600 for interpretation and analysis of the data collected from a diagnostic test 100 in association with a photograph of the diagnostic test 100 taken and interpreted by the smartphone 600 as more comprehensively described elsewhere herein.
  • the camera configured to collect the results of the diagnostic test. This is especially the case when recording an image of a diagnostic test via a computing device operated by a layperson in association with the systems and methods as described elsewhere herein.
  • the camera consists of a camera integrated into a smartphone 600 as is well understood in the art.
  • the camera is incorporated into a cartridge also housing a diagnostic test 100, or in a digital reader 670 configured to receive and interpret a diagnostic test 100 placed within the digital reader 670.
  • the camera of the system is incorporated within a smartphone 600 or tablet computer operating the Patient-Facing Application.
  • the system comprises a smartphone 600, mobile telecommunications device, or tablet computer featuring both a rear-facing or front-facing camera. It is the intent of the inventor that any camera of a smartphone 600 configured with multiple cameras may be utilized in association with the system as described herein.
  • the camera associated with the system is utilized to photograph the lateral flow assay
  • the processor associated with the system is utilized to interpret the color within each of a plurality of result indication lines on the lateral flow assay
  • the processor associated with the system is configured to interpret the intensity of the color within each of a plurality of result indication lines on the lateral flow assay to determine a result
  • the result is associated with the date the camera photographed the lateral flow assay
  • the result is stored in the communicatively connected storage medium, and optionally displayed in a calendar format via a graphical user interface.
  • the determining a result step is performed by photographing, via a camera integrated within a smartphone 600, the diagnostic test 1000, optionally comprising a lateral flow assay test.
  • the Patient Facing Application is preconfigured to identify, optionally by identifying the shape of the diagnostic test 100 depicted in a photograph captured by the camera, and measuring the distance from one end 111 or both ends of the diagnostic test 100, and in association with the Processor and distances that the Patient Facing Application is pre-configured to associate with one or more result indication line(s) each configured to evaluate for the presence or absence of a distinct hormone or analyte at a threshold.
  • the collection of a photograph in an optimal fashion is optionally by utilization of an alignment mechanism displayed within the display of a smartphone 600 as depicted in Fig. 7 to allow a user of the Patient Facing Application to align the test in a useful manner to aid in the determination of the distance to and identification of each result indication line on the lateral flow assay to be photographed.
  • the user is prompted to align one end 111 of the diagnostic test 100 with an element in the graphical user interface to facilitate the identification and measurement of the diagnostic test 100.
  • the lateral flow assay test referred to in such step optionally consists of a single test configured to simultaneously or near-simultaneously detect for the presence or absence of a plurality of hormones or hormonal analytes selected from the group consisting of pregnanediol glucuronide, luteinizing hormone, an estrogen metabolite such as E3G, FSH, estradiol, progesterone and human chorionic gonadotropin 2023.
  • hormones or hormonal analytes selected from the group consisting of pregnanediol glucuronide, luteinizing hormone, an estrogen metabolite such as E3G, FSH, estradiol, progesterone and human chorionic gonadotropin 2023.
  • an optical sensor of the disclosure can have several components, including 1) a raw camera sensor; 2) LED lights; 3) a microcontroller; 4) an aperture; 5) a shutter; and 6) a simple optical lens.
  • an optical sensor of the disclosure can have an optical system comprising of a fluid (e.g. poly(dimethylsiloxane) (PDMS)) or solid (e.g., glass) material lens and a complementary metal-oxide semiconductor (CMOS) or a charge-coupled device (CCD) image sensor.
  • a fluid e.g. poly(dimethylsiloxane) (PDMS)
  • CMOS complementary metal-oxide semiconductor
  • CCD charge-coupled device
  • the optical sensor can also use an orientation element located on the lateral flow device to locate the one or more result indication lines and the control line.
  • An optical sensor in an embodiment comprises a high-resolution camera configured to take an image of at least one result indication line and the control line of the diagnostic test 100.
  • the optical sensor can be a countertop device, a stand-alone device, the optical sensor module as described in PCT Patent Application PCT/US2019/038173 filed on June 20, 2019, incorporated by reference herein, the “detection instrument” as described in United States Patent Application 16/302,085 filed on May 19, 2017, incorporated by reference herein, or a smartphone camera.
  • the optical sensor may be contained within an apparatus intended for use apart from the diagnostic test 100, such as the digital reader 670 depicted in Fig 10b.
  • the optical sensor is contained within an apparatus sharing a containment mechanism with the diagnostic test 100, such as a cartridge 660, as depicted in Fig. lOd.
  • the camera is configured to collect one or more optical signals each originating from a distinct result indication line of a diagnostic test 100, optionally in coordination with the processor.
  • the camera is configured to receive a plurality of optical signals each originating from one of a plurality of result indication lines in coordination with mechanisms to measure the length to and sequence of each result indication line and match the result indicated by each result indication line, optionally via a Diagnostic Test Key, as described elsewhere herein.
  • the camera is configured to work in conjunction with the processor and/or other elements of a system to determine an amount of at least a first analyte, optionally the presence or absence of the first analyte at a threshold, and a second analyte, optionally the presence or absence of the second analyte at a threshold, in a biological sample applied to the fluid application zone 106 based on said optical signals, wherein an optical signal associated with the first result indication line 107 increases with decreasing amounts of said first analyte present in said biological sample, and an optical signal associated with the second result indication line 108 increases with increasing amounts of said second analyte present in said biological sample.
  • the RGB or HEX color codes associated with specific quantities of a hormone or hormone analyte are determined prior to use of the diagnostic test 100, optionally by applying spiked male urine containing pre-measured quantities of a hormone or hormone analyte as described elsewhere herein, and the RGB or HEX color codes associated with each indication for each quantity are recorded, optionally in association with the color intensity key and/or the diagnostic test key 200.
  • the “R” values associated with the “RGB” color codes are depicted as an example.
  • the quantity of a hormone or hormone analyte is determined by finding the closest RGB color code or HEX color code to the RGB color code or HEX color code pertaining to the color evident on a result indication line following the application of a fluid to a diagnostic test 100, and then estimating the quantity of the relevant hormone or hormone analyte or the presence or absence of a hormone or hormone analyte based upon the pre-measured quantity of the hormone or hormone analyte associated with said closest RGB color code or HEX color code, optionally as indicated on the color intensity key and/or diagnostic test key 200.
  • the camera may operate in coordination one or more light sources forming a part of the disclosure for illuminating the diagnostic test 100 or at least the first result indication line 107 of the diagnostic test 100 configured to detect for at least the presence or absence of pregnanediol glucuronide at a threshold selected from within the inclusive range of 1 pg/mL-10 pg/mL, or as further described in United States Patent Application 16/732,766 filed on January 2, 2020, hereby incorporated by reference with claim of priority made thereto.
  • “storage” as referred to herein refers to any technology used to place, keep and retrieve electronic data.
  • “Communicatively connected storage medium” as referred to herein refers to a medium within a computing device, such as a solid-state drive contained within a smartphone 600, but may alternatively refer to cloud storage in which data is transmitted and stored on remote storage systems, where it is maintained, managed, backed up and made available to users over a network (typically the internet) as is well understood by those skilled in the art.
  • the electronic personal health information, photographs of one or more diagnostic test(s) 100, results of one or more diagnostic test(s) 100, and/or any information relevant to a healthcare professional user or a patient user is stored within storage, which in an example consists of one or more communicatively connected storage medium(s).
  • processor or plural term “processors” generally refer to the electronic circuitry within a computing device that executes instructions that make up a computer program and/or application as well understood by those of skill in the art.
  • the processor consists of a cloud computing mechanism operating in conjunction with a smartphone as is well understood by those skilled in the art.
  • the processor consists of one or more processors of a smartphone 600 utilized in association with the system described herein.
  • the diagnostic test 100 configured to evaluate urine for the presence or absence of at least pregnanediol glucuronide at a threshold selected from the inclusive range of 1 pg/mL-10 pg/mL comprises at least the first result indication line 107 configured such that, optionally when used with a base unit, a first optical signal (e.g., a fluorescent signal) is capable of being detected at the first result indication line 107.
  • a first optical signal e.g., a fluorescent signal
  • the location of the first result indication line 107 and/or one or more other result indication lines is determined by a predefined sequence made available for use by the system, by a measurement of the diagnostic test 100 to determine the pre-programmed location of each result indication line as described elsewhere herein.
  • the first optical signal may be a readout for the amount of pregnanediol glucuronide in the sample, for example, by detecting the amount of first detection reagent, in an example comprising the colloidal gold-labeled PdG antibody, bound to the first capture reagent, in an example comprising the PdG-BGG conjugate, by correlating the color intensity of the first optical signal developed to a pre-determined measurement of the level of pregnanediol glucuronide correlating to the color intensity.
  • the average or median color intensity and/or RGB or HEX color code is determined by sampling a plurality of pixels contained within one result indication line to collect the result, optionally for incorporation the Diagnostic Test Key 200 and/or the color intensity key 800 to associate a specific color intensity, RGB color code or HEX color code with a quantity of hormone or hormone analyte present in the diagnostic test 100.
  • the average or median color intensity and/or RGB or HEX color code is collected for each of a plurality of tests, and then the average or median color intensity and/or RGB color code or HEX color code is then determined for the plurality of tests to determine a result, optionally for incorporation the Diagnostic Test Key 200 and/or the color intensity key 800 to associate a specific color intensity, RGB color code or HEX color code with a quantity of hormone or hormone analyte present in the diagnostic test 100.
  • An exemplary color intensity key 800 is depicted by Fig.
  • a single color intensity key 800 may provide associations with multiple color intensity combinations, whereby each color intensity optionally associated with a specific sequence or location coordinate as determinable by calculating the distance of the indication from one end 111 of a diagnostic test 100, correlating to multiple hormones and/or analytes.
  • a similar protocol is likewise used for one or more result indication line(s) configured to evaluate alternative hormones and analytes. It is a teaching of an embodiment in the preferred embodiment to utilize only diagnostic tests 100 in association with the methods described herein that were manufactured according to standardized manufacturing protocols in a similar manner to those utilized to create the color intensity key 800.
  • each of the plurality of diagnostic tests similarly configured to a diagnostic test 100 intended for subsequent real-world use is applied with a sample of male urine, each containing a specified quantity of precisely measured added amount of pregnanediol glucuronide.
  • each such sample may be referred to as a male urine sample spiked with pregnanediol glucuronide.
  • the intensity of each such sample is measured and optionally re-measured, and the average color intensity displayed across all diagnostic tests for which a male urine sample spiked with a standardized amount of pregnanediol glucuronide is associated with the standardized amount of pregnanediol glucuronide in association with evaluation purposes.
  • color intensity as referred to herein may also refer to or correspond to a specific RGB color code or HEX color code.
  • the present inventor has recognized the usefulness of the step of utilizing a plurality of color intensity keys each correlating to a specific hormone or analyte in a distinct result indication line in a specific diagnostic test 100 configuration.
  • the color intensity key facilitates the ability to determine one or more results from a diagnostic test 100, as the color intensity key applied in conjunction with the predetermined distances of each result indication line and/or the sequence of the hormone and/or analyte tested within each result indication line, determinable on a photographed diagnostic test 100 in association with the teachings as described elsewhere herein, facilitates the identification of both the hormone and/or analyte tested and the amount of the hormone and/or analyte indicated within the relevant result indication line.
  • the sequence of hormones/and or analytes associated with each result indication line is made available for evaluation in association with the relevant color intensity key to determine the amount of hormone and/or analyte precisely associated with each result indication line of the diagnostic test 100.
  • the color intensity key 800 and the sequence of hormones/and or analytes or the distance of each result indication line and the associated hormone and/or analyte of each result indication line, are programmed into the Patient-Facing Application or a digital reader 670 to facilitate the detection of each color intensity indicated within a result indication line on the diagnostic test 100.
  • the Patient-Facing Application in an example is also configured to interpret of the results of a diagnostic test 100 by selecting the closest matching color intensity on the color intensity key 800 for each detected indication within each of the result indication lines, and deriving the previously determined amount of hormone or analyte correlating to that closest matching color intensity as associated to the hormone or analyte associated with the relevant result indication line.
  • the color intensities associated with their correlated standardized amounts of pregnanediol glucuronide, optionally aggregated into a color intensity key 800, may be displayed on the Diagnostic Test Key for utilization in association with interpreting the diagnostic test 100 in an example.
  • the color intensity key 800 is utilized in association with a processor configured to compare the color intensity of a photographed diagnostic test with the closest color intensity indicated on the color intensity key 800 correlated to a previously determined amount of pregnanediol glucuronide correlating to the closest color intensity as to provide an estimation of the amount of pregnanediol glucuronide.
  • the processor is configured to evaluate a photographed diagnostic test 100 to which a fluid sample has been applied to compare the color intensity of the evident color within a result indication line of that diagnostic test 100 to the color intensity that the result indication line would exhibit at the threshold associated with that result indication line, to aid in determining a result for the presence or absence of the relevant hormone or hormone analyte at the threshold.
  • a diagnostic test 100 configured to evaluate urine for the presence or absence of pregnanediol glucuronide following the application of a male urine sample spiked with pregnanediol glucuronide in a specific amount selected from the inclusive range of 1 pg/mL-10 pg / mL (also referred to as the “Threshold Concentration”), and set the measured color intensity as the Threshold Color Intensity for the interpretation of similarly manufactured diagnostic tests, and optionally indicate the threshold color intensity on a color intensity key 800 and/or a diagnostic test key 200 for subsequent testing purposes.
  • Threshold Concentration and Threshold Color Intensity is only relevant in various configurations to the result indication line configured to detect for the presence of pregnanediol glucuronide, and specifically not necessarily relevant to other result indication lines configured to detect for the presence of other hormones or hormone metabolites.
  • a diagnostic test 100 is configured with a first result indication line 107 having the Threshold Color Intensity, wherein when the first result indication line 107 exhibits a color intensity less than the Threshold Color Intensity (for example, by the evident absence of a visually perceptible line), the associated interpreted indication is that of a positive result for pregnanediol glucuronide at the Threshold Concentration.
  • a processor configured to operate in conjunction with the other elements of the system as described herein configured to evaluate a diagnostic test 100 to which a fluid sample has been applied to compare the color intensity of at least the first result indication line 107 with the Threshold Color Intensity, and then based on the comparison, determine a result for the presence or absence of pregnanediol glucuronide at the Threshold Concentration and then optionally display the result via a graphical user interface or as a unique message 501 as described elsewhere herein.
  • the color intensity of one or more separately collected optical signals collected from the same diagnostic test 100 provides an indication or a plurality of indications for the presence or absence of one or more additional hormones and/or analytes.
  • the processor is configured in accord with the teachings herein to utilize the one or more separately collected optical signals to interpret an additional result or additional results indicated by the diagnostic test 100.
  • the color intensity of the optical signal obtained from the first result indication line 107 configured to analyze for the presence or absence of pregnanediol glucuronide at a threshold increases in intensity when the amount of pregnanediol glucuronide present in the sample is lower, and such optical signal decreases in intensity when the amount of pregnanediol glucuronide present in the sample is higher.
  • the optical signal obtained from within the first result indication line 107 configured to analyze for the presence or absence of pregnanediol glucuronide is inversely proportional to the amount of pregnanediol glucuronide in the fluid sample applied to the diagnostic test 100 containing the first result indication line 107.
  • the diagnostic test 100 further comprises at least a second result indication line 108 configured to produce an optical signal likewise corresponding to the presence or absence of a second analyte or hormone at a threshold, optionally luteinizing hormone (LH), wherein the optical signal obtained from within the second result indication line 108 configured to analyze for the presence or absence of luteinizing hormone is directly proportional to the amount of luteinizing hormone in the fluid sample applied to the diagnostic test 100 containing the second result indication line 108.
  • the diagnostic test 100 is configured for utilization in conjunction with a base unit or digital reader 670 as described elsewhere herein and in various applications incorporated by reference herein, together comprising a system embodiment.
  • a system comprising: a housing, comprising: a) a port for receiving an diagnostic test 100, the diagnostic test 100 comprising two or more result indication lines each corresponding to a testing zone of the conjugate pad 190, one result indication line of which is configured to provide an indication of the presence or absence of pregnanediol glucuronide at a threshold of a specific amount selected from the inclusive range of 1 pg/mL-10 pg / mL; b) a reader, comprising: i) one or more light sources for illuminating said two or more result indication lines; ii) one or more light detectors, optionally consisting of a camera or cameras as described elsewhere herein, configured to detect optical signals from each of the two or more result indication lines; and c) a data analyzer comprising one or more processors configured to receive the optical signals in association with other components of the system as described elsewhere herein and to determine for the presence or absence of pregnanediol glu
  • An exemplary system may include a housing for containing components as described elsewhere herein, optionally configured as illustrated in Fig. 10b.
  • the housing can be constructed of any suitable material.
  • the housing may be configured to receive a lateral flow assay configured to detect for at least the presence or absence of pregnanediol glucuronide as described elsewhere in the disclosure.
  • the housing may include a port or opening for receiving a diagnostic test 100, optionally contained within a cartridge.
  • the system may further include, optionally contained within the housing, a reader device.
  • the reader device in an embodiment comprises the camera as described elsewhere herein and the processor configured to interpret the results of the diagnostic test 100 as described elsewhere herein.
  • the reader device may include one or more light sources for illuminating the diagnostic test 100 or a first result indication line 107 configured to detect for at least the presence or absence of pregnanediol glucuronide.
  • the one or more light sources are calibrated to generate a light wavelength suitable to illuminate a detectable label, optionally a fluorescent label or colloidal gold, providing an indication of whether pregnanediol glucuronide is present or absent at a threshold within the first result indication line 107.
  • the detectable label provided on the immunoassay device is a fluorophore
  • the one or more light sources of the reader device should include a fluorescent light source (e.g., a light-emitting diode (LED)).
  • a fluorescent light source e.g., a light-emitting diode (LED)
  • the wavelength of light provided by the light source of the reader device should be selected based on the excitation wavelength of the detectable label, and can readily be selected by a person of skill in the art.
  • the reader may be configured to illuminate the both the first result indication line 107 configured to provide an indication for the presence or absence pregnanediol glucuronide in a sample applied to the diagnostic test 100, and a second result indication line 108, each at a wavelength of light calibrated to accurately obtain the optical signal from each label, optionally at separate wavelengths.
  • the reader is configured to scan across the diagnostic test 100, comprising a test strip of an immunoassay device. In such cases where the immunoassay device utilizes a single fluorophore, the reader may contain a single fluorescent light source. In cases where the immunoassay device utilizes more than one fluorophore, the reader may contain more than one fluorescent light source.
  • the processor is configured to interpret the optical signals obtained from within each result indication line and discern among the wavelengths to generate a result.
  • the interpretation is made with the assistance of the color intensity key 800, wherein the color intensity key 800 is pre-configured to indicate the presence of specified quantities of hormones and/or analytes following the application of fluorescent light from the fluorescent light source to the immunoassay device utilizing at least one fluorophore based upon the evident color intensity (ies).
  • the reader may further comprise one or more light detectors (e.g., a photodetector) for detecting optical signals from the diagnostic test 100.
  • the one or more light detectors should be capable of distinguishing between emitted light at a first discrete position and a second discrete position on the diagnostic test 100. This may be accomplished by, e.g., the one or more light sources scanning across the diagnostic test 100 and determining the position of the emitted light on the diagnostic test 100.
  • the data analyzer may have one or more processors configured to receive an optical signal.
  • the data analyzer is in operable communication with a reader device, optionally as described in as described in PCT Patent Application PCT/US2019/038173 filed on June 20, 2019, incorporated by reference herein, the “detection instrument” as described in United States Patent Application 16/302,085 filed on May 19, 2017, incorporated by reference herein.
  • the reader device is programmed to utilize the color intensity key 800 to interpret detected results.
  • the data analyzer may be configured to determine an amount of analyte or hormone present in an applied fluid sample, for example, by measuring the intensity of an optical signal obtained from within a result indication line of a diagnostic test 100 configured to detect for the presence or absence of pregnanediol glucuronide, optionally in association with the color intensity key 800.
  • the data analyzer may be configured to calculate the area under the curve of a signal intensity plot.
  • the data analyzer may further be configured to determine the differences between signal intensities among the multiple discrete result indication lines or regions on the diagnostic test 100, each optionally providing an optical signal deriving from a different wavelength of light.
  • the data analyzer may be configured to determine the difference between the signal intensity at the first result indication line 107 of a diagnostic test 100 and the signal intensity at the second result indication line 108 to provide a result.
  • each result is collected by evaluating the difference in intensity between the optical signal within a result indication line and the optical signal collected from another aspect of the diagnostic test 100 and determining whether the difference in color intensity exceeds a threshold.
  • the difference of color intensity between the control line 105 and a result indication line of a separate diagnostic test of a similar configuration following the application of a male urine sample spiked with pregnanediol glucuronide at a threshold is measured to provide a threshold difference for subsequent use, optionally for use in association with a Diagnostic Test Key 200 and/or color intensity key 800.
  • the threshold difference then previously obtained from the separate diagnostic test 100 of a similar configuration is compared by the data analyzer to determine any difference in a diagnostic test 100 to which a fluid sample is applied for testing, and if the difference in color intensity of the diagnostic test 100 to which a fluid sample is applied exceeds the threshold difference, then a positive result for pregnanediol glucuronide in the applied sample is determined by the data analyzer in the embodiment. In the case that the difference does not exceed the threshold difference in the embodiment, a negative result for pregnanediol glucuronide in the applied sample is determined by the data analyzer.
  • the data analyzer then generates and transmits the result to other components of the system, optionally including the display 605, by mechanisms as readily understood by those skilled in the art.
  • the data analyzer may further be configured to calculate an amount or concentration of the analytes present in the sample by similar mechanisms.
  • the data analyzer may be further configured to detect a binary optical pattern.
  • the binary optical pattern can be generated by two fluorescent materials which excitation and/or emission spectrum differs in wavelength.
  • the binary optical pattern can be generated by one fluorescent material and one light absorbent material.
  • the detection reagents may be conjugated with the two types of materials respectively and can be captured in the same result indication line, such that the result indication line may generate two different optical signal patterns in the data analyzer.
  • the system may comprise a housing 670 for containing the processor and/or other electronic components, such as those depicted in Fig. 10b. The encasement of Fig.
  • the lOd may also be characterized as a housing for purposes in accordance with the teachings herein.
  • the housing in an example consists of a top housing and a bottom housing.
  • the top housing in an example comprises a display 605 for indicating the results of the diagnostic test 100, as depicted in Fig. lOd, providing an indication at least for the presence or absence of pregnanediol glucuronide, said indication obtained by mechanisms as described elsewhere herein.
  • the system and/or its processor may further comprise a display cover.
  • the system may further comprise a battery.
  • the system and/or its processor in an embodiment comprises a circuit board containing electronic components.
  • the system and/or its processor in an embodiment further comprises an optomechanics module.
  • the optomechanics module in an embodiment comprises the one or more light sources and one or more light detectors as described elsewhere herein.
  • the optomechanics module comprises the optical sensor module as described in PCT Patent Application PCT/US2019/038173 filed on June 20, 2019, incorporated by reference herein, or the “detection instrument” as described in United States Patent Application 16/302,085 filed on May 19, 2017, incorporated by reference herein.
  • the optomechanics module is configured in an embodiment as comprising the one or more light sources for illuminating the diagnostic test 100 configured to detect for at least the presence or absence of progesterone or a progesterone analyte.
  • the optomechanics module in an embodiment is movable across an optical axis such that the optomechanics module moves laterally across the diagnostic test 100 to detect for at least the presence or absence of pregnanediol glucuronide by enabling alignment with the relevant result indication line of the diagnostic test 100.
  • the system may further comprise an actuation module.
  • the actuation module may comprise one or more motors configured to actuate/move the optomechanics module.
  • the motors may be coupled to a rack and pinion mechanism that is configured to translate the optomechanics module along one or more directions.
  • the optomechanics module can be translated along a longitudinal axis of the diagnostic test 100.
  • the direction(s) of translation may or may not be orthogonal to an optical axis of the optomechanics module.
  • the optomechanics module comprises, contains or is communicatively linked to the camera as described elsewhere herein.
  • the direction(s) of translation may be parallel to the longitudinal axis of the diagnostic test 100, and the optical axis may be orthogonal to the longitudinal axis or a planar surface of the diagnostic test 100.
  • the direction(s) of translation need not be parallel to the longitudinal axis of the diagnostic test 100, and the optical axis need not be orthogonal to the longitudinal axis (or a planar surface) of the diagnostic test 100.
  • the direction(s) of translation and/or the optical axis may be at an oblique angle relative to the longitudinal axis of the diagnostic test 100.
  • the system and/or its processor may include an optical configuration suitable for use with the diagnostic test 100 and positioning of the optics above a result indication line configured to detect for at least the presence or absence of pregnanediol glucuronide.
  • the optical configuration may include a light source (e.g., a light- emitting diode (LED) for illuminating the diagnostic test 100.
  • the optical configuration may further include one or more lens, a filter, a optical beamsplitters, or any combination thereof.
  • the optical configuration may further include a photodetector for detecting an optical signal from the diagnostic test 100.
  • the system is configured to an excitation/emission spectra with an excitation wavelength of 492 nm and an emission wavelength of 512 nm.
  • the processor is configured to perform an evaluation on the diagnostic test 100 to obtain a result by comparing the color intensity indicated on the diagnostic test 100 to at least one color intensity associated with a color intensity key 800 to derive the closest color intensity and retrieve the associated hormone or analyte concentration. This may be accomplished, for example, by utilizing the camera to calculate and detect the distance of one or more result indication line(s) from the proximal end of the diagnostic test by matching the dimensions with pre-determined diagnostic test 100 proportions, and detecting the evident color intensity(ies) within the result indication line(s) contained in the diagnostic test 100 at specified locations by comparing the evident color intensity(ies) to the color intensity(ies) included within the color intensity key 800 and/or the Diagnostic Test Key 200.
  • the processor may be configured to detect the dimensions of the diagnostic test 100 via a camera in association with a preconfigured known height of the diagnostic test 100.
  • the processor is configured to extrapolate the measurements of the length of the diagnostic test 100 by normalizing the height of the diagnostic test 100 as photographed to a pre-determined height and performing the appropriate mathematical equations (for example, the Pythagorean equation) to determine the length of the diagnostic test 100, and in particular to determine the length distance from one end 111 to one or more result indication line(s) located on the diagnostic test 100 and the length distance from the proximal end to the control line 105 located on the diagnostic test 100.
  • the appropriate mathematical equations for example, the Pythagorean equation
  • the processor is configured to evaluate for to detect the color intensity evident within one or more result indication line(s) located at a predetermined distance or distances from the one end 111 of the diagnostic test 100 in a predetermined sequence, and compare the color intensity evident within each result indication line(s) to the closest known color intensity with an associated known concentration corresponding to a quantity of the relevant hormone or hormonal analyte to determine the indicated result or results, the indicated result or results optionally indicating the presence or absence of one or more hormones and/or hormonal analytes at a threshold.
  • the processor is then configured to store and display the indicated result or results in coordination with the other inventive elements as described herein.
  • the processor is communicatively linked to the other components of the system to collect and transmit signals and/or the indicated result(s) to the other components as needed to enable functioning of the system as is well understood by those skilled in the art.
  • the display 605 consists of the screen of a smartphone 600 or a tablet computer.
  • the display 605 consists of a screen incorporated within a cartridge, as depicted in Fig. lOd.
  • the display 605 consists of a screen incorporated within a digital reader 670 or base unit, as depicted in Fig. 10b.
  • the display is configured to make visible a graphical user interface to a user.
  • the display is integrated with pressure-sensitive digitizers, such as the Apple Force Touch system.
  • the display 605 comprises the display as described in PCT Patent Application PCT/US2019/038173 filed on June 20, 2019, incorporated by reference herein, or the display as described in United States Patent Application 16/302,085 filed on May 19, 2017, incorporated by reference herein.
  • the display is configured as a small screen placed within a housing or cartridge also containing a diagnostic test 100 such as that illustrated by Fig. lOd.
  • the system comprises a graphical user interface.
  • the graphical user interface is configured in accordance with mechanisms as well understood by those in the art to operate on a display 605.
  • the processor may the graphical user interface to present one result or a series of results, and/or one or a series of unique message(s) 501 to a user within a graphical user interface, optionally via the Patient-Facing Application, such as is illustrated by Fig. 9.
  • results and/or one or a series of unique message(s) 501 are also presented to a separate user via a graphical user interface operating in conjunction with the Healthcare Professional Facing Application.
  • the graphical user interface is configured to operate on a smartphone 600, a personal computer, a tablet, or within a web browser operating on another such device.
  • the various phases of the menstrual cycle for instance menstruation, the follicular phase and the luteal phase, are indicated by color coding the days associated with each phase as indicated based on the results or indications of one or more diagnostic test(s) 100.
  • a listing of available times to consult with a healthcare professional located in the same jurisdiction as the detected location of the user 900 of the Patient-Facing Application optionally detected by utilizing the GPS of the smartphone 600, displayed in order of available dates starting with the nearest available date within a graphical user interface operating in conjunction with the Patient-Facing Application, as depicted in Fig. 12.
  • the preferred embodiment of the invention comprises a calendar 5000.
  • the calendar 5000 is configured for use in association with the collected results, each result from one of a plurality diagnostic tests, and the depiction of the collected results within a graphical user interface associated with the Patient-Facing Application as shown in Fig. 11.
  • the present inventor has recognized the unique usefulness of organizing the collected result(s), along with associated indication(s) and interpretation(s), of a series of diagnostic tests for depiction in a calendar format, in part due to the cyclical nature of the menstrual cycle, in part due to the ease by which specific trends are observable within a calendar format, and in part due to the ability to identify specific phases of the menstrual cycle and group certain messages associated with the menstrual cycle by color coding periods of consecutive days within a depicted calendar, which comprises a teaching of an embodiment.
  • the calendar 5000 configured for depiction within a graphical user interface associated with the Patient-Facing Application may depict the result(s), indication(s), or interpretation(s) of each diagnostic test 100, or a relevant unique message 501, collected for a single person on a daily basis on each date depicted within the calendar 5000.
  • each result, or category of results, for positive or negative is represented by a different color as depicted on the date of the collected diagnostic test result.
  • each of the phases of the menstrual cycle and/or the fertile and infertile timeframes of a menstrual cycle as interpreted by the collected series of diagnostic test results is represented by a different color depicted over a series of days on the depicted calendar 5000.
  • each date is labelled with text identifying the hormone or analyte for which the result and/or interpretation is derived from as illustrated by Fig. 11.
  • the calendar 5000 depicted within a graphical user interface in an embodiment is configured to display a positive or negative result for each diagnostic test 100 on the date which the test was collected.
  • each interpretation of each diagnostic test 100 is represented by a different color and associated with the date of the diagnostic test was performed in the calendar 5000 in the graphical user interface.
  • the present inventor has also recognized that such teaching representing an aspect of the invention in an embodiment is a solution to the confusion faced by a lay user of a diagnostic test with regard to interpreting an indicated result, particularly when a single diagnostic test 100 is configured to evaluate for the presence or absence of multiple hormones and/or analytes within a single sample of urine simultaneously.
  • the present inventor has recognized that such problem is especially mirant, and the relevant solution that the foregoing represents is especially valuable, when the diagnostic test 100 lacks plain language text labelling on a readable surface to distinguish between the result indication lines and/or visual indications of the diagnostic test 100.
  • a calendar 5000 similar to that configured for depiction within the graphical user interface associated with the Patient-Facing Application may also be configured for depiction within the Healthcare Professional-Facing Application when a user of the Healthcare Professional-Facing Application is accessing the information relevant to one subject person.
  • the Patient-Facing Application may be configured to utilize the calendar 5000 and more specifically its association of dates to the specific diagnostic tests performed to interact with a Patient Information Integration Tool associated with the invention.
  • the purpose of the Patient Information Integration Tool is to associate the interpreted result of the diagnostic test and the time that the interpreted result was collected with the patient’s demographic information and optionally other results associated with the patient.
  • the Patient Information Integration Tool may comprise an application programming interface (API) configured to facilitate the incoming and outgoing information formatted in an interoperable format, such as HL7 or others described in the Fast Healthcare Interoperability Resources specification, as is understood by those skilled in the art.
  • API application programming interface
  • the Patient Information Integration Tool is configured as the examples described in United States Patent Application 14/997,503 filed on January 16,
  • the calendar 5000 is configured to collect and depict information associated with a specific date from other electronic medical record (EMR) systems and other healthcare modalities via the Patient Information Integration Tool.
  • EMR electronic medical record
  • the Patient Information Integration Tool is configured to display alerts optionally in association with the calendar 5000, in an example as described in United States Patent Application 16/743,029 filed on January 15, 2020, which is hereby incorporated by reference.
  • the calendar 5000 is configured to display elements of a treatment plan collected from external sources optionally based in part on the results of the diagnostic test, for example as is described in more detail in United States Patent Application 15/596,356 filed on October 8, 2019 which is hereby incorporated by reference.
  • the method of use of the system further comprises the step of formatting the result from the diagnostic test, optionally comprising a lateral flow assay test, in combination with individually identifying information associated with the subject woman and the date the test was performed into formatted results for interoperable transfer to a computing device configured to interpret and store electronic personal health information 2011, optionally facilitated in association with the Processor, the Computing Device, the Patient Facing Application and/or the Patient Information Integration Tool as described herein.
  • each diagnostic test result is collected in association with other aspects of the invention as described elsewhere herein.
  • Each diagnostic test result may be correlated with a date provided or otherwise determined by the computing device as well understood in the art prior to association with the calendar 5000 for depiction on a specific date.
  • the diagnostic test 100 collected in alternative embodiments may comprise a diagnostic test configured as other than as described herein.
  • a step of the method of use of the system to engage in allocating the result from the diagnostic test 100 optionally a lateral flow assay test, configured to detect for the presence or absence of at least one additional hormone or hormonal analyte selected from the group consisting of luteinizing hormone, estrogen, E3G, FSH, and human chorionic gonadotropin, to the specific calendar date upon which the result was determined 2006.
  • a lateral flow assay test configured to detect for the presence or absence of at least one additional hormone or hormonal analyte selected from the group consisting of luteinizing hormone, estrogen, E3G, FSH, and human chorionic gonadotropin, to the specific calendar date upon which the result was determined 2006.
  • Such allocation of such a result to such a calendar date may facilitate the subsequent display of such a result within a calendar depicted within the graphical user interface associated with the Patient-Facing Application and/or the Healthcare Professional- Facing Application and further facilitate the identification of trends of hormonal levels which may prove relevant to or otherwise allow for the diagnosis of medical conditions, optionally by a healthcare professional utilizing a Healthcare Professional-Facing Application as described elsewhere herein.
  • Such information may be displayed with and/or in relation to the date of ovulation or date of suspected ovulation as determined in accordance with the mechanisms described elsewhere herein.
  • further steps of the method of use of the system include associating and storing a specific calendar date with the ovulation date of the subject woman 2007 and displaying the results via a graphical user interface 2008 as described herein.
  • the ovulation date is manually entered via the graphical user interface associated with the Patient-Facing Application, optionally by selecting a date within a calendar depicted therein as described herein.
  • the method of use of the system comprises the step of allocating the result from the diagnostic test, optionally a lateral flow assay test configured to detect for at least one additional hormone or hormonal analyte selected from the group consisting of luteinizing hormone, estrogen, an estrogen metabolite such as E3G, FSH, and human chorionic gonadotropin to the specific calendar date upon which the result was determined 2010, optionally in association with the calendar 5000.
  • a lateral flow assay test configured to detect for at least one additional hormone or hormonal analyte selected from the group consisting of luteinizing hormone, estrogen, an estrogen metabolite such as E3G, FSH, and human chorionic gonadotropin to the specific calendar date upon which the result was determined 2010, optionally in association with the calendar 5000.
  • the calendar is depicted on a printed insert within the packaging and designed for utilization in association with a Diagnostic Test Key, the Diagnostic Test Key optionally comprising a color intensity key 800, for visual interpretation of the results of the diagnostic test to allow a lay user of the diagnostic test to manually record results on the calendar in association with the date each of a plurality of diagnostic test results was collected.
  • the calendar depicted on a printed insert is optionally an aspect of the invention in addition to or as a backup to the calendar 5000 configured for depiction within a graphical user interface associated with the Patient-Facing Application.
  • the objective of the Scheduler is to establish a telemedicine appointment between a patient user and a healthcare professional user of the system.
  • the Scheduler is configured to operate on a distinct computing device from the computing device operating the Healthcare Professional-Facing Application and also distinct from the computing device operating the Patient-Facing Application, but communicatively connected to both the Healthcare Professional-Facing Application and the Patient-Facing Application, optionally via the internet.
  • the Scheduler is configured to direct the processor of the distinct computing device to access the communicatively connected storage medium of the system to retrieve the periods of availability of all healthcare professional users along with their jurisdictions of licensure and the demographic information of one particular patient user.
  • the Scheduler via the processor, is configured to then compare the retrieved demographic information of the one particular patient user to the retrieved jurisdictions of licensure of the healthcare professional users.
  • the Scheduler is configured to aggregate and then display, via the graphical user interface of the Patient-Facing Application operated by the one particular patient user, available periods of availability of healthcare professionals licensed within a jurisdiction matching the patient’s demographic information and a graphical user interface element associated with each available period to allow the one particular patient user to select an available period of availability and schedule an appointment, optionally following an additional screen displayed on the user providing an element to allow the one particular patient user to reconfirm his or her intent to schedule an appointment at the indicated time.
  • the patient may only retrieve anonymized periods of availability of healthcare professional users without seeing any information pertaining to any individual healthcare professional user, except optionally that the healthcare professional user is licensed to practice in the jurisdiction matching the demographic information of the patient user and/or that the healthcare professional user is capable of treating a condition relevant to the patient user.
  • the Scheduler may be configured by the patient user, via the Patient-Facing Application, to display only available periods of availability healthcare professional users capable of treating conditions relevant to the patient. Following the selection of a time by a patient user, the Scheduler is configured to disallow the period of availability for the relevant healthcare professional user from subsequent scheduling by any patient user.
  • the Scheduler is configured to activate and display a prompt to activate within the graphical user interface of the Patient-Facing Application following one or more collected results from diagnostic tests indicating a particular condition relevant to the patient user logged in to the Patient-Facing Application.
  • the Scheduler is configured to automatically activate to aggregate and display the available periods of availability of healthcare professionals licensed within a jurisdiction matching the demographic information of the relevant patient user relevant to a condition indicated by a result of a photographed diagnostic test of the relevant patient user.
  • the Scheduler in an example, is further configured to send a notification to a patient user, optionally as a unique message 501 illustrated by Fig. 5, after the patient user activates a graphical user interface element to select an available period of availability and schedule an appointment.
  • the notification to a patient user in various embodiments is provided within the graphical user interface of the Patient-Facing Application, e-mail communication, SMS communication, phone call, or via other communication mechanisms.
  • the notification includes a calendar invitation capable of adding the appointment between the patient user and the healthcare professional user relevant to the appointment to a digital calendar formatted as a calendar event, calendar appointment, or calendar invitation, optionally capable for import into a Google Calendar, Apple Calendar or Outlook Calendar managed by the patient user.
  • the notification to a patient user is made in the form of a calendar appointment that is automatically added to the patient user’s calendar by the Scheduler.
  • the notification includes a link or instructions to initiate a videoconference meeting between the patient user and the healthcare professional user relevant to the appointment.
  • the link or instructions is included within the calendar appointment or calendar invitation.
  • the Scheduler in an example, is further configured to send a notification to a healthcare professional user after the patient user activates a graphical user interface element to select an available period of availability directly relevant to the healthcare professional user and schedule an appointment.
  • the notification to a healthcare professional user in various embodiments is provided within the graphical user interface of the Patient-Facing Application, e-mail communication, SMS communication, phone call, or via other communication mechanisms.
  • the notification to a healthcare professional user is displayed within the electronic health record (EHR) system operated by the healthcare professional user, optionally in addition to the ePHI delivered to the EHR system by the Scheduler in an interoperable format.
  • EHR electronic health record
  • the Scheduler may be configured to communicate with an EHR via an application program interface and also may be configured to transmit information in an interoperable format relevant to the communication of digital health information.
  • the notification includes a calendar invitation capable of adding the appointment between the patient user and the healthcare professional user relevant to the appointment to a digital calendar formatted as a calendar event, calendar appointment, or calendar invitation, optionally capable for import into a Google Calendar, Apple Calendar or Outlook Calendar managed by the healthcare professional user.
  • the notification to a healthcare professional user is made in the form of a calendar appointment that is automatically added to the healthcare professional user’s calendar by the Scheduler.
  • the notification includes a link or instructions to initiate a videoconference meeting between the patient user and the healthcare professional user relevant to the appointment.
  • the link or instructions is included within the calendar appointment or calendar invitation.
  • the Scheduler is configured to deliver the results of one or more diagnostic test 100 collected via the components described herein and associated with a patient user and available in the communicatively connected storage medium, and/or additional electronic personal health information of the patient user, to the healthcare professional user relevant to the selected period of availability.
  • the Scheduler is configured to deliver information relevant to a patient into an interoperable format, such as HL7, a clinical document architecture, a continuity of care document or continuity of care record, structured product labeling, clinical context object workgroup, a format relevant to the fast healthcare interoperability resources, a format relevant to the services aware interoperability framework, Arden syntax, formats associated with the Trusted Exchange Framework and Common Agreement and/or other similar interoperable format to allow the interoperable export of information relevant to that patient’s profile.
  • the results of one or more diagnostic tests is directly delivered to the EHR system by the Scheduler, optionally directly via an application program interface (API) and optionally in an interoperable format.
  • API application program interface
  • the Patient-Facing Application in an embodiment incorporates a functionality to enable telemedicine via a button element contained within the graphical user interface configured to initiate a video chat with a healthcare provider or a phone call with a healthcare provider in association with the transfer of the relevant information to the healthcare provider.
  • the Scheduler is configured to operate via the coding paradigms relevant to the computing devices and processors utilized in association with the system described herein and via methods and mechanisms well understood by those skilled in the art.
  • the system described herein is configured to provide responsive suggestions for the consumption of certain seeds of a specific type and in a specific amount in an embodiment of the invention.
  • a prompt is generated and optionally repeated on a daily basis until the until the first diagnostic test 100 result indicating the presence of luteinizing hormone (LH), to consume, on a daily basis, pumpkin seeds in an amount selected from the range inclusive of 6.5 grams- 16 grams and flax seeds in an amount selected from the range inclusive of 6.5 grams- 16 grams, or optionally in an amount of 1 tablespoon of pumpkin seeds and 1 tablespoon of flax seeds.
  • LH luteinizing hormone
  • the prompt may also optionally include an instruction to pause consumption of sesame seeds and sunflower seeds during the period of consumption of pumpkin seeds and flax seeds, or until the first diagnostic test 100 result indicating the presence of luteinizing hormone (LH) at a threshold to obtain the optimal hormone balancing effect.
  • LH luteinizing hormone
  • the prompt may optionally suggest the consumption of a product containing pumpkin and flax seeds in specific amounts, optionally optionally incorporated into a single consumable food item, optionally a snack bar (optionally referred to as a “pumpkin and flax bar.”)
  • a product containing pumpkin and flax seeds in specific amounts, optionally optionally incorporated into a single consumable food item, optionally a snack bar (optionally referred to as a “pumpkin and flax bar.”)
  • the present inventor has discovered that such a combination of pumpkin seeds, in an amount selected from the range inclusive of 6.5 grams- 16 grams or an amount of 1 tablespoon, and flax seeds, in an amount selected from the range inclusive of 6.5 grams- 16 grams or an amount of 1 tablespoon, into a single consumable food item, optionally a snack bar, and optionally a single consumable food item comprising other ingredients, provides a desirable hormone regulating effect when consumed at specified times in the menstrual cycle, such specified times optionally prompted by the result or results of one or more diagnostic test(
  • the seed consumption system comprises a pumpkin and flax bar in the form of a single consumable food item, optionally a snack bar, consisting of pumpkin seeds, in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, crisp sorghum, tapioca syrup, ground flax seeds in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, honey and salt.
  • a prompt is generated, and optionally repeated on a daily basis until the onset of menstruation, to consume, on a daily basis, sesame seeds in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, and sunflower seeds in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, optionally incorporated within a single consumable food item,.
  • the prompt may also include an instruction to pause consumption of pumpkin seeds and flax seeds during the period of consumption of sesame seeds and sunflower seeds, and/or until the onset of menstruation, to acheive the optimal hormone regulating effect.
  • the prompt may optionally suggest the consumption of a product containing sesame seeds and sunflower seeds in specific amounts, optionally incorporated within a single consumable food item, optionally a snack bar (referred to as “a sesame and sunflower bar.”)
  • a sesame and sunflower bar referred to as “a sesame and sunflower bar.”
  • the present inventor has discovered that such a combination of sesame seeds, in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, and sunflower seeds in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, into a single consumable food item, optionally a snack bar, optionally comprising other ingredients provides the desired hormone regulating effect when consumed at specified times in the menstrual cycle, such specified times optionally prompted by the result or results of one or more diagnostic test(s) 100.
  • the system further comprises a sesame and sunflower bar in the form of a single consumable food item, optionally a snack bar, consisting of crisp sorghum, sunflower kernels in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, sesame seeds in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, tapioca syrup, honey and salt.
  • a sesame and sunflower bar in the form of a single consumable food item, optionally a snack bar, consisting of crisp sorghum, sunflower kernels in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, sesame seeds in an amount selected from the range inclusive of 6.5 grams- 16 grams or in an amount of 1 tablespoon, tapioca syrup, honey and salt.
  • a snack bar representing the general shape and form of either the sesame and sunflower bar or the pumpkin and flax bar in an embodiment, is depicted in Fig. 14.
  • a package comprising both a plurality of sesame and sunflower bars and plurality of pumpkin and flax bar comprises quantities of sesame and sunflower bars and pumpkin and flax bars corresponding to that needed for a once daily consumption during either the follicular phase (generally ranging in length from 11 to 27 days) or the luteal phase (generally ranging in length from 11 to 17 days) of the menstrual cycle, optionally with the quantity of a different type of bar relating to the number of days in either the follicular phase or the luteal phase.
  • the Seed Consumption System comprises such a quantity of sesame and sunflower bars and pumpkin and flax bars included in a single container or package further comprising quantities of diagnostic tests relevant to a single menstrual cycle as described elsewhere herein.
  • the single container or package further comprises instructions to obtain a Patient-Facing Application, optionally via a printed link on the single container or package or optionally instructions to download the relevant application from the app store via a specific search term.
  • the Seed Consumption System further comprises the Patient-Facing Application as described elsewhere herein, and further configured to prompt a patient user to consume one or more snack bars comprising sesame and sunflower seeds and/or one or more snack bars comprising pumpkin and flax seeds via a notification generated based on timing and/or the results of a single diagnostic test 100 or a plurality of diagnostic tests that have evaluated a bodily fluid sample collected from the patient user.
  • the Patient-Facing Application automatically triggers and facilitates the purchase and delivery of one or more snack bars comprising sesame and sunflower seeds and/or one or more snack bars comprising pumpkin and flax seeds following a single diagnostic test 100 indicating a result for the presence of luteinizing hormone at a threshold in an applied bodily fluid sample.
  • the Patient-Facing Application is configured to configured to prompt the consumption of the snack bars comprising sesame and sunflower seeds and the snack bars comprising pumpkin seeds and flax seeds at specified times as further described herein.
  • the Patient-Facing Application configured to automatically trigger the purchase and delivery of additional snack bars comprising sesame and sunflower seeds and snack bars comprising pumpkin and flax seeds following the passage of time or following a detected undesirable trend associated with the menstrual cycle as detected by a series of diagnostic tests, detected in association with the Patient-Facing Application as described elsewhere herein.
  • the purchase and delivery is facilitated, the delivery optionally occurring within two days, via Amazon.
  • the purchase and delivery takes place on a recurring basis, optionally via a subscription.
  • the quantity or quantities of sesame and sunflower bars and pumpkin and flax bars, optionally packaged together, purchased correlates to an estimated quantity of bars needed for the once daily consumption of a pumpkin and flax bar during the follicular phase and a sesame and sunflower bar during the luteal phase of a typical menstrual cycle.
  • menstrual cycles and the associated hormonal levels may vary greatly among healthy women, and especially among women experiencing menopause, perimenopause or puberty, it is an aspect of the invention that the consumption of a specific seed is instructed directly in response to the presence or absence of one or more specified hormone(s) or analyte(s) as indicated by a diagnostic test as described elsewhere herein.
  • the system features a prescribed action plan offered by a healthcare professional, optionally in association with utilization of the telemedicine system as described elsewhere herein.
  • the prescribed action plan in one example comprises a specified suggested change in diet, optionally comprising components of the seed consumption system such as the sesame and sunflower bars and/or the pumpkin and flax bars, with directions to consume at the specified times as described further herein.
  • the prescribed action plan offered by a healthcare professional optionally in association with utilization of the telemedicine system as described elsewhere herein, comprises a specified suggested change in diet guided in association with the utilization of the seed consumption system.
  • the method of use of the system comprises a step of communicating a prescribed action plan to the subject woman, the prescribed action plan comprising a specified suggested change in diet 2016, the suggested change in diet optionally comprising consumption of the sesame and sunflower bars and/or the pumpkin and flax bars at the specified times as described further herein.
  • the seed consumption system may benefit all women, but will particularly benefit women for which any diagnostic test 100 performed during the period of 7-10 days past ovulation yields at least one result for the absence of PdG at a threshold selected from the range inclusive of 1 pg/mL-10 pg/mL, which could be referred to as a suboptimal cycle.
  • the present inventor has recognized that the consumption of the seeds as described herein is associated with triggering the increased production of progesterone, correlating to elevated PdG results (as indicated by a plurality of diagnostic tests 100 performed daily each indicating the presence of PdG at a threshold selected from the range consistiove ofl pg/mL-10 pg/mL during the timeframe of 7-10 days past ovulation, and thereby indicating that a sufficient amount of progesterone has been produced to support conception, for example).
  • the effectiveness of the seed consumption system may be monitored during this time period with additionally performed diagnostic tests 100.
  • an indication of effectiveness is embodied when a woman, following a suboptimal cycle and her utilization of the seed consumption system in accordance with its teaching, experiences in a subsequent cycle positive results for PdG in association with her use of diagnostic tests on each day during the period of 7-10 days past ovulation.
  • the present inventor has also recognized that in association with diagnostic tests further configured to evaluate for the presence or absence of E3G at a threshold, if such tests indicate a negative result for E3G or the absence of a 1.5 fold increase in E3G during the follicular phase in a subject woman, that the subject woman may have a higher likelihood of benefiting from the consumption of certain seeds in association with her utilization of the seed consumption system as described herein.
  • Menopause Tracking and Treatment Management System is configured as a menopause tracking system.
  • the menopause tracking system may comprise all or a subset of the Diagnostic Test, Camera, Patient-Facing Application, Healthcare-Facing Application, Storage, Graphical User Interface, Processor, Computing Device, Calendar, and Scheduler as described elsewhere herein.
  • the preferred embodiment of the Menopause Tracking and Treatment Management system comprises a specially configured Patient-Facing Application as described elsewhere herein.
  • the specially configured Patient-Facing Application incorporates features to interpret the results of a diagnostic test 100.
  • the diagnostic test is configured as a lateral flow assay featuring three testing zones and corresponding result indication lines, each configured to detect the presence or absence of one of either Lutenizing Hormone (LH), estriol glucuronide (E3G) pregnanediol glucuronide (PdG), each at a pre-defined threshold, in a urine sample applied to the lateral flow assay, in an example as described with more particularity in PCT Patent Application PCT/US 18/68027 filed on December 28, 2018 incorporated by reference herein with priority claimed thereto and elsewhere herein.
  • LH Lutenizing Hormone
  • E3G estriol glucuronide
  • PdG pregnanediol glucuronide
  • the diagnostic test 100 may be performed with other aspects of the invention to provide one or more quantitative result(s), for instance whereby the color intensity of the line can be read be the smartphone reader to determine a hormone or hormone analyte concentration optionally in association with the Diagnostic Test Key 200 or color intensity key 800, such that such indicated result is not merely positive or negative.
  • the Patient-Facing Application is configured to utilize the camera of a computing device to photograph the diagnostic test.
  • the Patient-Facing Application is configured to provide instructions to the processor to determine the indication of a positive or negative result independently for each LH, E3G and PdG tested within a single diagnostic test by measuring the intensity of the color apparent within each result indication line and comparing it to the intensity of the color at the pre-defined threshold, or by another detection mechanism able to detect the result indicated depicted by each result indication line.
  • the diagnostic test further comprises a testing zone and corresponding result indication line configured to detect FSH.
  • a persistently high level of FSH may indicate permanent menopause
  • the detection of FSH in accordance with teachings of the system may trigger a message via the graphical user interface informing the user that she is likely experiencing menopause if persistently high levels of FSH are detected over periods of several consecutive days.
  • the menopause tracking and treatment management system further incorporates the seed consumption system and/or the progesterone supplementation system.
  • the present inventors have recognized that prompting the consumption of specified seeds in response to the presence or absence of specific hormones has particular benefit for perimenopausal or menopausal women, namely, the stimulation or suppression of the production of certain hormones in such a manner known to mitigate negative effects of menopause.
  • the menopause tracking and treatment management system also incorporates mechanisms to suggest a treatment protocol for the supplementation of certain hormones, for example progesterone, in response to certain indications or interpretations of a diagnostic test 100 or a series of diagnostic tests as further described elsewhere herein.
  • Embodiments of the invention comprise a fertility tracking system incorporating aspects of the methods described elsewhere herein and the diagnostic test(s) 100 described elsewhere herein.
  • the system provides information relevant to hormonal levels and changes of hormonal levels over a series of days within a single menstrual cycle, or optionally in comparison to hormonal levels or trends of hormonal levels occurring in previous or subsequent menstrual cycles.
  • the fertility tracking system in the preferred embodiment comprises a specified quantity of diagnostic tests 100, each diagnostic test 100 consisting of a lateral flow assay, optionally a sandwich assay, each comprising a testing zone and corresponding result indication line configured to detect for the presence or absence of pregnanediol glucuronide in urine at a threshold selected from the range of 1 pg/mL-10 pg/mL.
  • the lateral flow assay pertinent to any of PdG and E3G is a competitive assay and the lateral flow assay pertinent to any of LH, FSH and hCG is a sandwich assay.
  • the lateral flow assay comprising a testing zone and corresponding result indication line configured to detect for the presence or absence of pregnanediol glucuronide is configured to detect for the presence or absence of pregnanediol glucuronide at a threshold of 5 pg/mL.
  • the diagnostic tests consisting of a lateral flow assay, optionally a sandwich and/or competitive assay, comprising a testing zone and corresponding result indication line configured to detect for the presence or absence of pregnanediol glucuronide in urine are configured such that the presence of only one line (i.e. the control line 105) a positive result and the presence of two lines (i.e.
  • control line 105 and the first result indication line 107) indicates a negative result for the presence of pregnanediol glucuronide at a threshold selected from the range of 1 pg/mL-10 pg/mL.
  • a threshold selected from the range of 1 pg/mL-10 pg/mL.
  • the present inventor has noted the previous unavailability and unmet need of such diagnostic tests as is well established in the art.
  • the specified quantity is useful in association with the tracking of hormonal levels on a daily basis over a specified period corresponding to utilization during one single menstrual cycle.
  • the fertility tracking system comprises a quantity of diagnostic tests, the quantity selected from the range of 4-15 diagnostic tests 6003, each diagnostic test consisting of a lateral flow assay configured to detect for the presence or absence of pregnanediol glucuronide in urine individually placed within a sealed packet 6002.
  • the fertility tracking system comprises 5 diagnostic tests configured to detect for the presence or absence of pregnanediol glucuronide at a threshold in urine as depicted in Fig. 15.
  • the fertility tracking system further comprises a quantity of diagnostic tests, the quantity selected from the range of 7-25 diagnostic tests 6005, each diagnostic test consisting of a lateral flow assay comprising a testing zone and corresponding result indication line configured to detect for the presence or absence of luteinizing hormone at a threshold chosen from the range of 15 mlU/mL-50mlU/mL individually placed within a sealed packet 6004 as depicted in Fig. 15.
  • the lateral flow assay comprising a testing zone and corresponding result indication line configured to detect for the presence or absence of luteinizing hormone is configured to detect for the presence or absence of luteinizing hormone at a threshold of 25 mlU/mL.
  • the fertility tracking system comprising the specified quantities of diagnostic tests configured to detect for the presence or absence of pregnanediol glucuronide in urine at a threshold selected from the range of 1 pg/mL-10 pg/mL, and diagnostic tests configured to detect for the presence or absence of luteinizing hormone in urine at a threshold chosen from the range of 15 mlU/mL-50mlU/mL, aggregated together into a system in accordance with the teachings herein, facilitates usage by a layperson to allow for the collection of data relevant to the functioning of the menstrual cycle on consecutive days without the need for laboratory evaluation of bodily fluids.
  • the specified quantities of diagnostic tests configured to detect for the presence or absence of pregnanediol glucuronide in urine and diagnostic tests configured to detect for the presence or absence of luteinizing hormone in urine, when taken on a daily basis by a layperson user, provides for the collection of a series of test data without the need for a laboratory evaluation.
  • the present inventor has recognized that the quantities of diagnostic tests within the fertility tracking system as described herein correlate to the amounts of diagnostic tests to evaluate the critical fertility hormones relevant to the assessment of one menstrual cycle.
  • the collection and recording of results on a series of days within the period of a menstrual cycle may take place even without the use of an external device to collect and record results.
  • the quantity of diagnostic tests consisting of a lateral flow assay configured to detect for the presence or absence of pregnanediol glucuronide at a threshold in urine and the quantity of diagnostic tests consisting of a lateral flow assay configured to detect for the presence or absence of luteinizing hormone at a threshold in urine are aggregated together into a single package for ease of use by a lay user.
  • the present inventor has noted that the aggregation of such specified quantities of diagnostic tests into a single package solves the need for clarity and simplicity associated with the number of tests needed for a typical single menstrual cycle to test at least for the starting and/or ending dates associated for the highly fertile and highly infertile timeframes of the menstrual cycle.
  • each diagnostic test associated with the system is packaged into a sealed packet consisting of an airtight foil pouch containing a desiccant package and a single diagnostic test 100.
  • the benefit of the use of an airtight foil pouch is that it maintains the integrity of each diagnostic test 100 well beyond the timeframe associated with a single menstrual cycle.
  • testing for PdG and LH on the same day could be beneficial because if one does not obtain an indication on a diagnostic test indicating the presence of a PdG at a threshold following an indication on a diagnostic test indicating the presence of LH at a threshold on the same day or the previous day, it could mean that a false LH surge has occurred, meaning that the woman has not ovulated yet.
  • a false LH surge refers to a surge in LH hormone that does not result in ovulation or the release of progesterone, correlating to the presence of PdG in urine.
  • the present inventor has discovered that it is advantageous to continue to monitor LH until the subject woman tested has confirmed that ovulation has successfully and/or sufficiently occurred. This is indicated in accordance with a teaching of an embodiment by the presence of serum progesterone which correlates to the presence of pregnanediol glucuronide (PdG) above a threshold in urine.
  • PCOS polycystic ovary syndrome
  • PdG pregnanediol glucuronide
  • the fertility tracking system as, which combines diagnostic testing for at least both LH and PdG as facilitated by the specially configured diagnostic tests as described elsewhere herein - represents a significant and important improvement over prior art mechanisms and methods featuring only testing for LH.
  • the aforementioned teachings are utilized in the association of the creation of indications and interpretations, optionally for use in association with a unique message 501, as described elsewhere herein.
  • the present inventor has recognized the risk of a false LH surge associated with the usage of ovulation predictor kits as known in the prior art, which the teachings of the present invention specifically address and represent a significant improvement over the prior art. Therefore, in an aspect, it is a teaching of the fertility tracking system as described herein to facilitate the simultaneous and/or sequential testing of LH and PdG to mitigate the risk of detecting a false LH surge association with prior art utilization of diagnostic tests configured to detect LH only.
  • the steps of simultaneously and/or sequentially testing for PdG following a positive result for LH forms a teaching of the method embodiment of the invention, and is enabled by the specially configured diagnostic tests 100 configured to evaluate for the presence or absence of PdG at a threshold as described elsewhere herein.
  • method embodiment of the invention it is a teaching to perform the step of evaluating a bodily fluid once daily for the presence or absence of PdG at a threshold during a specified timeframe forming a portion of the menstrual cycle.
  • PdG testing should take place daily, for consecutive days up to 10 days past the date of suspected ovulation. In associated steps, the date of the first indicated LH surge in a menstrual cycle is considered the date of suspected ovulation.
  • the earliest a woman should start testing for PdG in an exemplary method is two days after the date of suspected ovulation.
  • a method embodiment of the invention featuring the step of evaluating the same bodily fluid sample for both LH and PdG by one or more diagnostic tests configured to evaluate for the presence or absence of both LH and PdG each at a unique threshold, if LH surges on one or more subsequent dates without a corresponding increase in PdG after the one or more previous surges in LH, the date of the most recent subsequent LH surge will replace the all other dates of suspected ovulation, as the new and overriding date of suspected ovulation for that menstrual cycle for purposes of timing the testing of diagnostic tests configured to detect for the presence or absence of pregnanediol glucuronide at a threshold in urine.
  • a single fertility tracking system comprising a quantity of up to 25 diagnostic tests configured to detect the presence or absence of LH in urine at a threshold within a sealed packet 6005 as described elsewhere herein and additionally a quantity of up to 15 diagnostic tests configured to detect for the presence or absence of pregnanediol glucuronide at a threshold within a sealed packet 6003, optionally a quantity of 8, each such individual diagnostic test 100 configured as described elsewhere herein, aggregated into a single package 6001, optionally to facilitate utilization of the diagnostic tests in association with the methods described herein.
  • the subject woman should perform a diagnostic test 100, the diagnostic test configured to detect for the presence or absence of pregnanediol glucuronide in urine at a threshold selected from the range inclusive of 1 pg/mL-10 pg/mL, to evaluate her urine once daily until 10 days after the date of suspected ovulation.
  • the subject woman in a related method performs such a diagnostic test on a daily basis during the timeframe inclusive of 7- 10 days past the date of suspected ovulation to evaluate her urine, and confirm sufficient ovulation following four consecutive diagnostic tests each taken once daily on four consecutive days each demonstrating an indicated result for the presence of pregnanediol glucuronide in the tested urine, optionally in accordance with the methods disclosed in United States Patent Application 16/732,766, filed on Jan. 2, 2020, hereby incorporated by reference in its entirety herein with priority claimed thereto.
  • a method embodiment to perform the step of evaluating urine for the presence or absence of pregnanediol glucuronide on a daily basis for a plurality of up to 12 consecutive days beyond 2-10 days past suspected ovulation (as indicated by the most recent diagnostic test indicating a positive result for the presence of luteinizing hormone as a threshold), and therefore a fertility testing system comprising a quantity of up to 15 such diagnostic tests (optionally to allow for user errors or associated duplicate testing in an example) or a quantity of as few as 4 such diagnostic tests each configured to detect for the presence or absence of pregnanediol glucuronide in urine is preferred.
  • Such a quantity corresponds to that necessary to evaluate urine on a once daily basis between the dates inclusive of 7-10 days after the date of suspected ovulation, in accordance with methods described with more particularity in United States Patent Application 16/732,766 filed on January 20, 2020, which as noted previously this application claims the benefit of and incorporates by reference in its entirety.
  • a sequence of diagnostic tests taken daily on the dates including days 7-10 past the suspected ovulation date is suggestive of proper corpus luteum functionality in one intended method of usage of the fertility tracking system.
  • LH testing is performed on a daily basis starting on the 10 th day of the menstrual cycle, indicating a LH surge on the third day of testing for LH (the 13 th day of the menstrual cycle), with the testing for PdG commencing on the second day following the first test indicating the presence of LH at a threshold in urine (the 15 th day of the menstrual cycle) in accordance with the preferred method of use of the fertility tracking system, that test indicating the presence of PdG in urine at a threshold on the 15 th day of the menstrual cycle.
  • the present inventor has recognized that the quantity of diagnostic tests configured to detect for the presence or absence of LH at a threshold is optimally selected from the range inclusive of 7-25 such diagnostic tests, in part because a subject woman may benefit from testing for LH on multiple times per day in certain circumstances. For example, the present inventor recognizes that LH can surge in the afternoon or the morning, and the surge could be for a very short duration. Therefore the present inventor has further recognized that in order to detect the transient increase in LH, testing multiple times per day can be advantageous.
  • Such teachings relate to the quantity of diagnostic tests configured to detect for the presence or absence of LH to incorporate into the system in association with additional diagnostic tests at least comprising a plurality of diagnostic tests configured to detect for the presence or absence of PdG chosen in association with embodiments of the system described herein.
  • the intended use of testing for LH and the testing for PdG occurs via a single strip containing separate result indication lines each configured to evaluate for the presence or absence of a distinct hormone or analyte each at a threshold.
  • each category of diagnostic test comprising a quantities of diagnostic tests configured to evaluate for the presence or absence of only one hormone or analyte - alternatively comprises as few as 10 and as many as 25 diagnostic tests configured to evaluate for at least for the presence or absence of PdG at a threshold in a first testing zone corresponding to a first result indication line 107 and the presence or absence of LH at a threshold in a second testing zone corresponding to a second result indication line 108.
  • each diagnostic test 100 comprises a single lateral flow assay comprising a plurality of separate testing zones, each testing zone configured to evaluate a separate hormone or analyte as described elsewhere herein.
  • each diagnostic test comprises a single lateral flow assay comprising a plurality of separate testing zones, each testing zone configured to evaluate for the presence or absence of a separate hormone or analyte at a threshold and to present a visual result on a corresponding result indication line.
  • an example of the invention additionally comprises diagnostic tests comprising testing zones and corresponding result indication lines other than those configured to detect for the presence of LH and PdG.
  • diagnostic tests configured to evaluate urine for the presence or absence of FSH at a threshold are included at a quantity selected from the range inclusive of 7-25 diagnostic tests.
  • the present inventor has recognized that a diagnostic test configured to evaluate for the presence or absence of FSH at a threshold is useful, as the presence of FSH signifies when the fertile window opens in the menstrual cycle, as a follicle is “stimulated” or selected by follicle stimulating hormone (FSH), thereby opening the fertile window.
  • FSH follicle stimulating hormone
  • the presence of FSH specifically the presence of FSH in an amount equivalent to a 1.5 fold decrease as compared to a prior diagnostic test indicating the presence of FSH performed in the same menstrual cycle, such fold change optionally determined by comparing the indicated colors to the colors indicated on the color intensity key 800 and associating the indicated FSH concentration with each diagnostic test 100, signifies the stimulation of the follicle and also confirms the opening of the fertile window.
  • FSH is generally elevated in the beginning of a healthy menstrual cycle. Measuring FSH is also uniquely beneficial for women experiencing menopause or perimenopause in association with the menopause tracking and treatment management system described elsewhere herein, as a persistently high level of FSH may indicate permanent menopause.
  • the indication for FSH in association with various embodiments may provide a marker for ovarian reserve.
  • the results indicated by diagnostic test 100 configured to evaluate for the presence of FSH are used in association with other elements of the system to generate indications and/or interpretations as described elsewhere herein, each optionally for display as a unique message 501.
  • the invention further comprises diagnostic tests configured to evaluate urine for the presence of Estrogen Metabolite (E3G), included at a quantity selected from the range inclusive of 7-25 diagnostic tests.
  • E3G Estrogen Metabolite
  • Examples of the invention incorporating a plurality of diagnostic tests configured to detect for the presence or absence of E3G can provide additional information.
  • the present inventor has recognized that in comparison to a diagnostic test indicating the presence FSH, a diagnostic test configured to evaluate for the presence of E3G provides a slightly different and potentially complementary indication, namely that after the follicle was selected (signaled by FSH) the maturing follicle has secreted estrogen.
  • a method embodiment comprises the step of instructing the subject woman, optionally via the graphical user interface, to commence utilizing a diagnostic test configured to detect the presence or absence of FSH in an applied fluid once daily 9001, optionally at a threshold or optionally by comparison of the degree of change compared to an earlier diagnostic test configured to detect the presence or absence of FSH as described elsewhere herein, on a daily basis commencing on a day chosen from the range inclusive of 2-3 days following the onset of a subject woman’s menstruation in a menstrual cycle.
  • the step of collecting, on a daily basis, the results of each of a plurality of diagnostic tests by comparing the color intensity indicated on each diagnostic test to a color intensity key 800 to estimate the FSH concentration 9002.
  • an exemplary method further comprises the step of instructing the subject woman, optionally via the graphical user interface, to commence utilizing a diagnostic test comprising a testing zone and corresponding result indication line configured to detect the presence of E3G once daily on a daily basis 9003.
  • the change is indicated or for example by a result on a diagnostic test configured to detect FSH in urine at a threshold demonstrating a level indicated above a threshold followed by a result on a diagnostic test configured to detect FSH in urine demonstrating an indicated level of FSH below a threshold
  • the change in FSH is determined by photographing a diagnostic test comprising at least one testing zone configured to evaluate the presence of FSH in the bodily fluid to determine a baseline indicated color intensity in a corresponding result indication line on a date 2-3 days from the onset of menstruation.
  • a Patient-Facing Application or digital device is preconfigured with color intensities of such result indication line corresponding to different levels of FSH in an applied fluid, for instance by recording the results for the color intensities occurring in each of a plurality of diagnostic tests each applied with a spiked male urine including known amounts of FSH, optionally in association with the color intensity key 800.
  • the applied fluid consists of male urine spiked with a known level of FSH.
  • the estimated amount is instead determined by substituting the closest color intensity to the indicated color intensity and estimating the level of the amount of hormone or analyte in the applied fluid to be that associated with the closest color intensity.
  • the present inventor has recognized that it is possible to determine fold changes in FSH in an applied fluid, for example a 1.5 fold decrease, evidenced by one diagnostic test as compared to a previously taken diagnostic test as a baseline, by correlating color intensities indicated on a diagnostic test to a known level of FSH and ensuring that in methods of use that each diagnostic test utilized in association with the relevant method is similarly configured. Similar mechanisms are useful in correlating color intensities with the levels in an applied bodily fluid of other hormones and/or analytes, such as E3G. Such correlated color intensities are useful in an embodiment comprising a Diagnostic Test Key 200 as described elsewhere herein.
  • a certain fold decrease in the color intensity indicated over a series of diagnostic tests does not necessarily equate to a similar fold decrease or increase in the actual relevant amount of hormone or analyte in an applied sample.
  • the present inventor has determined that some diagnostic tests configured with certain carrier proteins are difficult to consistently reproduce, and has also noted that the precision associated with manufacturing consistently reproduced diagnostic tests is important in the effective deployment of such method.
  • the instruction optionally configured as a unique message 501 as described elsewhere herein, optionally is delivered to the user of a Patient-Facing Application via the graphical user interface following the positive result for the presence of FSH in urine that the follicle has stimulated and/or that the fertile window has opened.
  • a diagnostic test 100 comprising a plurality of testing zones and corresponding result indication lines comprising one testing zone and corresponding result indication line configured to detect for the presence or absence of E3G at a threshold and further comprising another testing zone and corresponding result indication line configured to detect for the presence or absence of FSH at a threshold
  • an instruction to change the type of diagnostic test 100 utilized is not necessary and therefore not included.
  • the preferred method embodiment incorporates a step of repeating use of the diagnostic test 100 comprising a plurality of testing zones and corresponding result indication lines, each of which is configured to detect for the presence or absence of a distinct hormone or analyte, once daily on a daily basis throughout the period of fertility testing, as switching between a different type of tests each separately configured to detect for a different subset of hormones and/or analytes becomes unnecessary in such example.
  • a unique message 501 is delivered to the user of the system via the graphical user interface that the follicle has stimulated and/or that the fertile period of the subject woman’s menstrual cycle has begun.
  • the method further comprises the step of generating an interpretation following the evaluation of a result of each diagnostic test 100, the interpretation based on the specific indicated result 9051-9055. Following each of the generating an interpretation steps 9051-9055, the method further comprises the step of formatting each interpretation into a unique message 501 and depicting the unique message 501 onto a display 605.
  • a user is instructed, optionally via the graphical user interface, to commence utilizing a diagnostic test 100 comprising a testing zone and corresponding result indication line configured to detect and provide an indication correlating to a color intensity for the presence of E3G once daily on a daily basis 9003, the color intensity optionally indicating an amount of E3G in association with a color intensity key 800 and/or a Diagnostic Test Key 200.
  • a diagnostic test 100 comprising a testing zone and corresponding result indication line configured to detect and provide an indication correlating to a color intensity for the presence of E3G once daily on a daily basis 9003, the color intensity optionally indicating an amount of E3G in association with a color intensity key 800 and/or a Diagnostic Test Key 200.
  • the change is indicated by a result on a diagnostic test 100 configured to detect FSH in urine demonstrating a level indicated above a threshold followed by a result on a diagnostic test configured to detect FSH in urine demonstrating an indicated level of FSH below a threshold.
  • the change in FSH is determined by photographing a diagnostic test 100 comprising at least one testing zone and a corresponding result indication line configured to evaluate for the presence of FSH in the bodily fluid to determine a baseline indicated color intensity, optionally corresponding to a specific RGB or HEX color code, in such testing zone on a date 2-3 days from the onset of menstruation.
  • a Patient-Facing Application or digital device is preconfigured with color intensities, optionally derived from a color intensity key 800, of such result indication line corresponding to different levels of FSH in an applied fluid, for instance by recording the results for the color intensities occurring in each of a plurality of diagnostic tests each applied with fluid containing a known amount of FSH.
  • the applied fluid consists of male urine spiked with a known level of FSH.
  • the estimated amount is instead determined by substituting the closest color intensity included in the color intensity key 800 to the indicated color intensity and estimating the level of the amount of hormone or analyte in the applied fluid to be that associated with the closest color intensity.
  • the present inventor has recognized that it is possible to determine fold changes in FSH in an applied fluid, for example a twofold decrease, evidenced by one diagnostic test as compared to a previously taken diagnostic test as a baseline, by correlating color intensities indicated on a diagnostic test to a known level of FSH and ensuring that in methods of use that each diagnostic test utilized in association with the relevant method is similarly configured.
  • a diagnostic test comprising a plurality of testing zones comprising one testing zone configured to detect for the presence or absence of E3G at a threshold and further comprising another testing zone configured to detect for the presence or absence of FSH at a threshold
  • an instruction to change the type of diagnostic test utilized is not necessary and therefore not provided, as in the method depicted by Fig. 17.
  • a message is delivered to the user of the system via the graphical user interface that the follicle has stimulated and/or that the fertile window has opened.
  • the length of the menstrual cycle is determined as the duration between the onset of menstruation in a first menstrual cycle and the onset of menstruation in the subsequent menstrual cycle.
  • An average menstrual cycle length can be calculated by looking back at a number of recent menstrual cycles, optionally 6 menstrual cycles, and determining the average in accordance with basic mathematical principles.
  • the average length may be entered via the Patient-Facing Application or a digital device to assist in the determination of the dates for when testing for various hormones should change.
  • a Patient- Facing Application could be configured to subtract 21 from the average length of a subject woman’s menstrual cycle to arrive at an approximated length of time from the onset of menstruation in a single menstrual cycle until the detectible presence of E3G in tested urine, which could be used as a backup timeframe to change use of diagnostic tests configured to detect only one particular hormone or analyte on a daily repeating basis, if a 1.5 fold decrease in FSH is not detected over a series of diagnostic tests within such an approximated timeframe.
  • a message is delivered via the graphical user interface or otherwise to a display stating that ovulation is likely not to occur this cycle.
  • a 1.5 fold decrease in FSH is not observed on any of a series of diagnostic tests performed on a subject woman’s bodily fluid within a single menstrual cycle, optionally only if the woman is above a certain age (in an example, 35 years old) a message is delivered via the graphical user interface or otherwise to a display suggesting a likelihood that menopause has started.
  • a message is delivered via the graphical user interface or otherwise to a display suggesting a likelihood that the woman is experiencing PCOS or another medical condition and that it would be appropriate to discuss with a physician.
  • a message is delivered via the graphical user interface or otherwise to a display suggesting a likelihood that menopause has started.
  • a message is delivered via the graphical user interface or otherwise to a display suggesting that a follicle has been selected and/or that the subject woman’s fertile window has opened.
  • the present inventor has recognized that such information is useful to a subject woman in association with maximizing her chances for conception during a specific menstrual cycle.
  • a first step comprises testing for FSH, commencing on a date selected from the range inclusive of 2-3 days following the onset of menstruation in a subject woman’s menstrual cycle, by evaluating a bodily fluid of the subject woman by utilizing a first lateral flow assay comprising at least a testing zone and corresponding color intensity line configured to evaluate the presence of FSH in the bodily fluid to determine a baseline indicated color intensity in the result indication line corresponding to a level of FSH in the bodily fluid 3001.
  • a second step comprises repeating testing of the subject woman’s bodily fluid for FSH once daily with a series of subsequently performed lateral flow assays each comprising at least a testing zone configured to evaluate the presence of FSH and corresponding result indication line, until the color intensity evident on the result indication line of one of the lateral flow assays performed within the series corresponds to a color intensity evidencing at least a 1.5 -fold decrease in the level of FSH in the bodily fluid as compared to the level of FSH corresponding to the baseline indicated color intensity evident in the result indication line configured to provide an indication for the presence of FSH in the bodily fluid of the first lateral flow assay 3002.
  • a third step comprises following the earlier of an evidenced at least 1.5 -fold decrease in the presence of FSH within a series of previously taken diagnostic tests in the same menstrual cycle or the passage of 8 days following from the onset of menstruation of the same menstrual cycle of the subject woman, commencing testing for E3G by performing a lateral flow assay comprising at least a testing zone and corresponding result indication line configured to evaluate the presence of E3G in a bodily fluid to determine a baseline indicated color intensity for E3G in the result indication line corresponding to a level of E3G in the bodily fluid 3003.
  • a user is instructed, optionally via the graphical user interface, to commence utilizing a diagnostic test 100 comprising a testing zone and corresponding result indication line configured to detect the presence of E3G once daily on a daily basis.
  • the change is indicated by a result on a diagnostic test 100 configured to detect FSH in urine at a threshold demonstrating a level indicated above a threshold followed by a result on a diagnostic test configured to detect FSH in urine demonstrating an indicated level of FSH below a threshold.
  • the change in FSH is determined by photographing a diagnostic test 100 comprising at least one testing zone and corresponding result indication line configured to evaluate the presence of FSH in the bodily fluid to determine a baseline indicated color intensity in such result indication line on a date 2-3 days from the onset of menstruation.
  • a Patient-Facing Application or digital reader 670 is preconfigured with color intensities of such result indication line corresponding to different levels of FSH in an applied fluid, for instance by recording the results for the color intensities occurring in each of a plurality of diagnostic tests 100 each applied with a spiked male urine including known amounts of FSH.
  • the applied fluid consists of male urine spiked with a known level of FSH.
  • the estimated amount is instead determined by substituting the closest color intensity to the indicated color intensity and estimating the level of the amount of hormone or analyte in the applied fluid to be that associated with the closest color intensity.
  • the present inventor has recognized that it is possible to determine fold changes in FSH in an applied fluid, for example a 1.5 fold decrease, evidenced by one diagnostic test as compared to a previously taken diagnostic test as a baseline, by correlating color intensities indicated on a diagnostic test to a known level of FSH and ensuring that in methods of use that each diagnostic test utilized in association with the relevant method is similarly configured. Similar mechanisms are useful in correlating color intensities with the levels in an applied bodily fluid of other hormones and/or analytes, such as E3G. Such correlated color intensities are useful in an embodiment comprising a Diagnostic Test Key 200 as described elsewhere herein.
  • a certain fold decrease in the color intensity indicated over a series of diagnostic tests does not necessarily equate to a similar fold decrease or increase in the actual relevant amount of hormone or analyte in an applied sample.
  • the present inventor has determined that some diagnostic tests configured with certain carrier proteins are difficult to consistently reproduce, and has also noted that the precision associated with manufacturing consistently reproduced diagnostic tests is important in the effective deployment of such method.
  • a user is instructed, optionally via the graphical user interface, to commence utilizing a diagnostic test comprising a testing zone and corresponding result indication line configured to detect the presence of E3G once daily on a daily basis.
  • the message optionally is delivered to the user of the system via the graphical user interface following the positive result for the presence of FSH in an applied bodily fluid of at least a specified amount that the follicle has stimulated and/or that the fertile window has opened.
  • an alternative embodiment such as an embodiment configured to evaluate a fluid other than urine, as an alternative to testing for E3G it may be advantageous to test the fluid (i.e. saliva or blood) for estrogen.
  • a subsequent step comprises repeating the testing for E3G once daily with a series of subsequently performed lateral flow assays each comprising at least a testing zone and corresponding result indication line configured to evaluate the presence of E3G in a bodily fluid, until the color intensity evident within the result indication line configured to evaluate for the presence of E3G in a single lateral flow assay within the series displays a color intensity evidencing at least a 1.5 -fold increase in the level of E3G in the tested bodily fluid as compared to the level of E3G corresponding to the baseline indicated color intensity for E3G 3004.
  • LH testing should commence in accordance with teachings of an embodiment and be repeated on a daily basis until a result on a diagnostic test comprising a testing zone and corresponding result indication line configured to detect for the presence or absence of LH at a threshold indicates the presence of LH at a threshold, in accordance with teachings of an embodiment.
  • the method embodiment further comprises providing an instruction to a user to commence utilization of a diagnostic test 100 configured to detect for the presence of LH at a threshold once daily on a daily basis.
  • a diagnostic test 100 comprising a plurality of testing zones comprising one testing zone configured to detect for the presence or absence of E3G at a threshold and further comprising another testing zone configured to detect for the presence or absence of LH at a threshold, such instruction is not necessary and therefore not included.
  • the diagnostic test 100 comprising a plurality of testing zones and corresponding result indication lines, each of which is configured to detect for the presence or absence of a distinct hormone or analyte, once daily on a daily basis throughout the period of fertility testing.
  • a message is delivered via the graphical user interface of the Patient-Facing Application or to another display suggesting that a follicle has matured and/or confirming that the fertile window has opened and remains open. The present inventor has recognized that such information is useful to a subject woman in association with maximizing her chances for conception during a specific menstrual cycle.
  • the user is instructed to commence utilizing a diagnostic test configured to detect the presence or absence of LH at a threshold once daily on a daily basis.
  • a diagnostic test comprising a plurality of testing zones comprising one testing zone and corresponding result indication line configured to detect for the presence of E3G and further comprising another testing zone and corresponding result indication line configured to detect for the presence or absence of LH at a threshold
  • such instruction is not necessary and therefore not included.
  • a message optionally is delivered to the user (in one example only if the user is above a certain age, i.e. 35 years old) of the system that menopause has likely started.
  • a message optionally is delivered to the user of the system that ovulation is not likely during the present menstrual cycle.
  • a the persistence of many consecutive days (optionally defined as 8 consecutive days) without a result demonstrating a 1.5 fold increase in E3G as compared to a previous result indicated by a diagnostic test 100 previously performed during the same menstrual cycle indicates that the subject woman will not ovulate during the relevant menstrual cycle and that the subject woman is likely infertile during the relevant menstrual cycle, and such messages are optionally generated and displayed in association with the teachings herein.
  • a message optionally is delivered via the graphical user interface to the user of the system following a positive result for the presence of E3G, the term “positive result for the presence of E3G” optionally defined as a sequence of diagnostic tests 100 performed within the same menstrual cycle demonstrating at least a 1.5 fold increase in E3G, that the follicle has matured and/or that the fertile window has opened.
  • An example of such a message is provided in Fig. 9.
  • a fifth step comprises following the earlier of an evidenced at least 1.5 fold increase in the level of E3G in the tested bodily fluid within a series of previously taken diagnostic tests 100 in the same menstrual cycle or the passage from the onset of menstruation in the same menstrual cycle of a quantity of days equivalent to the number of days corresponding to the length of the subject woman’s average menstrual cycle less 18 days, commencing testing for LH by utilization of a diagnostic test 100 configured to detect at least the presence or absence of LH at a threshold once daily on a daily basis 3005.
  • a diagnostic test 100 configured to detect the presence or absence of LH at a threshold once daily on a daily basis.
  • a diagnostic test 100 comprising a plurality of testing zones comprising one testing zone and corresponding result indication line configured to detect for the presence of E3G and further comprising another testing zone and corresponding result indication line configured to detect for the presence or absence of LH at a threshold, such instruction is not necessary and therefore not included.
  • the diagnostic test 100 comprising a plurality of testing zones and corresponding result indication lines, each of which is configured to detect for the presence or absence of a distinct hormone or analyte, once daily on a daily basis throughout the period of fertility testing.
  • a message optionally is delivered via the graphical user interface to the user of the system following the positive result for the presence of E3G, optionally as evidenced by an indication of at least a 1.5 -fold increase in the level of E3G, that the follicle has matured and/or that the fertile window has opened.
  • a message optionally is delivered to the user of the system that menopause has likely started.
  • a sixth step comprises repeating the testing for LH once daily with a series of subsequently performed lateral flow assays each comprising at least a testing zone and corresponding result indication line configured to evaluate for the presence or absence of LH at a threshold until a single lateral flow assay in the series indicates a positive result for the presence of LH at a threshold 3006.
  • the user is instructed to commence utilizing a diagnostic test configured to detect the presence or absence of PdG at a threshold once daily on a daily basis.
  • a diagnostic test comprising a plurality of testing zones comprising one testing zone and corresponding result indication line configured to detect for the presence or absence of LH at a threshold and further comprising another testing zone and corresponding result indication line configured to detect for the presence or absence of PdG at a threshold
  • such instruction is not necessary and therefore not included.
  • a message optionally is delivered via the graphical user interface to the user of the system following the positive result for the presence of LH in urine that ovulation is imminent and/or that fertility may be at its maximum level.
  • such information is useful to the subject woman in association with timing sexual intercourse to maximize chances for conception.
  • the user is instructed to commence utilizing a diagnostic test configured to detect the presence or absence of PdG at a threshold once daily on a daily basis.
  • a message optionally is delivered via the graphical user interface to the user of the system following the positive result for the presence of PdG in urine that ovulation has occurred and/or that the user’s infertile phase has commenced and/or that the risk of pregnancy is low or decreased until menstruation begins.
  • the present inventor has recognized that generally progesterone production occurs at a timeframe equivalent to the length of the woman’s average menstrual cycle less 10 days following the onset of menstruation. Therefore, it is useful to commence testing for PdG in a menstrual cycle at this point if a positive result for LH has not occurred within this timeframe.
  • a message is delivered via the graphical user interface of the Patient-Facing Application or via another display suggesting that ovulation may not occur or may otherwise be insufficient in this menstrual cycle for the subject woman to conceive.
  • a message is delivered via the graphical user interface of a Patient- Facing Application or to another display suggesting that the infertile period has commenced and/or that the risk of pregnancy is low or decreased until menstruation begins.
  • a message is delivered via the graphical user interface that the subject woman has successfully ovulated, or alternatively that the woman has sufficiently ovulated.
  • the present inventor has recognized that such information is useful to a subject woman who wishes diagnose problems associated with ovulation, such as PCOS.
  • an embodiment configured to evaluate a fluid other than urine as an alternative to testing for PdG it may be advantageous to test the fluid for progesterone, and the relevant messages may be delivered in association with the teachings described elsewhere herein.
  • a further method step comprises following the earlier of the occurrence of a lateral flow assay indicating a positive result for the presence of LH at a threshold within a series of previously taken diagnostic tests within the same menstrual cycle or the passage from the onset of menstruation in the same menstrual cycle of a number of days corresponding to the length of the subject woman’s average menstrual cycle less 10 days, commencing testing for PdG by utilization of a diagnostic test configured to detect at least the presence or absence of PdG at a threshold once daily on a daily basis 3007.
  • the present inventor has also recognized the uniquely enabling attributes of the PdG test described herein and to the various references incorporated herein to which priority is claimed. It is therefore a critical step in one embodiment that comprises determining a result, the result at least comprising an indication for the presence or absence of pregnanediol glucuronide in the woman’s urine via an indication generated by a lateral flow assay test comprising at least one testing zone and corresponding result indication line configured to detect for the presence or absence of pregnanediol glucuronide in urine at a threshold selected from within the range of 1 pg/mL-10 pg/mL 4001.
  • the ovulation date is estimated in accordance with the teachings elsewhere herein.
  • Such step optionally takes place in accordance with or by otherwise utilizing the Calendar and/or the Patient-Facing Application as described elsewhere herein.
  • Such step optionally takes place in accordance with or by otherwise utilizing the Calendar and/or the Patient-Facing Application as described elsewhere herein.
  • the display 605 is configured as depicted by Fig. 10b or Fig. lOd.
  • a lateral flow assay test configured to detect at least one additional hormone or hormonal analyte selected from the group consisting of lutenizing hormone (LH) at a specific threshold, human chorionic gonadotropin (hCG) at a specific threshold, E3G at a quantity corresponding to an indicated color intensity and FSH at a quantity corresponding to an indicated color intensity, the result at least comprising an indication of the absence or presence of LH or hCG or an indication of the presence of E3G or FSH at an amount corresponding to the indicated color intensity, to the specific calendar date upon which the result was determined 4006.
  • Such a lateral flow assay optionally takes the form of the diagnostic test(s), and operates in coordination with the color intensity key 800 and other components as described elsewhere herein.
  • the prescribed action plan comprises a specified suggested change in diet, specifically commencing the once daily consumption of pumpkin seeds optionally in the amount of 1 tablespoon and flax seeds optionally in the amount of 1 tablespoon, and optionally in snack bar form, once daily upon the start of menstruation, or optionally once daily following the first indication in a single menstrual cycle for the presence of FSH on a diagnostic test 100 performed on the subject woman’s urine, and then subsequently changing to instead engage in daily consumption of sesame seeds optionally in the amount of 1 tablespoon and sunflower seeds optionally in the amount of 1 tablespoon, and optionally in snack bar form, following the first indication of a positive LH result on a diagnostic test 100 performed on the subject woman’s urine, or optionally in accordance with or by otherwise utilizing the Seed Consumption System as described elsewhere herein.
  • the determining a result step takes place in various embodiments by photographing, via a camera integrated within a smartphone, the diagnostic test 4020. Such step optionally takes place in accordance with or by otherwise utilizing the Patient-Facing Application, Camera and/or Smartphone as described elsewhere herein.
  • Such step optionally takes place in accordance with or by otherwise utilizing the Camera and smartphone 600 as described elsewhere herein.
  • Identifying the specific color intensity optionally a specific color intensity correlating to a specific level of analyte and/or hormone as described elsewhere herein, associated within the color detected by the camera within a result indication line of the lateral flow assay test 4022.
  • Such step optionally takes place in accordance with or by otherwise utilizing the Fertility Testing System as described elsewhere herein.
  • the diagnostic test comprising a lateral flow assay test may consist of a single test, such as the diagnostic test as described elsewhere herein, configured to simultaneously or near-simultaneously detect for the presence or absence of a plurality of hormones or hormonal analytes selected from the group consisting of pregnanediol glucuronide, luteinizing hormone, estrogen, estradiol, progesterone and human chorionic gonadotropin.
  • the method may further comprise triggering a delivery of additional lateral flow assay tests following the usage of a quantity of lateral flow assay tests correlative to one menstrual cycle 4024. Such step optionally takes place in accordance with or by otherwise utilizing the Fertility Testing System as described elsewhere herein.
  • the method further comprises depicting the results and/or interpretations onto a display, optionally via a graphical user interface, featuring a calendar 5000 with the result of each test displayed on in association with the date each diagnostic test was performed within the displayed calendar 4025.
  • Such step optionally takes place in accordance with or by otherwise utilizing the Calendar and graphical user interface as described elsewhere herein.
  • such a result generates a message to the user via the graphical user interface that a mature follicle has developed.
  • a negative result indicated on a diagnostic test for the presence of E3G at a threshold in urine and a positive result indicated on a diagnostic test for the presence of LH at a threshold in urine could signify a false LH surge or the release of an immature follicle and poor ovulation quality.
  • such a result triggers the generation of a unique message 501 to the user via the graphical user interface comprising of one or more statements selected from the group consisting of: “an immature follicle has developed,” “there is an elevated likelihood of poor ovulation quality,” and “there is a likelihood of false positive result for LH and that LH testing should continue.”
  • a message or several messages may be facilitated and delivered via other components of the system as described herein, in particular including the graphical user interface of the Patient- Facing Application.
  • the results of each test and the calendar date associated with each result is stored for use in association with the calendar 5000 and other elements of the graphical user interface, Patient- Facing Application and Healthcare Professional-Facing Application as described elsewhere herein.
  • ovulation quality may be measured via a measurement of a urine metabolite of estrogen (such as E3G), as the more mature a follicle is, the more estrogen will be produced.
  • a positive result is indicated on a diagnostic test for the presence of LH at a threshold in urine and a negative result is indicated on a diagnostic test for the presence of E3G at a threshold resulting from the evaluation of the same sample of urine with one or more diagnostic tests as described herein, it may signify that a follicle did not mature and that an immature egg incapable of fertilization was released during the relevant cycle.
  • a message is delivered via the graphical user interface providing notice of the poor ovulation quality, optionally stating that a follicle did not mature and/or that an immature egg incapable of fertilization has been released during this cycle.
  • a prompt to schedule and conduct a telemedicine appointment with a healthcare professional for further evaluation is optionally generated via the graphical user interface in an exemplary embodiment.
  • the threshold ranges associated with the diagnostic tests to evaluate for the presence or absence of the estrogen metabolite (i.e. E3G) and LH as described elsewhere herein correlate to the values that suggest whether a mature egg or an immature egg has been released, and as such, constitutes a teaching of an aspect of the invention.
  • Various embodiments of the system described herein incorporate quantities of individual diagnostic tests each configured to detect a separate hormone or analyte at a threshold, or a quantity of diagnostic tests configured to detect for the presence or absence of a plurality of hormones and/or analytes each at a separate threshold, needed to accomplish the mechanisms described herein over a single menstrual cycle, optionally corresponding to the typical number of days in a single menstrual cycle averaged over a typical population.
  • the system comprises a number of diagnostic tests needed to perform the methods described herein over a plurality of menstrual cycles. The diagnostic testing, message generation, display and other aspects of the performed methods as described are conducted in accordance with the teachings of the methods and apparatuses as described elsewhere herein.
  • Various methods incorporate the step of determining a result from a the lateral flow assay test described elsewhere herein comprising testing zones and corresponding result indication lines each configured to evaluate for the presence or absence of pregnanediol glucuronide and at least one additional hormone or hormonal analyte selected from the group consisting of luteinizing hormone, estrogen, and human chorionic gonadotropin, each hormone or analyte tested at a specific threshold.
  • the above sequences are performed without the assistance of a computing device or graphical user interface, with tracking performed with the assistance of a printed calendar included with the system as described elsewhere herein.
  • instructions for how to perform the sequence as described herein are printed and included in association with the diagnostic tests optionally on the Diagnostic Test Key, and a printed calendar and optionally a subset of other components of the system described herein.
  • Various embodiments are configured for visual reading or for reading with the assistance of external reading and tracking mechanisms.
  • the external reading and tracking mechanisms may comprise those described elsewhere herein.
  • the external reading and tracking mechanisms may take forms such as those described in PCT Patent Application PCTVUS2019/038173 filed on June 20, 2019; United States Patent Application 16/302,085 filed on May 19, 2017; and United States Patent Application 14/505,083 filed on October 2, 2014; each incorporated by reference herein.
  • Such embodiments of the system may also incorporate or interact with the mechanisms for recording, storing and communicating the collected diagnostic test results as described in the above-mentioned or similar references.
  • the fertility tracking system in certain configurations is more precisely described as a “predicting fertile window system.”
  • the present inventor has recognized that aspects of the invention described herein provide unique benefits to persons wishing to enhance the likelihood of conception by more clearly identifying the opening date and closing date of the fertile window, as indicated by the presence of certain hormones and analytes in urine.
  • the system is configured to provide prompts via the graphical user interface not only signaling that a certain hormone is present or absent in a sample evaluated with a diagnostic test as described herein, but also an interpretation of the relevance of that hormone or analyte to the certain user.
  • the detection of E3G or FSH in urine at a threshold in association with the utilization of an appropriately configured diagnostic test as described herein may prompt the system to display a message indicating that the subject woman’s fertile period has begun and that she should engage in intercourse to achieve pregnancy.
  • diagnostic tests configured to detect for the presence or absence of hCG at a threshold, optionally in association with the detection of other hormones in a single test, are utilized in association with the predicting fertile window system.
  • a result indicating the presence of hCG at a threshold indicates pregnancy.
  • a result indicating the absence of hCG at a threshold indicates that the subject woman is not pregnant.
  • a message is displayed in the graphical user interface that pregnancy has been achieved and that the woman can optionally cease testing, or continue testing especially for PdG on an ongoing basis to ensure that the woman’s progesterone levels remain sufficient to support a pregnancy (as indicated by a positive PdG result on a diagnostic test as described herein).
  • a diagnostic test indicates a positive result for hCG at a threshold in a tested bodily fluid and testing of the same sample of bodily fluid indicates a result of the absence of PdG at a threshold
  • an interpretation comprising an indication that the subject woman has likely not produced enough progesterone to sustain pregnancy.
  • the system described herein is configured as a system to predict the fertile window of a patient user.
  • the system may be configured for use with both diagnostic tests configured to detect for the presence or absence of PdG at a threshold in urine and separately diagnostic tests configured to detect for the presence or absence of LH at a threshold in urine.
  • the system may be configured for use with diagnostic tests configured to detect for at least both the presence or absence of PdG at a threshold in urine and for the presence or absence of LH at a threshold in urine within a single diagnostic test.
  • the present inventor has recognized that aspects of the invention described herein provide unique benefits to persons wishing to avoid conception and avoid pregnancy by more clearly identifying especially the closing date of the fertile window.
  • the system described herein is configured as a system to allow a patient user to avoid pregnancy.
  • the present inventor has identified a context for use of the system as a form of birth control.
  • the system is configured to provide prompts via the graphical user interface not only signaling that PdG is present at a threshold correlating to ovulation in a sample evaluated with a diagnostic test as described herein, but also an interpretation of the relevance of the presence of PdG in the sample to a user, namely that she has ovulated and that her infertile period has begun or that she may engage in sexual intercourse without the risk of becoming pregnant.
  • prompts via the graphical user interface not only signaling that PdG is present at a threshold correlating to ovulation in a sample evaluated with a diagnostic test as described herein, but also an interpretation of the relevance of the presence of PdG in the sample to a user, namely that she has ovulated and that her infertile period has begun or that she may engage in sexual intercourse without the risk of becoming pregnant.
  • An embodiment of the invention is configured as a telemedicine system.
  • the system comprises the Scheduler as described elsewhere herein, one or more Diagnostic Tests as described elsewhere herein, the Computing Device, Camera, Display, Graphical User Interface, Communicatively Connected Storage Medium and Processor each as described elsewhere herein, a Patient Information Integration Tool, a Healthcare Professional-Facing Application and a Patient-Facing Application.
  • the Healthcare Professional-Facing Application in association with the telemedicine system, is configured to provide users who are healthcare providers with the ability to indicate the conditions that they have the capability to treat via the graphical user interface 7060 and optionally other aspects of the system.
  • the Healthcare Professional-Facing Application, as illustrated in Fig. 20, is further configured to provide users who are healthcare providers with the ability to indicate the jurisdictions that they are licensed within, or otherwise have the capability to practice within, via the graphical user interface 7060 and optionally other aspects of the system.
  • the Healthcare Professional-Facing Application upon the healthcare provider’s initial use of the system, requires the healthcare provider to enter their national provider identifier (NPI) to facilitate the confirmation of licensure information, optionally configured to occur automatically following the healthcare provider’s entry of his or her NPI via via an application program interface (API).
  • NPI national provider identifier
  • API application program interface
  • a healthcare provider possessing the capability, as determined by training and licensure, for example, to treat infertility may so associate such ability in association with their profile.
  • a subject woman has captured a diagnostic test via a smartphone camera and a Patient-Facing Application indicating infertility, it is an object of the telemedicine system to facilitate a consultation among the subject woman and the qualified healthcare provider.
  • the Healthcare Professional-Facing Application is configured to allow the healthcare provider to choose his or her available times for a consultation via a graphical user interface 7062.
  • the times of all available healthcare providers licensed in a patient’s jurisdiction capable of treating the patient’s indicated condition are aggregated and displayed to the patient via the Patient-Facing Application without depicting the name or any other specifically identifying information associated with the available healthcare providers 900, as depicted in Fig. 12.
  • the present inventor has recognized the value in anonymously assembling a group of healthcare providers and organizing them merely by jurisdictional licensure and subspecialty for display to a patient, as it provides a more efficient mechanism for connecting a plurality of patients with a plurality of healthcare providers in advance of a telemedicine consultation, which forms a step of a method embodiment of the invention.
  • the plurality of healthcare providers are further vetted for reviews, lack of complaints and other qualifications prior to being granted the ability to select available times to provide telemedicine consultations in association with the system.
  • a method embodiment comprises the steps of assembling a group of healthcare providers by collecting their jurisdiction of licensure and subspecialty via a graphical user interface, optionally the graphical user interface associated with the Healthcare Provider-Facing Application as described elsewhere herein, displayed to each of the group of healthcare providers 7080; collecting, via the graphical user interface displayed to each of the group of healthcare providers, the times available to schedule a telemedicine consultation of each of the group of healthcare providers 7081; storing information, comprising the jurisdiction of licensure, subspecialty, and available appointment times, of each of the group of the healthcare providers in a communicatively connected storage medium 7082; accessing the information with an application, optionally the Patient-Facing Application, further configured to access the communicatively connected storage medium and retrieve the jurisdictions of licensure, subspecialty, and available appointment times of each of the group of the healthcare providers 7083; determining the location of a patient utilizing
  • the qualified healthcare provider may consult with the subject woman and generate a suggested treatment protocol, which may incorporate the provision of a prescription, for example.
  • the prescription may be for the ingestion, suppository and/or injection of progesterone.
  • the prescription for progesterone in one example is given by the qualified healthcare provider for delivery to the subject woman at a specific time measured by days past ovulation associated with the subject woman’s menstrual cycle, determined in association with one or more diagnostic test(s) 100 and the Patient-Facing Application.
  • the telemedicine system generates a message to a specified qualified healthcare provider via the graphical user interface of the Healthcare Professional-Facing Application and optionally associated notification mechanisms following a result on a diagnostic test 100 collected from a sample of a healthcare provider’s patient providing an indication of the absence of pregnanediol glucuronide a threshold on any day during the time period of 7-10 days past the date of ovulation, the date of ovulation determined as described elsewhere herein.
  • Such result is collected and formatted optionally in association with the patient’s use of the Patient-Facing Application.
  • the healthcare provider following the receipt of a diagnostic test result via the telemedicine system and its associated components, optionally the Healthcare Provider-Facing Application, indicating a level of pregnanediol glucuronide below a threshold on any day during the time period of 7-10 days past ovulation of the subject woman in association with the teachings of the invention, provides, optionally following a suggestion triggered as described elsewhere herein, a prescription to the subject woman, optionally during or after a telemedicine consultation with the subject woman, to ingest, supposit or inject progesterone during the time period of 3-14 days past ovulation of the following cycle, or during an expanded time period.
  • steps of the method of use of an exemplary system include determining a prescribed action plan to correct the undesirable absence of at least one hormone or hormonal analyte 2014, and communicating the prescribed action plan to the subject woman 2015 optionally via a consultation facilitated as described herein, or a communication facilitated at least in part via the graphical user interface of the Patient-Facing Application.
  • the telemedicine system is configured to store each healthcare professional’s demographic and contact information within a Communicatively Connected Storage Medium, optionally configured to store at least the qualified healthcare professional’s jurisdictions of licensure.
  • Such information may be gathered by the telemedicine system via the graphical user interface of the Healthcare Professional-Facing Application upon the healthcare professional logging in to an Healthcare Professional-Facing Application and stored in the Communicatively Connected Storage Medium for subsequent retrieval.
  • the qualified healthcare professional logging in to the telemedicine system, such information is then made accessible and editable to the healthcare professional.
  • One additional type of information that the qualified healthcare professional may input into the telemedicine system via the graphical user interface are the available starting and ending time options for the qualified healthcare professional to engage in a consultation with a patient. It is therefore a step of the method embodiment to engage in designating the time options for the healthcare professional to consult with a patient 2051. It is a teaching of an embodiment to store such available starting and ending time options for subsequent utilization by the system, optionally in coordinating consultations with patients. It is therefore a step of the method of use of the telemedicine system to engage in storing the resulting period or periods of availability for subsequent access by the graphical user interface of an application accessible for use by a patient, optionally the Patient-Facing Application 2052.
  • the Healthcare Professional-Facing Application is configured to allow the qualified healthcare professional to provide such information via the associated graphical user interface of the Healthcare Professional-Facing Application. It is therefore a step of the method of use of the telemedicine system to engage in displaying starting and ending time options to a healthcare provider via the graphical user interface of an application accessible for use by a healthcare provider, optionally the Healthcare Professional-Facing Application; the healthcare provider selecting a starting time and an ending time to define a period of availability via the Healthcare Professional-Facing Application 2053.
  • the system is configured to allocate non-PACS medical image taken by a layperson, for instance a photograph of a diagnostic test, to the patient information storage system in association with a specified patient user.
  • the system is configured to store and allow for retrieval of the patient’s demographic information. It is therefore a step of the method of use of the telemedicine system to engage in retrieving the patient’s demographic information upon the patient logging in to a patient-facing application 2054.
  • the telemedicine system incorporates a camera configured to collect the results of a patient’s lateral flow assay test.
  • a camera configured to collect the results of a patient’s lateral flow assay test.
  • it is therefore a step of the method of use of the telemedicine system to engage in collecting the image of a patient’s diagnostic test via a device operated by the patient, optionally a smartphone 600, running the Patient-Facing Application and the device’s camera 2055.
  • the system incorporates a processor configured to interpret the result of the diagnostic test in part by evaluating the intensity of the color displayed thereon and comparing such color to another basis color.
  • a processor configured to interpret the result of the diagnostic test in part by evaluating the intensity of the color displayed thereon and comparing such color to another basis color.
  • it is therefore a step of the method of use of the telemedicine system to engage in interpreting the result of the diagnostic test 100 by comparing the intensity of the color displayed within the result indication line of the diagnostic test 100 with either the predefined threshold intensity signifying the positive or negative nature of the result of the test or a color intensity correlating to a concentration amount as indicated on a color intensity key 800 as described elsewhere herein 2056.
  • the components of the system as described herein work to allocate the result to associate with a specified patient. For instance, it is an aspect of the system to provide a Patient Information Integration Tool to instruct the Processor to associate each diagnostic result with a specified person, optionally a person logged in to the Patient-Facing Application at the time a diagnostic test is photographed with the Camera of the associated Computing Device. In association with such teaching, it is therefore a step of the method of use of the telemedicine system to engage in associating the interpreted result of the diagnostic test and the time that the interpreted result was collected with the patient’s demographic information and optionally other diagnostic test results associated with the patient 2057.
  • the components of the system as described herein work to aggregate the periods of availability. Further, it is an aspect of the invention to provide a Patient - Healthcare Provider Integration Tool to display the aggregated periods of availability filtered by jurisdictions of licensure for each healthcare professional matching the locale of an individual patient. In association with such teaching, it is therefore a step of the method of use of the telemedicine system to engage in aggregating the periods of availability of healthcare providers with at least one jurisdiction of licensure matching the demographic information of the patient 2058.
  • the system optionally is configured to detect and interpret the result of a diagnostic test, associate a medical condition to such result, and then filter healthcare professionals who are qualified to treat such medical condition and display their periods of availability.
  • it is therefore a step of the method of use of the telemedicine system to engage in associating the result read from the result of the diagnostic test captured by the camera with a medical condition appropriately treated by a healthcare provider of a subspecialty 2059, and aggregating available healthcare providers of that subspecialty for subsequent display 2060.
  • the system facilitates transfer of electronic personal health information, optionally including results from one or more diagnostic tests specific to the patient who scheduled an appointment with the healthcare professional.
  • Such delivery optionally takes place via e-mail, the provision of delegated access to a Communicatively Connected Storage System, via the Healthcare Professional-Facing Application, by direct transfer to the healthcare professional’s electronic medical records system, or by another mechanism.
  • it is also therefore a step of the method of use of the telemedicine system to engage in delivering the results associated with one or more diagnostic tests that have evaluated the patient and the patient’s demographic information in an interoperable format to the healthcare professional associated with the chosen appointment time 2064.
  • the communication takes place via a videoconferencing system configured to take place within both the Healthcare Professional-Facing Application and the Patient-Facing Application, facilitated within the Healthcare Professional-Facing Application for the healthcare professional and within the Patient-Facing Application for the patient.
  • the videoconferencing system consists of another separate videoconferencing application, optionally the Skype, VeeSee or Zoom applications.
  • a notification generated by the system contains a hyperlink configured to trigger the videoconferencing mechanism at the time of the scheduled appointment.
  • the videoconferencing is encrypted to accomplish compliance with relevant regulations such as HIPAA.
  • the communication between the healthcare provider and the patient is a phone call.
  • the phone call is configured as a VOIP call facilitated within the Healthcare Professional-Facing Application for the healthcare professional and within the Patient-Facing Application for the patient.
  • it is also therefore a step of the method of use of the telemedicine system to engage in facilitating the communication between the patient and the healthcare professional associated with the chosen appointment time at the chosen appointment time 2065.
  • the results during a period within one period within a menstrual cycle can be used in identifying a trend if similar results are observed during the same or similar period one menstrual cycle to the next or to subsequent menstrual cycles, such periods optionally measured from menstrual cycle to menstrual cycle in days past ovulation or days past suspected ovulation.
  • a method of use of the system further comprises the step of suggesting a telemedicine consultation with a healthcare professional following the identification of one or more trends associated with the undesirable absence of at least one hormone or hormonal analyte during a specified timeframe 2017.
  • the one or more trends associated with such step comprises the undesirable absence of pregnanediol glucuronide as indicated by the stored results associated with any of the dates occurring from 7-10 days past the subject woman’s ovulation date over a plurality of that subject woman’s menstrual cycles 2018.
  • the one or more trends associated with such step comprises the undesirable absence of pregnanediol glucuronide as indicated by the stored results associated with any of the dates occurring from 7-10 days past the subject woman’s ovulation date over a plurality of that subject woman’s menstrual cycles 2018.
  • failing to receive an indication of a positive result for the presence of PdG by a diagnostic test as described herein during the entirety of a woman’s single menstrual cycle constitutes another example of an undesirable result.
  • the present inventor has recognized that the quantities of diagnostic tests needed to facilitate the deployment of the above system may be specific, therefore it is a teaching of an embodiment to provide specific quantities of various configurations of diagnostic tests as described elsewhere herein.
  • the present inventor has recognized that for many, it is convenient and easy to download the Patient-Facing Application configured to enable such telemedicine system in association with the specified quantities of diagnostic tests as described herein. It is therefore a teaching of an embodiment of the system described herein to package the diagnostic tests in the specified quantities as described elsewhere herein into a single container additionally comprising instructions for utilization of the Patient-Facing Application.
  • the present inventor has recognized that it is advantageous to estimate and trigger the purchase and delivery of diagnostic tests on a recurring basis.
  • the purchase and delivery takes place in association with a subscription.
  • the system is configured with the specific quantity or quantities of diagnostic tests configured to evaluate a bodily fluid for the presence or absence of a plurality of hormones and analytes at a threshold, such hormones and analytes, such hormones and analytes including LH and PdG, included in a single container.
  • the single container comprises a quantity selected from the range inclusive of 4-15 of diagnostic tests configured to evaluate a bodily fluid for the presence or absence of PdG at a threshold.
  • the single container comprises a quantity selected from the range inclusive of 5- 25 of diagnostic tests configured to evaluate a bodily fluid for the presence or absence of LH at a threshold.
  • the present inventor has recognized the significance of these ranges in that the ranges correspond to the amount of such tests necessary for adequately testing a single menstrual cycle in the vast majority of women.
  • the single container comprises a quantity of diagnostic tests configured to evaluate a bodily fluid for the presence or absence of PdG at a threshold selected from the range inclusive of 4-15 diagnostic tests.
  • the system is further configured to automatically trigger the purchase and delivery of an additional such container on a date not later than the date the user of the system would run out of diagnostic tests if the user consumed a diagnostic test once daily.
  • the amount of diagnostic tests corresponds to the number of diagnostic tests required for use in one menstrual cycle as described elsewhere herein.
  • it is also therefore a step of the method of use of various embodiments of the system including optionally the telemedicine system to engage in triggering a purchase and delivery of additional lateral flow assay tests following the usage of a quantity of lateral flow assay tests correlative to one menstrual cycle 2024.
  • the invention including its methods of use, disclosed herein comprise one or more steps or actions for achieving the described method.
  • the method steps and/or actions may be interchanged with one another without departing from the scope of the claims.
  • the order and/or use of specific steps and/or actions may be modified without departing from the scope of the claims.
  • a includes ... a”, “contains ... a” does not, without more constraints, preclude the existence of additional identical elements in the process, method, article, or apparatus that comprises, has, includes, contains the element.
  • the terms “a” and “an” are defined as one or more unless explicitly stated otherwise herein.
  • the terms “substantially”, “essentially”, “approximately”, “about” or any other version thereof, are defined as being close to as understood by one of ordinary skill in the art, and in one non-limiting embodiment the term is defined to be within 10%, in another embodiment within 5%, in another embodiment within 1% and in another embodiment within 0.5%.
  • the terms “coupled,” “connected” and “linked” as used herein is defined as connected, although not necessarily directly and not necessarily mechanically.
  • a device or structure that is “configured” in a certain way is configured in at least that way, but may also be configured in ways that are not listed. Also, the sequence of steps in a flow diagram or elements in the claims, even when preceded by a letter does not imply or require that sequence. Any noun in the singular is also intended to encompass the noun in the plural and vice versa, unless specifically stated as otherwise intended. Any pronoun or other identifier in the female form is also intended to encompass the pronoun or other identifier in the male form and vice versa, unless specifically stated as otherwise intended.
  • the invention described herein has particular applicability in the healthcare industry. More specifically, the invention as described herein has specific applications in telemedicine applications, diagnostic testing applications, and fertility applications as described elsewhere herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un système et des procédés d'évaluation et de suivi du fonctionnement du cycle menstruel et de traitement de tendances indésirables associées au cycle menstruel. Divers aspects du système et des procédés décrits dans la description reposent sur le fonctionnement de tests de diagnostic spécialement conçus pour évaluer un fluide corporel quant à la présence ou à l'absence d'hormones ou d'analytes, et plus précisément conçus pour évaluer un fluide corporel au moins quant à la présence ou à l'absence de glucuronide de prégnanediol à un seuil choisi dans la plage comprise entre 1 µg/ml et 10 µg/ml y compris. Les résultats du ou des tests de diagnostic sont interprétés conformément aux enseignements du système. Les interprétations sont utiles dans le cadre de traitements facilitants associés à des pathologies corrélées aux interprétations générées, éventuellement délivrées pendant une consultation avec un prestataire de soins médicaux pendant une consultation de télémédecine, les traitements comprenant éventuellement des changements de régime alimentaire intégrant la consommation de certaines graines destinées à atténuer des déséquilibres hormonaux.
EP20854747.1A 2019-08-19 2020-07-02 Systèmes et procédés de test de cycle menstruel Pending EP4017375A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16/544,554 US20210055310A1 (en) 2019-08-19 2019-08-19 Method and apparatus for a pregnanediol urine assay
US16/732,823 US11061026B2 (en) 2017-02-17 2020-01-02 System of evaluating corpus luteum function by recurrently evaluating progesterone non-serum bodily fluids on multiple days
US16/732,766 US11029321B2 (en) 2017-02-17 2020-01-02 Method of evaluating corpus luteum function by recurrently evaluating progesterone non-serum bodily fluids on multiple days
PCT/US2020/040600 WO2021034412A1 (fr) 2019-08-19 2020-07-02 Systèmes et procédés de test de cycle menstruel

Publications (2)

Publication Number Publication Date
EP4017375A1 true EP4017375A1 (fr) 2022-06-29
EP4017375A4 EP4017375A4 (fr) 2023-12-06

Family

ID=74659923

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20854747.1A Pending EP4017375A4 (fr) 2019-08-19 2020-07-02 Systèmes et procédés de test de cycle menstruel

Country Status (2)

Country Link
EP (1) EP4017375A4 (fr)
WO (1) WO2021034412A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11061026B2 (en) 2017-02-17 2021-07-13 MFB Fertility, Inc. System of evaluating corpus luteum function by recurrently evaluating progesterone non-serum bodily fluids on multiple days
EP4079229A1 (fr) * 2021-04-22 2022-10-26 Claire Marie Elisabeth De Belloy de Saint Liénard Calcul d'un point dans le temps pour une action médicale de fertilité
US20240215904A1 (en) * 2021-08-23 2024-07-04 University Of Cincinnati Ovulation Monitoring Platform
CN114527269A (zh) * 2022-02-25 2022-05-24 棒糖科技(杭州)股份有限公司 一种连续测试多种人体生理指标的装置
CN114527287A (zh) * 2022-02-25 2022-05-24 棒糖科技(杭州)股份有限公司 一种连续测试多种激素用于女性备孕期管理的方法
WO2024079483A1 (fr) * 2022-10-14 2024-04-18 Wlness Science Ltd Dosage hormonal
US20240329061A1 (en) * 2023-03-27 2024-10-03 Spd Swiss Precision Diagnostics Gmbh Testing method and kit

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9217866D0 (en) * 1992-08-21 1992-10-07 Unilever Plc Monitoring method
WO1995016920A1 (fr) * 1993-12-16 1995-06-22 Abbott Laboratories Procedes et moyens de determination de la periode de fecondation chez une femme
GB9807134D0 (en) * 1998-04-02 1998-06-03 Unilever Plc Test methods devices and test kits
NZ568489A (en) * 2005-10-24 2011-08-26 Manawatu Diagnostics Ltd Ovulation cycle monitoring and management
US20170007215A1 (en) * 2014-01-30 2017-01-12 SALVME, Inc. System for saliva collection
CN106146651B (zh) * 2015-04-17 2019-08-23 南京济朗生物科技有限公司 女性黄体功能快速无创监测技术
US20170011195A1 (en) * 2015-07-09 2017-01-12 MI Express Care Licensing Company, LLC System And Method Of User Identity Validation in a Telemedicine System
US11061026B2 (en) * 2017-02-17 2021-07-13 MFB Fertility, Inc. System of evaluating corpus luteum function by recurrently evaluating progesterone non-serum bodily fluids on multiple days
EP3731751B1 (fr) * 2017-12-28 2024-06-19 MFB Fertility, Inc. Systèmes et procédés de suivi de la progestérone

Also Published As

Publication number Publication date
EP4017375A4 (fr) 2023-12-06
WO2021034412A1 (fr) 2021-02-25

Similar Documents

Publication Publication Date Title
EP4017375A1 (fr) Systèmes et procédés de test de cycle menstruel
US20220341951A1 (en) Systems and methods for menstrual cycle testing
US11573225B2 (en) System for evaluating urine for the presence or absence of pregnanediol glucuronide and other hormones and analytes
US20220165427A1 (en) System and method for handing diagnostic test results to telemedicine provider
US11915810B2 (en) System and method for transmitting prescription to pharmacy using self-diagnostic test and telemedicine
Thomas-Teinturier et al. Ovarian reserve after treatment with alkylating agents during childhood
US20210396750A1 (en) System and method for digital remote primary, secondary, and tertiary color calibration via smart device in analysis of medical test results
US10352920B2 (en) Supplements and monitoring systems for dosing of the supplements
US11935657B2 (en) System and method for a digital consumer medical wallet and storehouse
JP2023530226A (ja) 疾病診断用の試料検定の遠隔評価用のシステム及び方法
US20230408512A1 (en) System for evaluating urine for the presence or absence of pregnanediol glucuronide and other hormones and analytes
US12009078B2 (en) System and method for medical escalation and intervention that is a direct result of a remote diagnostic test
US20220051763A1 (en) System and method for correlating retail testing product to medical diagnostic code
US11131665B1 (en) Method for evaluating urine of a subject to estimate the fertile window
US11164680B2 (en) System and method for initiating telemedicine conference using self-diagnostic test
US11651866B2 (en) System and method for real-time insurance quote in response to a self-diagnostic test
TW201235663A (en) Biomarker monitoring device and method
US20190027259A1 (en) System and method for remote mapping of gold conjugates
Tomlinson et al. Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome
US20190027258A1 (en) System and method for mapping a diagnostic test to an individual user to create a unique profile on a remote database
CN114008454A (zh) 用于检测治疗剂以监测对治疗方案的依从性的系统和方法
Sharma et al. Measurement Tools and Utility of Hair Analysis for Screening Adherence to Antihypertensive Medication
US20190035491A1 (en) System and method for remote mapping of agent-induced material swab
WO2018112265A1 (fr) Système et procédé permettant de mettre en corrélation un produit de test destiné à la vente avec un code de diagnostic médical
KR102697774B1 (ko) 진료서비스의 제공이 가능한 통합 의료 관리 장치 및 방법

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/76 20060101ALI20230728BHEP

Ipc: G01N 33/558 20060101ALI20230728BHEP

Ipc: A61B 5/02 20060101ALI20230728BHEP

Ipc: A61B 5/00 20060101ALI20230728BHEP

Ipc: A61B 10/00 20060101AFI20230728BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20231106

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/76 20060101ALI20231030BHEP

Ipc: G01N 33/558 20060101ALI20231030BHEP

Ipc: A61B 5/02 20060101ALI20231030BHEP

Ipc: A61B 5/00 20060101ALI20231030BHEP

Ipc: A61B 10/00 20060101AFI20231030BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN